John Holzman Chair, Board of Regents University of Hawai'i

Home , Bachelor of Pharmacy, Master of Pharmacy

April 7, 2014

MEMORANDUM

TO: John Holzman Chair, Board of Regents University of Hawai‘i

VIA: David Lassner Interim President, University of Hawai‘i

VIA: Donald Straney Chancellor, University of Hawai‘i at Hilo

FROM: Matthew Platz Vice Chancellor for Academic Affairs, University of Hawai‘i at Hilo

SUBJECT: REQUEST TO APPROVE THE CHANGE OF STATUS FROM “PROVISIONAL” TO “ESTABLISHED” FOR THE PHARMD DEGREE OFFERED AT THE DANIEL K INOUYE COLLEGE OF PHARMACY, UNIVERSITY OF HAWAIʻI AT HILO

SPECIFIC ACTION REQUESTED:

It is requested that the University of Hawai‘i Board of Regents approve the change of status from “provisional” to “established” for the PharmD degree offered at the Daniel K Inouye College of Pharmacy, University of Hawai‘i at Hilo (UH Hilo). In addition to the summary of the program below, please find attached a self-study of the program and appendices for your review.

Approval of: __ New Program Proposal _X “Provisional” to “Established” for the PharmD degree offered at the Daniel K Inouye College of Pharmacy, University of Hawai‘i at Hilo

RECOMMENDED EFFECTIVE DATE:

Upon Board approval

John Holzman April 7, 2014 Page 2

ADDITIONAL COST:

No additional costs are associated with this request.

PURPOSE:

The PharmD degree completed its provisional cycle, and in accordance with Board of Regents’ policy, was reviewed under the procedures of program review at UH Hilo, and recommended for established status.

The Pharm.D program is a four-year course of study leading to the Doctor of Pharmacy (Pharm.D.) degree. The curriculum, rooted in basic, biomedical, and pharmaceutical sciences, is designed for students to acquire knowledge of the scientific underpinnings of pharmacy practice. The social, behavioral and administrative sciences that inform pharmaceutical care are integrated throughout the curriculum. Pharmacy practice arenas of therapeutics, drug information, pharmaceutical care, and experiential education permeate each year through Pharmacy Practice Experiences (PPE). PPE capitalizes on community outreach and service learning that taps into Hawaii’s cultural values and diverse biosphere inclusive of its Native Hawaiian Health systems and community practices that embody cultural healing and alternative therapeutics.

BACKGROUND:

Board of Regents’ Policy 5-1 confers upon the Board the authority to grant established status to provisional degree programs. University of Hawaiʻi Exeuctive Policy E5.201 requires that requests for a change from provisional to established status respond to questions in Appendix D of the policy. This response is presented in the attached document.

Summary for BOR Academic Affairs Committee review.

Significance/Contribution of this degree:

Thus far three classes of student pharmacists have completed the program and received the Pharm.D. degree. Enrollment in the Pharm.D. program currently stands at 344. Graduates of our PharmD program are now fully licensed registered pharmacists who are gainfully employed throughout the entire State of Hawai‘i , on every neighbor island, in community pharmacies, chain pharmacies, hospitals, long term care facilities, industry, academia, and in PGY1 residency programs. In addition, our graduates are employed in the following states: Alaska, Arizona, California, Colorado, Connecticut, Florida, Hawai‘i, Idaho, Illinois, Indiana, Louisiana, Michigan, Minnesota, New Jersey, New Mexico, Nevada, New York, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington and Wisconsin, as well as in Washington DC and Guam.

John Holzman April 7, 2014 Page 3

Employment prospects for professionals in pharmacy are currently good in Hawai‘i and in many other areas of the United States. More distinctive jobs become available all the time for someone with a PharmD degree. An example is one of our inaugural graduates working as a Clinical Coordinator in the MS in Clinical Psychopharmacology program offered by the Daniel K. Inouye College of Pharmacy (CoP). Below are the placement rates for our PharmD graduates from the first two graduating classes.

Both locally and nationally, there is a significant and growing need for the medication expertise only found in those professionals with a PharmD degree. The cost of medication- related hospitalizations and ER visits in Hawai‘i alone is staggering. According to Hawai‘i Health Information Corporation, the charges to payers for medication-related acute care (hospital and ER) in 2010 were $869,528,960. There is ample evidence in the peer-reviewed literature that adding pharmacists to care teams improves quality and reduces costs. Thus, the PharmD program is critical to improving healthcare in Hawai‘i through expansion of the workforce with needed expertise in medication management.

Cost and resource allocation/reallocation implications:

The CoP has become a major economic engine in the State of Hawai‘i. An independent economic impact study revealed the CoP contributes over $50 million per year in economic activity throughout the State. No doubt this is an under-estimate, since the College has attracted over $30 million in extramural support that was not taken into account.

John Holzman April 7, 2014 Page 4

The CoP budget projections have been prepared to cover the start-up phase through FY2016. The 5-year pro forma budget is shown in Appendix E. At full enrollment, the current level of State appropriation to the CoP and tuition will lead to a balanced budget. We expect any surpluses will be used to enhance the pharmacy program. The cost template form can be seen following this summary.

Demand projections:

The following is taken directly from the American Association of Colleges of Pharmacy website:

http://www.aacp.org/resources/student/pharmacyforyou/Pages/joboutlook.aspx

“A shortfall of as many as 157,000 pharmacists is predicted by 2020 according to the findings of a conference sponsored by the Pharmacy Manpower Project, Inc. Complete findings are detailed in the final report, ’Professionally Determined Need for Pharmacy Services in 2020.’”

“In December 2000, Health Resources and Services Administration (HRSA) of the Department of Health and Human Services (HHS) released a report, "The Pharmacy Workforce: A Study of the Supply and Demand for Pharmacists." This report, mandated by Congress, was conducted to determine whether and to what extent a shortage of pharmacists exists. The report concludes that there is an increasing demand for pharmacists' service that is outpacing the current and possibly future pharmacist supply. This conclusion is based largely on the growth of vacant positions across the entire range of pharmacy practice sites. "While the overall supply of pharmacists has increased in the past decade, there has been an unprecedented demand for pharmacists and for pharmaceutical care services, which has not been met by the currently available supply," the report says. The report also states that factors causing the shortage are not likely to abate in the near future.”

Job prospects are expected to be good over the 2008-18 period. Employers in many parts of the country have previously reported difficulty in attracting and retaining adequate numbers of pharmacists. However, the economic downturn has impacted the need for pharmacists and the number of available hours for pharmacists to work and this is decreasing the level of difficulty in attracting pharmacists. The other factor that may affect job prospects is healthcare reform and its impact on the services that pharmacists provide and the manner that healthcare is delivered. This factor could be variable in either direction. Once the economy stabilizes, we may see a return to the excellent job prospects that have been experienced in the last five years.

John Holzman April 7, 2014 Page 5

Another factor that bodes well for the professional employment is the Affordable Care Act. First of all, it has been estimated by the CBO that approximately 40,000,000 more Americans will receive prescription drug benefits as a result of this Act. In addition, the creations of groups such as Accountable Care Organizations (ACO) are mandated by the Act, and the ACO will include pharmacy services most logically managed by those holding the Pharm.D. degree. At the same time, Medication Therapy Management (MTM), is becoming more prevalent throughout the country, and will likely be commonplace in the near future.

Accreditation impact (if any):

The CoP has obtained full accreditation from the Accreditation Council for Pharmacy Education (ACPE) and meets all the requirements set forth by the Western Association of Schools and Colleges (WASC).

Examples (2-3) of similar models from peer institutions:

Given that all colleges of pharmacy must abide by the standards and guidelines set forth by ACPE, all colleges of pharmacy can be considered peers. Alternatively, Southwestern Oklahoma State University and Ferris State University may be considered as peers in that they are two State Universities, located in rural areas, and offer a PharmD degree. Links to their mission and vision statements follow:

http://www.swosu.edu/academics/pharmacy/docs/COP-mission-vision-values.pdf

http://www.ferris.edu/HTMLS/colleges/pharmacy/mission/homepage.htm

Similar programs at other UH campuses (if duplication, why is this program necessary):

The Daniel K. Inouye College of Pharmacy is the only college of pharmacy in the State of Hawai‘i. There are no similar programs in the UH System.

Statement from campus administration of new program’s strategic value within the UH priorities.

UH Hilo is proud to be home to the Daniel K. Inouye College of Pharmacy, the only College of Pharmacy in the state of Hawai’i and in the Pacific Region. In a few short years the College has become a mature success. It has now graduated several outstanding

John Holzman April 7, 2014 Page 6

classes of students, and these graduates have matriculated to excellent professional placements at impressive rates. The faculty have successfully competed for federal funds and do research that improves the health care of the people of Hawai‘i. The Pharm D program of the Daniel K. Inouye College of Pharmacy is among the top strategic priorities of UH Hilo.

ACTION RECOMMENDED:

It is recommended that the University of Hawai‘i Board of Regents approve the change of status from “provisional” to “established” for the Pharm D degree offered at the Daniel K Inouye College of Pharmacy, University of Hawai‘i at Hilo.

Attachments Academic Program Cost and Revenues Template Self-Study in Support of Change from Provisional to Established Status

Cc: Cynthia Quinn, Executive Administrator and Secretary of the Board of Regents Joanne Itano, Interim Executive Vice President for Academic Affairs

Doctor of Pharmacy (PharmD) Program

The Daniel K. Inouye College of Pharmacy

University of Hawai‘i - Hilo

A SELF-STUDY IN SUPPORT OF CHANGE FROM PROVISIONAL TO

ESTABLISHED STATUS

1. IS THE PROGRAM ORGANIZED TO MEET ITS OBJECTIVES?

Program Description:

The Daniel K. Inouye College of Pharmacy University of Hawai‘i – Hilo (CoP) offers a four-year course of study leading to the Doctor of Pharmacy (PharmD) degree. The curriculum, rooted in basic, biomedical, and pharmaceutical sciences, is designed for students to acquire knowledge of the scientific underpinnings of pharmacy practice. The social, behavioral, and administrative sciences that inform pharmaceutical care are integrated throughout the curriculum. Pharmacy practice areas of therapeutics, drug information, pharmaceutical care, and experiential education permeate each year through Introductory and Advanced Pharmacy Practice Experiences (IPPE and APPE). These IPPE and APPE capitalizes on community outreach and service learning that taps into Hawai‘i’s cultural values and diverse biosphere inclusive of its Native Hawai‘ian Health systems and community practices that embody cultural healing and alternative therapeutics. The wide range of medical specialties available among different healthcare institutions throughout the United States and U.S. Territories such as Guam, American Samoa and Puerto Rico provide clinical sites to fulfill ACPE requirements. The CoP embraces the Institute of Medicine's (IOM) five core competencies for the health science disciplines as key components of the curriculum. These include patient safety, patient centered care, team relationships, technologically informed practices and inter-professional education (IPE), which are also endorsed by the American Association of Colleges of Pharmacy (AACP).

Objectives of the program:

1. Produce graduates with competencies of entry-level pharmacists. 2. Satisfy the educational requirements for licensure as a pharmacist. 3. Socialize doctoral students to pharmacy as a profession and a health science discipline. 4. Educate pharmacists to deliver healthcare within the quality philosophy of Institute of Medicine (IOM) and IOM core competencies in health professions education. 5. Stimulate doctoral students in the quest for scholarship in research and practice. 6. Prepare the next generation of pharmacy leaders.

Prospects for graduates:

Graduates of the PharmD program seek employment with community pharmacies, chain pharmacies, hospitals, long term care facilities, industry, academia, and in PGY1 residency programs. Our graduates are employed in the following states: Alaska, Arizona, California, Colorado, Connecticut, Florida, Hawai‘i, Idaho, Illinois, Indiana, Louisiana, Michigan, Minnesota, New Jersey, New Mexico, Nevada, New York, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington and Wisconsin, as well as in Washington DC and Guam.

Employment prospects for professionals in pharmacy are currently good in Hawai‘i and in many other areas of the United States. More distinctive jobs become available all the time for someone with a PharmD degree. An example is one of our inaugural graduates working as a Clinical Coordinator in the MS in Clinical Psychopharmacology program offered by the CoP. A partial list of the employment of the PharmD graduates can be seen in Appendix A. Below are the placement rates for our PharmD graduates from the first two graduating classes.

Admission Requirements:

To be eligible for admission to the PharmD program, students must meet the following minimum requirements:

• Prerequisite Courses: Admission is contingent upon the successful completion of all prerequisite courses with a minimum grade of "C" (C- grades are not accepted). Students may be in the process of completing prerequisite coursework (see below) at the time of application.

International Applicants must also complete a minimum of 30 semester hours of coursework in the United States at any regionally-accredited college or university. Of the 30 required semester hours, 15 semester hours must be allocated to non-remedial science courses.

Semester Quarter Required Prerequisite Courses Hours Hours

General Biology I & II for Science Majors with Labs 8 12

Microbiology with Labs 4 6

General Chemistry I & II for Science Majors with Labs 8 12

Organic Chemistry I & II for Science Majors with Labs 8 12

Human Anatomy & Physiology I & II with Labs 8 12

Calculus I or Advanced Calculus 3 4.5

English (including 3 credits composition) 6 9

Humanities 6 9

A course that includes a World/Cultural Diversity 3 4.5 component

Social/Behavioral Sciences 6 9

Economics 3 4.5

Communications (with a public speaking component) 3 4.5

Total Credit Hours 66 99

• Pharmacy College Admission Test (PCAT): The PCAT is required for applying to the CoP. The CoP will not accept any other admission test in place of the PCAT. All PCAT scores must be sent to PharmCAS (this is an organization that disseminates applications to all enrolled college of pharmacy’s). Applicants are encouraged to take the PCAT in July or September of the application year or earlier.

• PharmCas Application: Students must apply and submit a complete application through PharmCAS. A complete application includes a personal statement, PCAT scores, two professional letters of recommendation (electronic letters of reference are acceptable), applicable fee(s), and official transcripts from all regionally-accredited colleges and/or universities attended.

• Early Decision Deadline: The CoP participates in the PharmCas Early Decision Program which is a binding option for applicants who have decided that a particular pharmacy degree program is their first choice and that they will enroll if accepted. • Supplemental Application: Upon receipt of an applicant’s PharmCAS application, the CoP Admissions Committee formally requests, via email, that the applicant complete a supplemental application, technical standards form, and residency declaration form, as well as submit a non-refundable $50.00 application fee. A due date is indicated in the email.

The CoP operates on a competitive, rolling admissions process. Early submission of applications is strongly recommended. Applicants are responsible for tracking the progress of their application and verifying that all necessary documents have been received by the UH Hilo Office of Student Services. The application review process begins in August each year and continues until all seats are filled. Upon receipt of all required application components noted above, the complete file and applicant profile will be reviewed by the CoP Admissions Committee. At that time, the Committee decides to invite the candidate for an interview, place the candidate on hold for further review, or reject the applicant. Eligible students are invited for a personal interview. CoP conducts closed file interviews. This approach was selected by the Admissions Committee as it helps remove preconceived biases based on students' experiences, grades, test scores, personal statements, etc. Interviews are conducted from December through May with additional interviews as needed. Complete applications and interview scores are reviewed by the Admissions Committee for final admission decisions. 4

Transfer Applicants:

The CoP may accept transfer students from other ACPE accredited pharmacy schools, as long as these students are in good academic standing and have legitimate reasons for seeking a transfer. Transfer applicants must have completed or be in the process of completing all required prerequisite courses listed on the admissions website.

Transfer students will only be accepted for Fall enrollment. Complete applications for transfer are due by February 1st of the matriculation year. It is important to note that there is no guarantee that coursework taken at a previous College of Pharmacy will transfer into The Daniel K. Inouye College of Pharmacy at the University of Hawai‘i at Hilo. Students may only transfer didactic coursework, Introductory Pharmacy Practice Experience (IPPE), or Advanced Pharmacy Practice experience (APPE) will not be considered for transfer credit.

To be considered for transfer the applicant must meet all of the following criteria:

1. Complete, or be in the process of completing all required prerequisite courses with a grade of C or better, as listed on the admissions website. 2. Have a minimum GPA of 3.0 or higher and be in good academic standing in an ACPE accredited pharmacy school. 3. Have a legitimate reason for seeking transfer. 4. Submit all of the application materials as indicated below.

To apply as a transfer student, they do not complete a PharmCAS application, but instead they need to submit the following documents:

1. A letter to the Director of Student Services indicating why the applicant wishes to transfer and explaining any difficulties encountered at his/her current institution. 2. Official transcripts from all institutions attended - undergraduate, graduate, and professional. 3. A catalog and a detailed pharmacy syllabus for any courses for which advanced standing consideration is requested. 4. A letter from the Dean of the pharmacy school/college in which the student is enrolled. The letter must indicate the student’s current academic status and/or terms of withdrawal/dismissal.

5. The applicant must also complete a CoP Supplemental Application Form, residency declaration form and submit a $50 application fee (instructions for this process and application forms are available via email request to pharmacy@Hawai‘i.edu).

Upon receipt of all required application components noted above, the complete file and applicant profile will reviewed by the Associate Dean for Academic Affairs. If the review is positive the applicant’s file will be forwarded to the Admissions Committee for consideration. Additional documents, or letters of recommendation may be required as determined necessary by the Associate Dean for Academic Affairs of CoP, or by the Chair of Admissions Committee. After review of the application, the Admissions Committee will decide to invite the applicant for an interview or reject the applicant.

Students who are not currently in good academic standing at their pharmacy school will not be considered for transfer admission.

Advanced Standing and Transfer of Credits:

All requests for advanced standing by newly admitted, transfer, readmitted, or enrolled students are processed on a course-by-course basis. Advanced standing will be considered only for coursework taken in which a letter grade of “C” or better has been achieved. To request such consideration, a student would need to submit a letter of request to the Associate Dean for Academic Affairs in which the student lists a course(s) previously taken, which might be similar in content to a profession all course(s) that he/she is scheduled to take. The student is also advised to provide an official course description(s) and a syllabus (syllabi) of the course(s) previously taken. All requests must be submitted prior to the start of the course being considered. The materials are forwarded to the Course Coordinators who provide a recommendation to the Associate Dean for Academic Affairs of UHH CoP. The Associate Dean will either grant or deny advanced standing.

Program Curriculum:

Professional Year 1 Fall Courses - Total of 17 credits

• PHPP 501 Introductory Pharmacy Practice Experiential (IPPE) I (1) • PHPS 504 Pharmaceutical Immunology (3) • PHPS 501 Biochemistry—biomolecules (3) • PHPS 505 Pharmaceutics I (3) • PHPP 511 Culture & Inter-professional Health Care (2) 6

• PHPS 503 Pharmaceutical Calculations (2) • PHPS 512 Introduction to the Pharmaceutical Sciences (3)

Professional Year 1 Spring Courses - Total of 17 credits

• PHPP 502 Introductory Pharmacy Practice Experiential (IPPE) II (1) • PHPP 508 Introduction to Biostatistics (3) • PHPS 509 Pathophysiology (4) • PHPS 502 Biochemistry—metabolism (3) • PHPS 506 Pharmaceutics II (3) • PHPP 510 Foundation of Integrated Therapeutics and OTC drugs (3)

Professional Year 2 Fall Courses - Total of 19 credits

• PHPP 503 Introduction Pharmacy Practice Experiential (IPPE) III (1) • PHPP 506 IPPE Retail Rotation (1) • PHPP 514 Evidence-Based Medicine (3) • PHPP 515 Integrated Therapeutics I (7) • PHPS 511 Pharmacokinetics (3) • PHPP 527 Drug Information (2) • PHPP 528 Pharmacy Communications (2) 50% of Cohort • Elective (2). Choose two credits of elective – 50% of Cohort

Professional Year 2 Spring Courses - Total of 17 credits

• PHPP 504 Introduction Pharmacy Practice Experiential (IPPE) IV (1) • PHPP 520 Pharmacy Law and Ethics (3) • PHPP 523 Wellness, and Disease Prevention (2) • PHPP 516 Integrated Therapeutics II (7) • PHPP 528 Pharmacy Communications (2) – 50% of Cohort • PHPP 519 Health Care Systems (2) • Elective (2). Choose two credits of elective - 50% of Cohort

Professional Year 3 Fall Courses - Total of 16 credits

• PHPP 505 Introduction Pharmacy Practice Experiential (IPPE) V (1) • PHPP 522 Pharmacy Practice Management and Marketing (2) • PHPP 517 Integrated Therapeutics III (7) • PHPP 525 Complementary Medicine (3) • Electives (3). Choose three credits of electives:

Professional Year 3 Spring Courses - Total of 16 credits

• PHPP 524 Pharmacoeconomics (3)

• PHPP 518 Integrated Therapeutics IV (7) • PHPP 521 Applied Pharmaceutical Care (3) • PHPS 591 Basic and Applied Toxicology (3)

Professional Year 4 Courses - Total of 36 credits

• Fourth Year (P-4) - Advanced Professional Practice Experiences: 42 weeks

 PHPP 540 Advanced Pharmacy Practice Experiential - Ambulatory Care (6)  PHPP 541 Advanced Pharmacy Practice Experiential - Community Practice (6)  PHPP 542 Advanced Pharmacy Practice Experiential - Medicine (6)  PHPP 543 Advanced Pharmacy Practice Experiential - Hospital Pharmacy (6)  PHPP 544 Advanced Pharmacy Practice Experiential - Elective I (6)  PHPP 545 Advanced Pharmacy Practice Experiential - Elective II (6)

Electives – 6 credits • PHPP 546 Advanced Pharmacy Practice Experiential – Elective III (6)

Electives - 2 Credits

• PHPP 550 History of Pharmacy (2) • PHPS 550 Genetics in Medicine (2) • PHPP 555 Overview of Veterinary Medicine and Veterinary Pharmacology (2)

Electives – 1 Credit

• PHPP 553 Current Topics in Health Care • PHPP 557 Personal Finance • PHPP 554 Zoonotic Diseases • PHPP 564 Advanced Managed Health Care • PHPP 560 Pharmacy Leadership • PHPS 553 Radioactivity in Pharmacy • PHPS 554 Herbal Medicine and Hawai’ian Medicinal Plants • PHPS 555 Geographic (Tropical) Medicines • PHPS 559 Environmental Toxicology • PHPS 562 Discovery & Development of Blockbuster Drugs • PHPS 563 Current Advances in Neuropharmacology • PHPS 565 Genetics & Pharmacology of Malaria • PHPS 561 Emerging Trends of Drug Discovery • PHPS 567 Pharmacogenetics • PHPS 568 Antibiotic Mechanisms • PHPS 569 Cancer Prevention • PHPP TBD Pharmacy and Therapeutics Committees

Curriculum in professional schools such as colleges of pharmacy is much more dynamic than in most undergraduate and graduate programs. This is due to many factors including the constant influx of new drugs, new understanding of disease states, changing evidence based on new findings in clinical trials, all forming the basis for changing in practice guidelines. Elective course offerings change based on the areas of expertise of new faculty hires.

All changes in the Curriculum must go through a rigorous process before being implanted: starting at the CoP Curriculum Committee followed by approval of the entire faculty of the CoP, after that all changes go through the UH Hilo curricular review process. Some of the more significant changes since the original curriculum was proposed include, decreasing the credit hours for biochemistry, increasing the credit hours of the Integrated Therapeutics courses (that include the disciplines of pathophysiology, pharmacology, medical chemistry and therapeutics), and decreasing the hours dedicated to pharmacokinetics. The most recent significant change was adding courses in Drug Information and Communication. These changes are related to program objective four: Educate pharmacists to deliver healthcare within the quality philosophy of Institute of Medicine (IOM) and IOM core competencies in health professions education. The creation of a Pharmacy Leadership elective goes toward fulfilling program objective five: Prepare the next generation of pharmacy leaders.

Student Services Offered:

The CoP Office of Student Services works in conjunction with the UH Hilo Division of Student Affairs in order to offer CoP students the broadest and most comprehensive range of services and to encourage their academic and personal success while at the CoP. Students of the CoP have access to personal and professional counseling, personal mediation services, crisis services, academic aid, and financial aid.

Academic Advising and Career Counseling for PharmD Students:

Academic, career, and personal counseling and advising is a recognized need for PharmD students. In order to meet this need, CoP has made these services easily accessible to our students. Academic and career advising and counseling is facilitated through faculty advisors who are able to address the specific academic and career concerns and questions for CoP students effectively. Each CoP student is assigned to an academic advising group nominally composed of six students and an advisor (faculty member) during orientation of their P1 year. An attempt is made to have the composition of the groups be as culturally diverse as possible.

Faculty advisor responsibilities include:

• Serving as the student’s advisor and academic/professional counselor. • Overseeing and monitoring the academic progress and professional growth of the student. • Assisting the student in seeking academic and personal counseling services provided by the institution. • Serving as an advocate for the student when appropriate.

Student advising is required of all CoP faculty members. Faculty advisors meet with each student individually at least once per semester. In addition to faculty advisors, the Dean, Associate Deans, Director of Student Services, and the Academic Advisement Specialist as well as other faculty members are also available to assist students with academic advising, counseling, enrichment, and non-academic concerns. This goes toward fulfilling program objective three: Socialize doctoral students to pharmacy as a profession and a health science discipline.

Student Organizations and Leadership Opportunities:

The CoP offers its student pharmacists numerous opportunities to get involved in student organizations. During the 2013-2014 academic year the college will have fifteen student organizations; nine professional pharmacy organizations, two student-led community service project initiatives, and four student councils that represent each of the four cohorts of professional students.

Professional Student Pharmacist Organizations • UHH Student Chapter of American Association of Pharmaceutical Scientists (AAPS) • Academy of Managed Care Pharmacy Student Chapter (AMCP) • American Pharmacist Association – Academy of Student Pharmacists Hawai‘i Chapter (APhA-ASP) • Hawai‘i Student Society of Health-Systems Pharmacy (HSSHP) • Kappa Psi Pharmaceutical Fraternity Epsilon Psi Chapter • UHH Chapter of National Community Pharmacist Association (NCPA) • Phi Delta Chi Professional Pharmacy Fraternity Gamma Theta Chapter • Phi Lambda Sigma Pharmacy Leadership Society Delta Lambda Chapter • Rho Chi Academic Honor Society in Pharmacy Delta Iota Chapter

Student-Led Community Service Project Initiatives • A Life of Healing and Awareness (A.L.O.H.A.) Project • Pacific Islander Mobile Screening Clinic (P.I.M.S.C.)

Student Councils • Class of 2014 Student Council • Class of 2015 Student Council • Class of 2016 Student Council • Class of 2017 Student Council

Each student organization has a different focus and mission: Some of the organizations have interests based on community pharmacy, clinical pharmacy, or research, and some are focused on professional development in different areas such as leadership or academics. All of the student organizations practice community service to varying degrees. All CoP student organizations have a designated faculty advisor. Also, a student services staff member is designated to support all organizations in their operations. Every student pharmacist in the college has the opportunity to become involved in any of the twelve student organizations available to them, and many do get involved. Total membership in each organization can range from over 20 to 120 student pharmacists. Across all of the organizations, there are over 70 elected positions available for student pharmacists to gain various types of leadership experience. These student groups help toward fulfilling program objectives three: Socialize doctoral students to pharmacy as a profession and a health science discipline, and five: Prepare the next generation of pharmacy leaders.

Passing the North American Pharmacist Licensure Examination (NAPLEX):

After a PharmD student has graduated from an accredited college of pharmacy, but before they can practice pharmacy, they must pass the NAPLEX. The NAPLEX is administered and controlled by the National Association of Boards of Pharmacy (NABP). The following is taken directly from the NABP website, “The NAPLEX, or North American Pharmacist Licensure Examination, measures a candidate’s knowledge of the practice of pharmacy. It is just one component of the licensure process and is used by the boards of pharmacy as part of their assessment of a candidate’s competence to practice as a pharmacist.” The overall pass rate of our first two CoP graduating classes is approximately 96.5%. This goes toward fulfilling program objective two: Satisfy the educational requirements for licensure as a pharmacist.

Student Scholarly Endeavors:

It can be readily seen by the following lists the level of involvement our students demonstrate in the area of research and goes toward fulfilling learning objective five: Stimulate doctoral students in the quest for scholarship in research and practice. At any point in time during an academic semester a minimum of 50 PharmD students are engaged in either pharmaceutical science or pharmacy practice research.

Publications: (student names are in bold)

Blank B., Alayoglu P., Engen W., Choi J., Berkman C., Anderson M O. (2011). N-Substituted Sulfonamides as Inhibitors of Glutamate Carboxypeptidase II (GCP2). Chemical Biology & Drug Design, 77(4), 241-7.

Cheenpracha, S., Park, E., Yoshida, W.Y., Barit, C., Wall, M., Pezzuto, J., Chang, L.C. (2010) Potential ainti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. Bioorganic & Medicinal Chemistry, 18 (2010) 6598-6602.

Engen, W., O'Brien, T., Anderson, M. O., et al. (2010). Synthesis of aryl-heteroaryl ureas (AHUs) based on 4- aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R). Bioorganic and Medicinal Chemistry, 18(16), 5995-6005.

Gawecka, J.E., Geerts, D., Koster, J., Caliva, M.J., Sulzmaier, F.J., Opoku-Ansah, J., Wada, R.K., Bachmann, A.S., Ramos, J.W. (2012) International Journal of Cancer, 131, 1556-1568 (2012).

Ibarra-Rivera, T.R., Opuku-Ansah, J., Ambadi, S., Bachmann, A.S., Pirrung, M.C. (2011) Synthesis of cytotoxicity of syringolin B-based proteasome inhibitors. Tetrahedron, 67 (2011) 9950-9956.

Kelman, D., Posner, E. K., McDermid, K. J., Tabandera, N. K., Wright, P. R., & Wright, A. D. (2012). Antioxidant Activity of Hawai‘ian Marine Algae. Marine Drugs, 10(2), 403-416.

Lai Hipp, C., Goldberg, T., Scott, E., Ziman, A., Vyas, G.N. (2011) Pooled peripheral blood mononuclear cells provide an optimized cellular substrate for HIV-1 isolation during acute infection. Transfusion, 2011 Feb;51(2):333-7. doi: 10.1111/j.1537-2995.2010.02831.x. Epub 2010 Aug 26. PMID: 20796251

Opoku-Ansah J., Ibarra-Rivera, T.R., Pirrung, M.C., Bachmann, A.S. (2012) Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma. Pharmaceutical Biology, 2012; 50(1)L 25-29.

Wongwiwatthananukit S., Zeszotarski, P., Thai, A., Fuller, R., Owusu, Y., Tan, C., Gomez, L., & Holuby, S. (2013). Assessment of diabetes training program on pharmacy students' competence, confidence, and attitudes in providing diabetes care. Am J Pharm Educ. 2013 (in press)

Youngren, S.R., Mulik, R., Jun, B., Hoffmann, P.R., Morris K.R., Chougule, M.B. (2012) Freeze Dried Targeted Mannosylated Selenium-loaded Nanoliposomes: Development and Evaluation , Communicated to AAPSPharmSciTech, 2012 12

Poster Presentations and Abstracts:

Bartlett, M., Nishimoto, S., (2012) The Social Impact of Community Outreach in a Rural Population. 2012 American Society of Health System Pharmacists Midyear Meeting, Student Showcase

Batz, F., Henderson, V. (2011) Pharmaceutical Disposal- What Pharmacists Need to Know (online accredited continuing education course). GreenPharmEdu.org, 2011.

Batz, F., Hwang, A., Kaluhiokalani, M., Park, A. (2012) Herbal Medicine Survey of Health Professionals in Hawai‘i. Hawai‘i J Med Public Health, 2012;71(6):148.

Batz, F., Rahman, S., Henley, D., Narcisco, P., Blair, J., Ikeda, T., Kamei, C., Kouma, M., Sasaki, M., Rostami, B., Sana, J., Cornela, A., Behina, B., Kalahiki, M., McConnell, C., Stafford, L. (2011) Cross-campus Collaboration to Develop a Mobile Learning App for Pharmacy Students; presented at the American Association of Colleges of Pharmacy (AACP) 2011 Annual Meeting, San Antonio, TX (July 2011).

Batz, F., Hwang, A., Kaluhiokalani, M., Park, A. (2012) Herbal Medicine Survey of Health Professionals in Hawai’i (poster); presented at the Hawai’i Pharmacists Association 2012 Annual Meeting, Honolulu, HI (Apr 2012).

Berger, L.S., Kobashikawa, D.D., Oyadomari, K.E., Pezzuto, M.F., & Goo, R.A. (2013) Pharmacist Led Protocol for IV to Oral Antibiotic Switch in an Antibiotic Stewardship Program. 25th Academy of Managed Care Pharmacy Annual Meeting 2013.

Chong, M., Shimabuku, S. (2011) Impact of the “Ohana” Diabetes Education Program on the Clinical Outcomes of a Marshallese Patient in Hawai‘i: a six month evaluation (case report). Presented at the 2011 APhA annual conference in Seattle, WA.

Chong, M., Shimabuku, S., Lai Hipp, C., Kim, C., Heffernan, L. (2012) Marshallese Mobile Clinic Screening Clinic Project. Presented at the 2012 HPhA annual conference in Honolulu, HI.

Engen W., Morris K., Hamad M. Impact of hydration state on levothyroxine sodium chemical stability (Poster). American Society of Health System Pharmacist (ASHP) 2011 Midyear Clinical Meeting, New Orleans, LA; presented December 5, 2011

Goldsberry, J., Stevens, J., Tokumaru, S., Goo, R. (2012) Appropriate Use of Epoetin Alfa (Procrit) for Patients with Chronic Renal Insufficiency on Kaua’i, HI. Presented at ASHP Midyear Clinical Meeting 2012 in Las Vegas, NV

Hu, D., Vordtriede, C., Goo, R. (2011) Theophylline and N-acetylcysteine in the prevention of contrast induced nephropathy in a patient undergoing a coronary angiogram: a case study. Presented at ASHP Midyear Clinical Meeting 2011 in New Orleans, LA

Ikeda, T., Kamei, C., Kouma, M., Sasaki, M., Rostami, B., Sana, J., Batz, F. Impact of a Community Medication Take Back Event (abstract). Hawai‘i J Med Public Health. 2012;71(6):149-50.

Ikeda, T., Kamei, C., Kouma, M., Sasaki, M., Rostami, B., Sana, J., Batz, F. (2012) Impact of a Community Medication Take Back Event (poster); presented at the Hawai’i Pharmacists Association 2012 Annual Meeting, Honolulu, HI (Apr 2012).

Kelman, D., John, K., Wright, P.R., Tabandera, N.K., Hagiwara, K., and Wright, A.D. (2011). Antioxidant Activity of Hawai‘ian Lichens. 2011 PSNA 50th Anniversary meeting, Poster Session: Natural Product Drug Discovery 4.

Kim, P, Sakamoto, S, Ma, C. Reviewing the transition and aftermath of patients switched over from Warfarin to dabigatran in an outpatient clinic, Follow up and Results, ASHP Midyear Meeting 2012, Las Vegas, NV

Kim, P, Sakamoto, S, Cheng, B, Voidtriede, C, Ma, C. “Reviewing the transition and aftermath of patients switched over from warfarin to dabigatran in an outpatient clinic”, ASHP Midyear Meeting 2011, New Orleans, LA

Konorev, E., Sun, Z., Taylor, F., Malmo, J. (2012) Targeted anticancer drug sorafenib impairs vascular network formation by human cardiac endothelial cells. American Heart Association Basic Cardiovascular Sciences 2012 Scientific Session,. P278, p. 101 (2012).

Lai Hipp, C., Kim, C., and Shimabuku S. (2012) “Marshallese Mobile Screening Clinic”. Poster presentation at the Hawai‘i Pharmacists Association Annual meeting April 2012, Honolulu, Hawai‘i.

Lai Hipp, C. and Kamei, C. (2011) “Professional Development Speaker Series: Using Technology to Maximize Student Experiences”. Poster presentation at ASHP Mid-Year Clinical Meeting Student Society Showcase 2011, New Orleans, LA.

Masri, J., Goldsberry, J., Kang, M., Batz, F. (2013) Student-directed implementation of a community health fair in a rural setting (poster); presented at the University of Hawai’i at Hilo Inaugural ALEX Student Research Conference, Hilo, HI (Feb 2013).

Masri, J., Goldsberry, J., Kang, M., Batz, F. (2013) Student-directed implementation of a community health fair in a rural setting (poster); presented at the Hawai’i Pharmacists Association 2013 Annual Meeting, Honolulu, HI (Apr 2013).

Mulik, R., Jun, B., Connelly, L., Chougule, M.B. (2012) Targeted nanocarriers of siRNA for the treatment of cancer. Presented at the 103th AACR Annual Meeting, Chicago, IL, USA, March 31-April 4, 2012.

Peric, K., Yoneda, M., Goo, R., Tokumaru, S. (2012) Pharmacy Students Role in an Antimicrobial Stewardship Program. Presented at ASHP Midyear Clinical Meeting 2012 in Las Vegas, NV.

Shimabuku, S., Kim, C., Lai Hipp, C., Heffernan, E. (2012) Marshallese Mobile Screening Clinic. Hawai‘i J Med Public Health, June 2012; 71 (6): 148-149. Print.

Sangngern, M., Jun, B., Hamad, M., Chang, L.C., Rosanoff, A., Chougule M.B. (2012) Preliminary study of Transdermal permeation of Magnesium cream formulations across skin. Presented at the XIIIth International Magnesium Symposium, Mérida, Yuc., México, 16 - 19 October 2012. 14

Thai, A., Fuller, R., Wongwiwatthananukit, S., & Holuby, S. (2011). Assessment of diabetes skill- based training program on pharmacy students' competence, self-confidence, and attitudes in providing diabetes care. Poster presentation accepted for the 2011 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition. New Orleans, Louisiana, December 4-8, 2011.

Txakeeyang, A., Wendel, A., Oki, N., Hanai, D., Shimabuku, S., Owusu, Y., Wongwiwatthananukit, S., & Anderson, K. (2013). Prevalence of diabetes and hypertension among Marshallese identified in pharmacist-led health screenings in Hawai’i. Poster presentation accepted for the 2013 American Pharmacists Association (APhA) Annual Meeting and Exposition. Los Angeles, California, March 1-4, 2013. J Am Pharm Assoc. 2013, 52(2), e33.

Venegas, M., Miguel, T., Tonthat, D., Kurosawa, P., & Wongwiwatthananukit, S. (2010). Evaluation of automated dispensing cabinet use in a rural isolated community hospital. Poster presentation accepted for the 2010 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition. Anaheim, California, December 5-9, 2010.

Venegas, M., Miguel, T., Tonthat, D., & Wongwiwatthananukit, S. (2011). Impact of Blind Counts and Cost Analyses of Automated Dispensing Cabinet Use on Medication Discrepancies in a Rural Isolated Community Hospital. Poster presentation accepted for the 2011 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition. New Orleans, Louisiana, December 4-8, 2011.

Vyas, G.N., Stoddart, C., Fileding, C., Norman, J., Goldberg, T., Lai Hipp, C., Brennan, T. (2010) Membrane-bound HIV-envelope proteins from inactivated viri9ons of newly transmitted HIV-1 in humans are infection-free in SCID-hu Thy/Liv mouse model. AIDS Research and Human Retroviruses, 2010: 26(10). A26

Vyas, G.N., Stoddart, C., Fielding, C., Norman, J., Goldberg, T., Mou, T., Lai Hipp, C., Ziman, A., and Brennan, T. (2010) “Membrane-Bound Envelope Proteins from Inactivated Virions of HIV-1 Newly Transmitted in Humans are Infection-free in SCID-hu Thv/Liv Mouse Model”. Poster presentation at AIDS Vaccine 2010 , Atlanta, GA.

Weichhaus, M., Segaran, P., Geerts, D. & Connelly L. (2012) Osteoprotegerin production by breast cancer cells: regulation by NF-kappaB and role in metastasis. 103rd American Association for Cancer Research Annual Meeting 2012, Proceedings Volume 52, #1364.

Weichhaus, M., Segaran, P., Le, A., Geerts, D. & Connelly L. (2013) Stable knockdown of osteoprotegerin increases cell proliferation and metastasis in breast cancer cells. 104th American Association for Cancer Research Annual Meeting 2013, Proceedings Volume 53, #1394

Wongwiwatthananukit S., Tan, C., Zeszotarski, P., Owusu, Y., Thai, A., Fuller, R., & Holuby, S. (2012). Assessing diabetes training program on pharmacy students' competence, self- confidence, and attitudes in providing diabetes care. Poster presentation accepted for the 2012 AACP Annual Meeting and Seminars. Gaylord Palms Resort & Convention Center, Kissimmee, Florida (Orlando area). July 14-18, 2012. Am J Pharm Educ. 2012; 76 (5) Article 99, 45.

Yamashiro, A., Yeh, M., Tokumaru, S., Goo, R. (2011) Transient Elevations in Partial Thromboplastin Time due to Telavancin: A Case Study. Presented at ASHP Midyear Clinical Meeting 2011 in New Orleans, LA.

Yoneda, M., Peric, K., Goo, R., Tokumaru, S. (2012) Pharmacy Students Impact on a Rural Community Hospital. Presented at ASHP Midyear Clinical Meeting 2012 in Las Vegas, NV.Instructional Videos Developed at UHH for PharmD Curriculum:

Batz, F., Liu, A., Kang, M., Uyeno, R. (2012) SOAP Presentation Example Video- Good Quality. UH Hilo College of Pharmacy, Jul 2012.

Batz, F., Liu, A., Kang, M., Uyeno, R. (2012) SOAP Presentation Example Video- Medium Quality. UH Hilo College of Pharmacy, Jul 2012.

Batz, F., Liu, A., Kang, M., Uyeno, R. (2012) SOAP Presentation Example Video- Poor Quality. UH Hilo College of Pharmacy, Jul 2012.

Mapping of Course Material to Professional Outcomes:

The CoP recently mapped all the content of core courses, both didactic and experiential, to our Professional Terminal Degree Outcomes for Student Pharmacists. The map can be found in Appendix B. The mapping was done by the faculty in each course focusing on what students should be able to do in a professional environment upon completion of the curriculum. The Assessment Committee chose a performance level scale originally developed by Miller (1990) for medical education, and subsequently used by other health professions including nursing and pharmacy (level 1 knows, level 2 knows how, level 3 shows how, level 4 does) to insert into map. This map was reviewed by both the Assessment and Curriculum Committee to assure that all terminal outcomes were adequately covered in the curriculum. This mapping goes toward fulfilling program objective one: Produce graduates with competencies of entry-level pharmacists.

2. IS THE PROGRAM MEETING ITS LEARNING OBJECTIVES FOR STUDENTS?

The American Association of Colleges of Pharmacy (AACP) annually administers anonymous, standardized surveys of preceptors (professional pharmacists who supervise students in their clinical rotations), alumni, and faculty on various aspects of program quality. The results reported below are from the “Curriculum” section of each survey, which measures the impact of the program on students’ professional knowledge and abilities.

Results of Annual Surveys administered by American Association of Colleges of Pharmacy

% of Respondents who Agree or Strongly Agree with the Following Statements

Alumni Faculty Preceptor (Class of 2012 Outcomes 2012 (n= 2011) 115) (n=34) (n =39)

1.The PharmD program prepares students to develop and use patient- 93.8% 100.0% 96.4% specific pharmacy care plans.

2.The PharmD program prepares students to effectively manage a patient- 93.6% 100.0% 89.3% centered pharmacy practice.

3.The PharmD program prepares students to develop disease management 90.0% 93.9% 96.3% programs.

4. The PharmD program prepares students to manage the system of 99.1% 96.9% 92.9% medication use.

5. The PharmD program prepares students to promote the availability of 98.1% 97.1% 100.0% health promotion and disease prevention initiatives.

6.The PharmD program prepares students to communicate with patients, 96.5% 97.1% 89.3% caregivers, and other members of the interprofessional health care team.

7.The PharmD program prepares students to search the health sciences 96.5% 100.0% 81.3% literature.

8. The PharmD program prepares students to evaluate the health sciences 92.9% 97.1% 90.6% literature.

9.The PharmD program prepares students to demonstrate expertise in the 93.7% 94.1% 89.7% area of informatics (resources, devices, and methods required to optimize the acquisition, storage, retrieval, and use of information in pharmacy and healthcare).

10.The PharmD program prepares students to apply state and federal laws 97.2% 85.3% 96.7% and regulations to the practice of pharmacy.

11.The PharmD program prepares students to maintain professional 99.1% 97.0% 90.6% competence.

Surveys of student satisfaction with instructional aspects of the program: Each term the College administers online, anonymous, course and instructor evaluations for all didactic courses.

Results of Instructor Evaluations for Most Recent Term, Fall 2012

(Scale 1= Strongly Disagree, 2= Disagree, 3 = Agree, 4 = Strongly Agree)

Non- Applicable Question Mean Std response Answers

The course covered the material this instructor stated it would in the 119 3648 3.55 0.55 syllabus.

The reading materials assigned for the course facilitated my learning. 298 3469 3.45 0.61

The instructor was available during office hours or by appointment 665 3102 3.54 0.56 when requested.

When students asked the instructor questions, the instructor 116 3651 3.51 0.59 responded in a helpful way.

Students seemed comfortable interacting with and asking questions of 113 3654 3.52 0.59 the instructor.

The instructor was consistently well-prepared for class. 126 3641 3.55 0.58

The instructor was able to explain concepts clearly. 124 3643 3.46 0.63

The instructor facilitated my learning of the subject. 126 3641 3.45 0.63

The instructor’s lectures met the relevant course objectives. 140 3627 3.53 0.56

The instructor clearly identified the learning objectives for his/her 144 3623 3.52 0.58 lectures.

The content provided by the instructor increased my knowledge of the 122 3645 3.49 0.60 topic.

The instructor explained the concepts in a manner that facilitated 126 3641 3.46 0.63 learning.

The instructor's lectures were well-organized. 141 3626 3.50 0.62

The instructor's quiz and exam questions reflected the learning 349 3418 3.45 0.66 objectives.

The instructor regularly checked for student understanding. 161 3606 3.46 0.61

It is apparent from the results of the two surveys shown above that the PharmD program is meeting its learning objectives for students.

3. ARE PROGRAM RESOURCES ADEQUATE? The Dean heads the CoP. There are currently two Associate Deans positions (Research and Academic Affairs). The College consists of two Departments each headed by a Chair. Currently, the Department of Pharmaceutical Sciences consists of 15 full-time tenure-track/tenured faculty, two non- tenure-track instructors, one non-tenure-track Assistant Specialist, and one staff member, located in four buildings on the Island of Hawai’i (Hilo). The tenure-track/tenured faculty members are responsible for teaching the curriculum, performing research in their area of specialty, and providing a variety of committee-based service at the CoP and UH Hilo. The two instructors are integrated in the curriculum and offer laboratory-based practical coursework in pharmacy and genetics. The Assistant Specialist teaches individual classes in her field of expertise, assists in the pharmacy laboratory course, and acts as senior laboratory manager in Dean Pezzuto’s laboratory. One staff position is occupied by the department secretary who reports to the Department Chair and assists faculty in departmental matters on a day-to-day basis. In the Department of Pharmacy Practice, there are currently 19 full-time faculty and two staff members located on four main islands. Fifteen full-time tenure track faculty maintain responsibility for teaching both didactic and experiential/clerkship rotations, maintain active patient care services, and provide service and scholarship activities. Three non-tenure track specialists and one instructor also teach didactic coursework, maintain active practices, and teach in the experiential setting. They also have service responsibilities and some scholar activities. The Department of Pharmacy Practice contains the Office of Experiential Education which employs four individuals. This group oversees all activities related to the experiential/clerkship rotations. There is also a department secretary who reports to the Department Chair.

We have recently hired office assistants in each department who will provide support for the unit secretary.

Currently the CoP has 44 active Affiliate Faculty, many serve as preceptors, but others are UH Hilo faculty in various disciplines. The number of faculty and staff continues to increase. Full staffing will entail about 91 employees and will be achieved by 2014 (see Appendix C).

A biographical one-page summary for all current FTE appointments and can be found in Appendix D.

The Daniel K. Inouye College of Pharmacy is part of the financial management of the UH System. A fiscal officer and an assistant fiscal officer have been retained by the CoP. They help to manage financial matters with the assistance of departmental and administrative secretaries. The CoP budget projections have been prepared to cover the start-up phase through FY2016. The 5-year pro forma budget is shown in Appendix E. At full enrollment, the current level of State appropriation to the CoP and tuition will lead to a balanced budget. We expect any surpluses will be used to enhance the pharmacy program.

The initial annual tuition of the College was set at $15,000 for residents and $30,000 for nonresidents. The current tuition schedule endorsed by the BOR is shown in Appendix F. We have established our own academic calendar such that P4 students working through the summer of their third year are not required to pay additional tuition (i.e., the entire program is eight semesters). The entering class size is 90. Our attrition rate is low. We aim to maintain a student body of 50% residents and 50% nonresidents.

A list of extramural funding received by CoP faculty is summarized in Appendix G. We anticipate growth in this area over the years.

Projections:

The table below shows the total staffing plan, student body, and budget surplus. It is expected any surplus will be utilized for program development. More details are provided in Appendices C, E, and F)

Planned Growth for CoP

2012 2013 2014 2015 2016

Compensated Staff 75 88 91 91 91

Student Body 350 350 350 350 350

Surplus $147,568 $24,172 $162,464 $2,156 $47,348

UH Hilo College of Pharmacy Private Fundraising Update:

As part of the University of Hawai‘i System, CoP continues to partner with the University of Hawai’i Foundation, the private, not-for-profit 501(c)(3) organization which raises private, non-governmental funds on behalf of the UH System. Since beginning private fundraising on behalf of the newly established College of Pharmacy in 2004-2005, the UH Foundation has raised a total of $2,110,615 to date. This represents approximately 10% of total fundraising results ($21,880,698) for the entire UH Hilo campus during that same period. Of the $2.1 million raised, some $282,933 has been directed by donors to be invested in the UH Foundation endowment to provide a permanent source of funding for College of Pharmacy initiatives. The endowment has earned an annualized 8.8% rate of return over the past three years and has paid out 4-5% per year for expenditure in accordance with the terms of donor agreements. Endowed funds currently being invested on behalf of the College of Pharmacy include four endowed scholarship funds and one endowed faculty development fund. In addition to its four permanently endowed scholarships, the CoP has also benefited from an array of 13 annual scholarship funds. Donors include national pharmacy chains (CVS Caremark, Walgreens, Wal-Mart, etc.), as well as local companies (Aloha Shoyu Company), and community members, including retired pharmacists. During 2012-2013, a total of 39 PharmD students are benefiting from private scholarships at the College of Pharmacy.

The corporate community has also been generous in supporting the college through sponsorship of other activities, including the annual White Coat Ceremony (which KTA Super Stores, CVS Caremark and Walgreens have all supported), the Dean’s Welcome Reception, marketing case study competitions, diversity training programs, student job fairs, and the like. Most recently, Target has stepped forward to support a unique student-run mobile health screening clinic targeted at the underserved Pacific Islander population on Hawai‘i Island.

Another role of the UH Foundation—through its Office of Alumni Relations—is to support the work of the volunteer-led UH Alumni Association through membership services, alumni programming and partnerships, and alumni communication. In 2010-2011, the UH Foundation assisted a group of CoP friends and faculty with the formation of a new UH Hilo College of Pharmacy Alumni and Friends Association. Alumni from the first two graduating classes are being encouraged to give back to the college. Despite the fact that they are just getting started in their careers, and many carry significant student loan obligations, CoP alumni are beginning to respond in encouraging numbers. The inaugural Class of 2011, the Class of 2012, and the Class of 2013 raised funds to establish a new

21 student scholarship as their graduation class gifts. As of this date, over 25% of CoP’s first two cohorts of PharmD graduates have already made contributions to the CoP.

The next challenge on the horizon for the CoP is to secure funding for the construction of a permanent building. While primary funding is being sought from the Hawai‘i State Legislature, we are working on supplementing this core funding with private gifts. Named giving opportunities have been crafted by the UH Foundation, with the approval of the UH Board of Regents, and thus far, a total of $98,450 has been contributed toward the building/design fund. This is in addition to the $1 million gift received in 2009-2010 from the J.M. Long Foundation enabling the expansion of the temporary modular facility which the College currently occupies.

Merit Scholarships:

As summarized in Appendix E under revenue, the budget of the CoP has been reduced by about $1,300,000 and the money goes into a scholarship pool. In working with the UHH Financial Aid Committee, some internal resources have been allocated to support CoP students based on merit. For FY2011, the allocation was $225,000. The CoP has created a paradigm in which approximately 25% of this amount was utilized to attract highly competitive students based on merit. The plans allowed us to admit four students, two residents and two nonresidents, who will receive a scholarship that is approximately 50% of the tuition charge. The scholarship will be provided for four years, pending superior performance in the program. In the first three years, the balance of the scholarship allocation will be used to support current students who have demonstrated superior performance. Once the Class of 2014 graduates, equilibrium will be established in which each of the four classes’ will have students who will receive a total of 25% of the allocation. We are confident this program will help us recruit highly competitive students and maintain a robust program. In the current fiscal year, the amount of merit scholarship funding allocated for the CoP was increased to $425,000. We are hopeful further increases will be provided in the future.

Fiscal Administration:

Each Department and major unit in the CoP has been assigned a budget for management. The unit secretary, who reports to the unit director, is primarily in charge, receiving supervision from the college budget officer. Adjustments are being made in the overall budget assignments and categories based on our ongoing experience. We expect after one or two more years of adjustments, the entire process will be stabilized.

Physical Facilities:

Long Term Plan: The College continues to pursue its goal of constructing a state-of-the-art permanent facility. It is estimated that this facility will require an expenditure of approximately $66M. To this end, the state legislature has provided $5.5M in funding to plan this new facility. These funds were released by the Governor and the University on October 31, 2009. On September 9, 2010, the University of Hawai’i named WCIT Architecture of Honolulu to design the permanent home for the College of Pharmacy. Final design plans were completed by December, 2011.

Funding for this building was requested but not provided by the State Legislature in 2012 or 2013. In concert with our University Relations Office, we will continue to be diligent in meeting with our State Representatives and the community-at-large.

Short Term Accommodations: The administrative team, faculty and staff offices are now distributed among the County Annex Building on Rainbow Drive, the College’s Interim Modular Facility on campus, and the Waiakea Research Station south of Hilo. Phase 1-B of the Interim Modular Facility, supported by a generous gift from the J. M. Long Foundation, has added a second 2,190 square foot lecture hall, a 1,680 square foot pharmaceutical compounding teaching laboratory, a pharmacy practice laboratory, a 715 square foot student center for student meetings, and eight faculty offices. Both lecture halls are now equipped with audiovisual and distance learning technologies linking our students to professors on Oahu and Maui (and potentially anywhere worldwide), reducing or eliminating the need for faculty to travel to Hilo to deliver their lectures. These additions have allowed us to consolidate all of our didactic activities at the Interim Modular Facility, and we no longer require use of classroom or laboratory space on campus. The completion of Phase 1-B of the Interim Modular Facility has also allowed us to further consolidate the faculty and staff formerly housed at the Wainaku Executive Center with those at the County Annex and the Interim Modular Facility.

Forestry Building, Nowelo Street: The College continues to lease one laboratory (1,200 square foot) and associated office space in this facility. This laboratory houses the Dean’s research group as well as some instrumentation used by several other faculty members.

County Annex Building: Office space at the County Annex Building on Rainbow Drive currently houses 19 faculty members, including the Chair of Pharmaceutical Sciences, eight staff members and the Pre-Pharmacy Program office. The Dean also maintains his offices in this location. Four

23 conference rooms of varying size and two support rooms are also located in this facility. A Polycom system has been installed in one of the larger conference rooms at this location.

Waiakea Research Station: In addition to research laboratories located at the Interim Modular Facility, the Waiakea Research Station, located five miles south of Campus on Stainback Highway, continues to be a center for much of the research ongoing at the College. This facility houses the research laboratories for 10 of our faculty members as well as a shared instrumentation facility.

While it is clear that having facilities and activities spread across five locations spanning the town of Hilo is somewhat less than optimal, the current situation allows us to move forward with both our teaching and research missions. The faculty, staff, and students all understand that this is a temporary necessity while we work toward our permanent building. The current situation serves to highlight the importance of the construction of a permanent building to consolidate the College’s activities and optimize the relationships of our faculty, staff, and students.

Research Infrastructure: Over the last five and a half years, the College has invested heavily in research equipment and infrastructure in order for our faculty to be competitive with their peers when seeking extramural support. A list of major equipment is summarized in Appendix H. This investment is paying off as the research programs of several of our faculty members have attracted federal grants or foundation support. The College will continue to invest in its research infrastructure to the limits of the available budget in order to provide state of the art laboratory capabilities for all of its faculty members.

IT Infrastructure: The College has invested in upgrading the internet access capabilities throughout the Interim Modular Facility. Upgrading from 100BaseTX to Gigabit Ethernet service and doubling the number of wireless access points throughout the facility has virtually eliminated internet access problems. Our existing one gigabit/sec Ethernet trunk line to campus will be replaced with a 10 gigabit/sec trunk line as soon as the campus line will accommodate it.

Outer island offices and sites: Additional office sites have been added to the various outer islands since there has been placement of faculty to the islands of Oahu (seven faculty), Maui (one faculty) and Kauai (one faculty).

On the island of Oahu, the College maintains an approximately 4,000 square foot facility that houses seven office cubicles for six faculty, three private offices, one conference room, one classroom,and a student lounge. The faculty uses this facility for weekly student seminars in medicine, ambulatory

24 care, retail and hospital experiential rotations for P2, P3, and P4 students. The distance learning technology enables sharing of sessions with Kauai, Hilo and Maui.

On the island of Kauai, faculty member Dr. Roy Goo is currently housed in a temporary space at Wilcox Memorial Hospital and has access to a distance technology classroom at Kauai Community College. Future plans include leasing an approximate 1,000 square foot office that will house an office and small classroom.

On the island of Maui, faculty member Dr. Anita Ciarleglio retains office space and distance learning capabilities at the Maui Community College continuing education department.

As can be seen in the following figure Pharmacy Practice Faculty practice at sites throughout Hawai‘i, on the four major islands, collaborating in the advancement of patient care services. These sites provide both IPPE and APPE rotations.

The figure below shows the IPPE and APPE practice sites across the State of Hawai’i. Students complete IPPE rotations in Hilo during the fall and spring semesters of both P1 and P2. Students can complete the P1 and P2 summer IPPE rotations at various locations throughout the State.

The APPE sites across the mainland and US Territories are shown below. Students have the opportunity to complete APPE rotations with affiliated sites throughout the mainland including the US Territories. Unique learning opportunities are available to students in Guam, American Samoa, and Saipan. Not depicted below is the affiliated site in Bangkok, Chulalongkorn University, where students have the opportunity to complete an international APPE rotation.

4. IS THE PROGRAM EFFICIENT?

Given the unique accreditation requirements of the PharmD degree, comparisons with other programs in the UH System are not feasible. The PharmD program is exceptionally productive, generating nearly $10M per year in tuition revenue, and operating at a surplus which has allowed the program to subsidize less financially viable initiatives. With no additional resources, the College of Pharmacy has leveraged the resources used to deliver the PharmD degree to offer the following additional degrees:

- BA in Pharmacy Studies - PhD in Pharmaceutical Sciences

This portfolio of degree offerings distinguishes the UH Hilo PharmD program from others and demonstrates optimal use of College resources. This thriving scholarly environment has resulted in securing numerous competitive federal grants, including prestigious NIH and NSF grants, as well as over $30M in healthcare transformation grants.

Another indicator of program efficiency is the program’s graduation rate. Presently the CoP has graduated three classes of students, the Class of 2011, 2012 and 2013. At this time the graduation success rate is 95%. Since its beginning the CoP has enrolled 537 students into six cohorts of students and less than 3% of these students have left the program due to personal or academic reasons.

Year Enrolled Left Program Graduated Fall 07-Sp 08 91 3 0 Class of 2011 91 3 0 Fall 08 – Sp 09 178 3 0 Class of 2011 88 3 0 Class of 2012 90 0 0 Fall 09 – Sp 10 267 2 0 Class of 2011 84 0 0 Class of 2012 90 1 0 Class of 2013 91 1 0 Fall 10 – Sp 11 351 3 84 Class of 2011 84 0 84 Class of 2012 89 2 0 Class of 2013 86 1 0 Class of 2014 92 0 0 Fall 11 – Sp 12 353 1 88 Class of 2012 88 0 88 29

Class of 2013 85 0 0 Class of 2014 88 1 0 Class of 2015 92 0 0 Fall 12 – Sp 13 351 1 85 Class of 2013 85 0 85 Class of 2014 84 0 0 Class of 2015 94 1 0 Class of 2016 88 0 0

Application Class of Class of Class of Class of Class of Class of Cycle for the 2011 2012 2013 2014 2015 2016 Total Number 229 1035 1161 1042 1088 888 of Applicants Matriculated 91 90 90 89 89 88 into Program

5. EVIDENCE OF PROGRAM QUALITY

Accreditation or other external evaluation: The CoP PharmD program is fully accredited by the Accreditation Council for Pharmacy Education (ACPE). Full accreditation status is awarded to a program that has met all ACPE standards for accreditation and has graduated its first class. Based upon an on-site visit and thorough review, the UH Hilo College of Pharmacy was granted full accreditation in June 2011 for a period of two years. Continuation will be determined at a future ACPE Board meeting, following a site visit to assess the ongoing progress of the program.

Student performance on external exams: As stated above the NAPLEX is the qualifying exam for pharmacists. Shown in the table below our first time pass rate has increased to 92.86% for the class of 2012. Of the172 students who graduated in 2011 and 2012, 166 have passed the NAPLEX which represents a overall pass rate of 96.5%.

NAPLEX (National Licensing Multistate Pharmacy Jurisprudence Examination) Examination (MJPE)

Calendar School's Candidates National School's Candidates National Year Passing Average Passing Average Rate Passing Rate Passing Rate Rate 2011 81.25% 80 95.95% 91.43% 35 95.61%

2012 92.59% 81 96.93% 92.86% 70 93.14%

Another key indicator of the quality of the PharmD program at UH Hilo is that 95% of students graduate on schedule (i.e., within 4 years).

Student Satisfaction: The CoP results from the AACP survey of graduating students demonstrated that the large majority (81.6% in 2012) of students, after four years in the pharmacy program, would still choose CoP over other schools of pharmacy.

86. If I were starting my pharmacy program over again I would choose the same college/school of pharmacy. 100.0% 80.0% 60.0% 40.0% 20.0% 0.0% CoP 2011 CoP 2012 National 2012 Unable to comment 3.6% 13.8% 3.7% Strongly Disagree 0.0% 0.0% 4.5% Disagree 1.8% 4.6% 8.8% Agree 45.5% 50.8% 42.8% Strongly Agree 49.1% 30.8% 40.1%

Student Awards/Recognitions:

2011:

• Cherie Chu – Mylan Excellence in Pharmacy Award • Jill Gelviro – United States Public health Service Excellence in Public Health Pharmacy Practice Award • Chris Lai Hipp – ASHP Student Leadership Award

2012:

• Wendy Yamasaki-Herring – Mylan Excellence in Pharmacy Award • Prabu Segaran – United States Public Health Service Excellence in Public Health Pharmacy Practice Award • Christopher Lai Hipp - CoP Student Leader of the Year • National Community Pharmacist Association Hawai‘i Chapter - CoP Student Organization of the Year • Shanele Shimabuku - Healthy Eating and Active Living (HEAL) Grant, $16,000  Pacific Islander Mobile Screening Clinic

2013:

• Pacific Islander Mobile Screening Clinic – AACP Student Community Engaged Service Award

• Amanda Nicolas – UH Hilo Ka Lama Ku Student Leadership Recognition Ike Papalua Award: To have the gift of vision • A Life of Healing & Awareness (A.L.O.H.A.) Project - UH Hilo Ka Lama Ku Student Leadership Recognition Laulima Certificate: No task is too big when done by all • Lara Berger, Denise Kobashikawa, Keri Oyadomari – Poster Presentation Honorable Mention, “Pharmacist led protocol for IV to Oral antibiotic switch in an antibiotic stewardship program.” AMCP National Convention • Kappa Psi, Epsilon Psi Chapter – Traveler’s Award, Pacific West Province • William Engen – Mylan Excellence in Pharmacy Award • Marcus Kouma – Natural Medicines Comprehensive Database Recognition Award • Davis Hanai – United States Public Health Service Excellence in Public Health Pharmacy Practice Award • Ann Txakeeyang – Lilly Achievement Award

Student scholarship opportunities and recipients for the 2012-2013 school year are as follows: Community Health Center Success Scholarship in Pharmacy:

The purpose of this award is to provide an annual scholarship to support one UH Hilo College of Pharmacy student through four consecutive years in the Pharm.D. program. To be eligible for consideration students must have graduated from a high school in the state of Hawai’i, be enrolled full time in the UHH CoP Pharm.D. program, and demonstrate financial need. Preference for this award is for students with an interest in pursuing a career as a pharmacist in a community health center setting and with prior volunteer or work experience, preferably in a federally qualified community health center setting, or alternatively in a hospital. The recipient must maintain good academic standing in the College to continue the award for four years.

Recipient: Edwina Leung, Class of 2015

CoP Inaugural Class of 2011 Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a minimum GPA of 3.0 and demonstrate leadership and community service that promotes the CoP. This scholarship is available to second, third and fourth year students only.

Recipient: Nicole Tabandera, Class of 2014

CoP Class of 2012 Scholarship:

Recipient: Christine Lucas. Class of 2013 Steven Nishimoto, Class of 2014

CoP Wal-Mart Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have financial need, a minimum 3.0 GPA, desire to enter community practice upon graduation and demonstrated evidence of leadership. Preference for this award will be for individuals who have 33

achieved high academic standing over the past three years and have previous experience in community practice. The amount of the scholarships will be based on the availability of funds.

Recipient: Mylan Phan, Class of 2013

CVS Caremark:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have an interest and commitment to practice in a retail pharmacy setting upon graduation. This scholarship will not be awarded twice to the same individual. The number and amount of the scholarships will be based on the availability of funds.

Recipients: Angela Li, Class of 2013 Cassie Kim, Class of 2013 Hai Huang, Class of 2014 Antonio Verduzco, Class of 2015 Naoto Oki, Class of 2014 Trina Tran, Class of 2015 Nicole Young, Class of 2015 Michelle-Yen Le-Fisher, Class of 2013 Keith Acab, Class of 2014 James Yi, Class of 2014

Elwin and Valerie Goo Endowed Excellence Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a minimum GPA of 3.5. This scholarship is available to third year and fourth year students.

Recipient: Margaret Kang, Class of 2013

Good Neighbor Pharmacy Scholarship:

The purpose of this award is to provide scholarship assistance for third or fourth year students enrolled in the University of Hawai’i at Hilo College of Pharmacy. Funds shall be used for costs associated with attendance (tuition, books, fees, etc.). Recipients must show academic merit as demonstrated by a minimum cumulative GPA of 2.5, be a student member of the National Community Pharmacists Association for at least six months, and provide evidence of community service. In addition, preference shall be given to past participants of the NCPA Student Business Plan Competition.

Recipient: Nicole Tabandera, Class of 2014

Haga Family Endowed Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Selection will consider both academic merit and financial need. Recipients must have a 3.0 GPA or higher. Preference is given to Big Island High School graduates. The number and amount of the scholarships will be based on the availability of funds.

Recipients: Tasha Medeiros, Class of 2013 Dayna Wong, Class of 2014

Grace Mizuko Miyawaki Pharmacy Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Preference is given to students who have graduated from a high school in Hawai‘i and demonstrates some degree of financial need. The number and amount of the scholarships will be based on the availability of funds.

Recipient: Jarred Prudencio, Class of 2015

Hawai‘i Independent Pharmacies Endowed Excellence Scholarship

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a minimum GPA of 3.5, be a graduate of a high school in the state of Hawai‘i and demonstrate financial need.

Recipient: Reece Uyeno, Class of 2013 Ericson Ganotisi, Class of 2015

J.M. Long Foundation Pharmacy Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo and preference is given to students in their 2nd or 3rd professional year of study. Recipients must have interest in practicing in a retail community setting. The number and amount of the scholarships will be based on the availability of funds.

Recipients: Jillian Wewers, Class of 2015 Stacie Takahashi, Class of 2014 Jaymie Kanda, Class of 2014 Darian Oshiro, Class of 2015 Tracy Ng, Class of 2015 Madison Karr, Class of 2015 Jizan-Anne Evangelista, Class of 2014 Mariko Katagiri, Class of 2014 Shadi Obeidi, Class of 2014 Chi Ngo, Class of 2015

Edwin and Georgiana Kam Endowed Excellence Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a cumulative grade point average of 3.5 or above, be graduates of a high school in the state of Hawai`i, and preference shall be given to recipients who demonstrate creative initiative and exceptional practices utilizing the skills of a student pharmacist to benefit a need in the community as identified through personal essay, clubs,or activities.

Recipients: Jozelle Gabriel, Class of 2015 Melissa Yoneda, Class of 2013

National Association of Chain Drug Stores (NACDS) Foundation Pharmacy Partners Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have interest in pursuing a career in community pharmacy. The number and amount of the scholarships will be based on the availability of funds.

Recipient: Koon Ting, Class of 2014

UH Hilo College of Pharmacy Alumni Association Scholarship

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a 3.0 GPA or higher and demonstrate a strong interest in participating in UHH CoP Alumni Association activities and show leadership and community service that promotes the UH Hilo CoP. This award is available for second, third or fourth year students.

Recipient: Kelly Ishizuka, Class of 2015 Christopher Lai Hipp, Class of 2013

Walgreens Diversity Scholarship:

Scholarships are for full-time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a minimum 2.0 GPA and have demonstrated efforts toward raising awareness and/or educating others of diversity in the Pharmacy profession. This scholarship will not be awarded twice to the same individual. The number and amount of the scholarships will be based on the availability of funds.

Recipient: Shanele Shimabuku, Class of 2013

Aloha Shoyu CoP Scholarship:

Scholarships are for full time students who are pursuing a Pharm.D. degree at UH Hilo. Recipients must have a 3.0 GPA, demonstrate financial need not necessarily as determined by federal guidelines, and must be graduates of a high school in the state of Hawai’i.

Recipient: Kristi Anne Nishek, Class of 2015

UH Hilo College of Pharmacy Merit-Based Scholarship Award:

This prestigious award recognizes exceptional academic achievements. Scholarship recipients are chosen based on a competitive process which takes into consideration academic and leadership success. Awards are available for incoming and current students enrolled full time in the Pharm.D. program.

Recipients: Christopher Kamei, Class of 2013 Victor Lin, Class of 2013 Marcus Kouma, Class of 2013 Tina McDonald, Class of 2013 Prabu Segaran, Class of 2013 Cheryl Lopez, Class of 2013 36

Kaylene Peric, Class of 2013 William Engen, Class of 2013 Alison Kobayashi, Class of 2013 Matthew Sasaki, Class of 2013 May Yu, Class of 2013 Diem le, Class of 2013 Tracy Nakama, Class of 2014 Behnam Rostami, Class of 2014 Maurina Bartlett, Class of 2014 Miho Aoki, Class of 2014 Kyle Kumashiro, Class of 2014 Yan Lin, Class of 2014 Jack Goldsberry, Class of 2014 Jed Sana, Class of 2014 Daniel Kim, Class of 2014 Andy Le, Class of 2014 Keri Oyadomari, Class of 2014 Joanne Daproza, Class of 2014 Andrea Brauer, Class of 2015 Jennie Lim, Class of 2015 LaTasha Riddick, Class of 2015 Daniel Leong, Class of 2015 Akio Yanagisawa, Class of 2015 Davis Hanai, Class of 2015 Jeremy Daube, Class of 2015 Thao Le, Class of 2016 Alexander Guimaraes, Class of 2016 Tina Liu, Class of 2016 Joson Perreira, Class of 2016

Faculty publication record As can be seen from Appendix I the faculty of the CoP have published extensively.

6. ARE PROGRAM OUTCOMES COMPATIBLE WITH THE OBJECTIVES?

Student Job Placement: In addition to the overall placement rates of our PharmD graduates shown below that exemplifies the worth of their degree and education: Twenty-eight are currently in residencies or fellowships, one is attending another professional school, and at least three have obtained jobs in academia. This data clearly indicates that we have fulfilling all six of our Program Objectives.

7.ARE PROGRAM OBJECTIVES STILL APPROPRIATE FUNCTIONS OF THE COLLEGE AND UNIVERSITY?

The PharmD degree is well aligned with both campus and university missions and planning priorities. At UH Hilo, the strategic plan clearly states that it is a core responsibility of the University to improve the quality of life of the people of Hawai‘i, the Pacific region, and the world. Both locally and nationally, there is a significant and growing need for the medication expertise only found in those professionals with a PharmD degree. The cost of medication-related hospitalizations and ER visits in Hawai‘i alone is staggering. According to Hawai‘i Health Information Corporation, the charges to payers for medication-related acute care (hospital and ER) in 2010 were $869,528,960. There is ample evidence in the peer-reviewed literature that adding pharmacists to care teams improves quality and reduces costs. Thus, the PharmD program is critical to improving healthcare in Hawai‘i through expansion of the workforce with needed expertise in medication management. 38

The PharmD program also makes a significant contribution to the UH System strategic outcomes and performance measures. As mentioned previously, the PharmD program offers a pipeline to support Native Hawai‘ians in achieving the PharmD degree. The College of Pharmacy also makes a major contribution to the state’s economy, with economic impact estimated at $50M per year, not including the grants and contracts generated by its faculty.

On top of being the only College of Pharmacy in the state of Hawai‘i, it’s the only one in the Pacific region. As such, our mission includes serving every neighbor island as well as territories through the Pacific. Our vision is to improve health in Hawai‘i and throughout the Pacific and to become a top ranked college of pharmacy – more specifically, in the top 25. Essential to this goal is a strong commitment to research and scholarship.

Hawai‘i and the University’s unique and extraordinary biological, physical and cultural resources are assets to international collaborative research, teaching, and learning. International collaborations have given students an intellectual and cultural enriching experience and increases their marketability worldwide; faculty an expanded platform for both research and teaching; and economic growth opportunities for Hawai‘i and the University.

The College of Pharmacy extends its reach by sending students to conduct clinical rotations in Guam, Saipan, Alaska, and American Samoa. The U.S.-THAI Student Pharmacists and Pharmacists Exchange Program was established in Fall 2011 aiming to promote global health through the exchange of international experiences. The first two student pharmacists visited Chulalongkorn University in Bangkok, Thailand in April 2012. During this six week rotation, the students visited community pharmacies and clinics, both government and private hospitals, along with a traditional Thai medicine pharmacy and patient home visits. The second group of students traveled to Bangkok in November 2012 and the third group of students will visit this upcoming November 2013. A Memorandum of Understanding (MOU) is under discussion for students to conduct rotations at several clinical sites in China. Counter agreements are under review for Chinese students from collaborating Universities to come to CoP’s clinical sites for rotation or clinical observation. Students and research exchanges with Chinese collaborators (e.g. Zhejiang University, Xiamen University, Hainan University, Shanghai Jiaotong University, etc.) are expected to start in Fall 2013. Additionally, CoP has initiated research collaborations and exchanges with a very prestigious Japanese University, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime.

Through educating international students, international research collaboration, and clinical rotation programs, the CoP reaches out to countries and areas that need help in health care development. The importance of pharmacists’ role in health care community has been widely accepted around the world. More and more developing countries are in the process of employing higher standards in Pharmacist educational requirements, and higher degree requirements for pharmacy health professional (similar to the PharmD degree). While centered between the East and the West, College of Pharmacy at UH Hilo is positioned and ready to offer valuable contributions to the larger community through various layers of collaborations.

Through our strategic planning process, careful qualitative and quantitative analyses were conducted, and action plans developed to support the achievement of this vision. It is clear from our analyses that Top 25 pharmacy programs are distinguished from others in research excellence that is reflected in significantly greater research funding1. Accordingly, faculty are recruited with solid credentials and proven track records. They come here with the intent of being associated with a research intensive college and contributing to the achievement of our vision.

In the recent US News and World Report rankings, UH Hilo College of Pharmacy was ranked #74 out of 123 ranked pharmacy programs. Of the 42 new pharmacy programs established in or after 2000, only 3 programs ranked higher than UH Hilo. One of those is in a university that has achieved an undergraduate ranking (#12) as one of the Top Public Schools in the Midwest region. The other two are in universities dedicated exclusively to healthcare. Thus, a ranking of #74 for a pharmacy program in a small, primarily undergraduate institution that is categorized as a Liberal Arts College and not ranked is a significant accomplishment and indication of progress toward our vision. The following charts demonstrate how favorably the UHH College of Pharmacy compares with other ranked programs:

1 Pellegrin KL and Pezzuto JM. Strategic direction for high demand degrees: An analysis of the U.S. pharmacy degree competitive market. International Journal of Management in Education special issue on “Quest for a Competitive Edge in Higher Education”, 2011; Vol. 5 (No. 2/3):285-300. 40

Mean Total Grants Per Year $14,000,000

$12,000,000

$10,000,000

$8,000,000

$6,000,000

$4,000,000

$2,000,000

$0 Top 25 Top 26-50 Top 51-75 UHH CoP Others

Number of Funded Faculty PI 80

Total # funded faculty PI 40 Total FTE faculty

0 Top 25 Top 26- Top 51- UHH CoP Others 50 75

Percentage of Funded Faculty PI 40% 35% 30% 25% 20% 15% 10% 5% 0% Top 25 Top 26-50 Top 51-75 UHH CoP Others

Doctor of Pharmacy (PharmD) Program

The Daniel K. Inouye College of Pharmacy

University of Hawaii - Hilo

A SELF-STUDY IN SUPPORT OF CHANGE FROM PROVISIONAL TO

ESTABLISHED STATUS

Appendices

Appendix A

Employment of the PharmD graduates UHH-CoP GRADUA EMPL TION EMPLOYER OYER Name YEAR EMPLOYER POSITION CITY STATE EMPLOYER PRIMARY PRACTICE Edlynne K. Akana 2011 Waianae Coast Comp. Health Ce Pharmacist Waianae HI Clinic Based Pharmacy Jason J. Braithwaite 2011 Intermountain Health Care PGY2 Pharmacy AdminSalt Lake City UT Other Dan Feng Cai 2011 Kmart Pharmacy Pharmacist Chehallis WA Chain Community Pharmacy Cheri H.L. Chu 2011 Queen's Medical Center Staff Pharmacist Honolulu HI Hospital Zoe K. Chun-DeLa Cruz Dante 2011 Kapiolani Community College Instructor HI Academia Benjamin J. Cloud 2011 Indian Health Service Clinical Pharmacist San Carlos AZ Government/Regulatory Agency Natalie G Codianne 2011 CVS/Caremark Pharmacist CA Chain Community Pharmacy Marcus R. Cressal 2011 Roe RX Valley Market Pharmacy Pharmacist Eden UT Independent Community Pharmacy Ben R. Curry 2011 CVS/Caremark Pharmacist CA Chain Community Pharmacy Krystin A. Duong 2011 Omnicare Clinical Consultant Chico CA Consultant Han N. Duong 2011 Santa Clara Valley Health & HospPharmacist Locum TenSan Jose CA Hospital Robert D. Esteban 2011 Healthsouth Desert Canyon RehaStaff Pharmacist Las Vegas NV Hospital Angelina M. Eustaquio 2011 Guam Memorial Hospital GUAM Hospital Steven J. Evans 2011 CVS/Caremark Pharmacist Kailua-Kona HI Chain Community Pharmacy Ken H. Everly 2011 Walgreens Pharmacist Hilo HI Chain Community Pharmacy Ashley Ann NHL Fukumae 2011 CVS/Caremark Pharmacist CA Chain Community Pharmacy Rovigel J. Gelviro 2011 U.S. Public Health Service-South Advanced Clinical Pha Anchorage AK Government/Regulatory Agency Lisa Mei Hagiwara 2011 Corner Pharmacist Staff Pharmacist Honolulu HI Independent Community Pharmacy Paul A. Haiola 2011 GE Nuclear TX Other Garrett T. Hand 2011 Naval Branch Health Clinic Clinical Pharmacist CT Clinic Based Pharmacy Danita Dee Henley 2011 UHH CoP MSCP Clinical Coordin Hilo HI Academia Jenny L. Higa 2011 Retail Pharmacy on Oahu Pharmacist Waipahu HI Chain Community Pharmacy Ashley L. Hori 2011 Menehune Pharmacy Pharmacist HI Independent Community Pharmacy Jenice R. Jacobs 2011 Safeway Float Pharmacist Anchorage AK Chain Community Pharmacy Madelina E. Jimenez 2011 Fred Meyer Pharmacist AK Chain Community Pharmacy Elissa-Marie E.K. Kahahane 2011 KTA Superstores Relief Pharmacist Kamuela HI Independent Community Pharmacy Sarah A. Kaufman 2011 CVS/Caremark Pharmacist IL Chain Community Pharmacy Ben Laurent 2011 Safeway Pharmacist Bellevue WA Chain Community Pharmacy Ellen Ann Loney 2011 Safeway Pharmacy Manager Kahului HI Chain Community Pharmacy Daniel A. Lupi 2011 Walgreens Pharmacist Kenosha WI Chain Community Pharmacy Harikela Mano 2011 PharMerica Consultant FL Nursing home/long-term care facility Annie M. Mar 2011 Walmart Pharmacist CA Chain Community Pharmacy Michael Maradik 2011 CVS/Caremark Pharmacist Chain Community Pharmacy Ryan A. Mashiyama 2011 Safeway Pharmacist Hilo HI Chain Community Pharmacy Mandy J. Medina 2011 Target Pharmacy Manager Visalia CA Chain Community Pharmacy Holly N. Miracle 2011 K-VA-T Food City Pharmacist TN Chain Community Pharmacy Erika M. Miyahira 2011 Safeway Pharmacist HI Chain Community Pharmacy Bradley K. Miyashiro 2011 Seattle Children's Hospital Seattle WA Hospital Ross A. Murakami 2011 Castle Medical Staff Pharmacist HI Hospital Nelson Nakatsu 2011 Hilo Medical Center Pharmacist Hilo HI Hospital Paul B. Narciso 2011 Lihue Pharmacy Pharmacist HI Independent Community Pharmacy Daniel A. Navas 2011 Maui Memorial Medical Center Staff Pharmacist Wailuku HI Hospital Hong Phuc T. Ngo 2011 Rite Aid Pharmacist Antioch CA Chain Community Pharmacy Yen T. Ngo 2011 Walgreens Registered Pharmacist Peoria IL Chain Community Pharmacy Lindsey Y Nikaido 2011 Medipharm Pharmacy Pharmacist Honolulu HI Independent Community Pharmacy Jennifer J. Nikitin 2011 Walgreens Pharmacist Phoenix AZ Chain Community Pharmacy Stan Nikitin 2011 Walgreens Pharmacist Avondale AZ Chain Community Pharmacy Wilson Nyagassa Njinuwo 2011 SINA RX Relief Pharmacist Dallas TX Independent Community Pharmacy Seul-Ki "Hannah" Noh 2011 Mina Pharmacy Pharmacist HI Independent Community Pharmacy Casey K. Ogata 2011 Kapiolani Medical Ctr. For WomenStaff Pharmacist Honolulu HI Hospital Rochelle R Oledszki 2011 CVS/Caremark Midnight Pharmacist Portage IN Chain Community Pharmacy Tehane C. Ornellas Han 2011 Mina Pharmacy Pharmacy Manager HI Independent Community Pharmacy Ambrish N. Patel 2011 K-Mart Pharmacist NM Chain Community Pharmacy Kaitlan M. Pham-Ngo 2011 Standard Homeopathy Staff Pharmacist King of Prussia PA Other Mark D. Reeves 2011 Walgreens Pharmacist IL Chain Community Pharmacy Enoch John G. Ronduen 2011 Walmart Staff Pharmacist Eagle River AK Chain Community Pharmacy Zachery L. Royer 2011 Safeway Pharmacist Gresham OR Chain Community Pharmacy Tiffany Pualei Santore 2011 Foodland Pharmacist-Manager Hilo HI Independent Community Pharmacy Marisa N. Schroeder 2011 Safeway Pharmacist Kailua-Kona HI Chain Community Pharmacy Amber L. Schwarz 2011 CVS/Caremark Staff Pharmacist Phoenix AZ Chain Community Pharmacy Megan Solava 2011 Walgreens Pharmacist IL Chain Community Pharmacy Curtis T. Start 2011 Walgreens Pharmacist MI Chain Community Pharmacy Adrienne S. Start 2011 VA Ann Arbor Healthcare System Clinical Pharmacist Ann Arbor MI Clinic Based Pharmacy Keegan Sugimoto 2011 Walgreens Pharmacist HI Chain Community Pharmacy Quinn K. Taira 2011 PharmaCare Pharmacist Honolulu HI Home Care Eugene Talatala 2011 Pfizer Safety Surveillance AssBridgewater NJ Pharmaceutical Industry Jonathan M. Tam 2011 Safeway Pharmacy Manager Pleasant Hill CA Chain Community Pharmacy Cari T. Tamiko 2011 KTA Superstores Relief Pharmacist Kamuela HI Independent Community Pharmacy Trenton D. Teruya 2011 Foodland Pharmacy Manager Kapolei HI Independent Community Pharmacy Jessica P. Toyama 2011 Walgreens Pharmacist Wahiawa HI Chain Community Pharmacy Namrata U. Trivedi 2011 Johns Hopkins Staff Pharmacist Baltimore MD Hospital Ryan T. Trombley 2011 Safeway Pharmacy Manager HI Chain Community Pharmacy Venata P. Tsonev 2011 Palos Community Hospital IL Hospital Cody A. Walker 2011 The Pharmacy at Park City Clinic Pharmacist in Charge Park City UT Clinic Based Pharmacy Nikki S. Warner 2011 Marsh Pharmacist IN Chain Community Pharmacy Jim B. Wassel 2011 Walmart Pharmacy Manager Jackson CA Chain Community Pharmacy Ismail Abdolahi 2012 Puna Pharmacy Staff Pharmacist Pahoa HI Independent Community Pharmacy Justin Arias 2012 PETNet Solutions/ Siemens MedicNuclear Pharmacist Irvine CA Other Jake Bachino 2012 Target Executive Staff PharmaSanta Maria CA Chain Community Pharmacy Chaz K. Barit 2012 VA Pacific Island Health Care Ser Resident Pharmacist Honolulu HI Clinic Based Pharmacy Lauren Emily Brunke 2012 Eli Lilly & Company Visiting Scientist Indianapolis IN Pharmaceutical Industry Thomas Anh Bui 2012 Walgreens Pharmacist San Jose CA Chain Community Pharmacy Candice Marie Carbaugh 2012 CVS/Caremark Pharmacy Manager Philadelphia PA Chain Community Pharmacy Irene Chaisri 2012 Walgreens Pharmacist CA Chain Community Pharmacy Lawrence Yapui Chan 2012 Walgreens Pharmacist CA Chain Community Pharmacy Megan Ching 2012 Kaiser Permanente Northwest HeStaff Pharmacist Portland OR Clinic Based Pharmacy Aaron C. Chun 2012 KTA SuperStores Pharmacist HI Independent Community Pharmacy Derek Anthony Dominguez 2012 Medical Arts Pharmacy Graduate Intern/PharmUpland CA Other Lauren R. Etienne 2012 Children's Hospital New Orleans Pharmacist New Orleans LA Hospital Catherine J. Fadrowsky 2012 CVS/Caremark Pharmacist-in-Charge Reno NV Chain Community Pharmacy Raeanne Georgette Fuller 2012 Phoenix Indian Medical Center Pharmacy Resident Phoenix AZ Hospital Carol Lynn Gah Yan Goo 2012 CVS/ Caremark Staff Pharmacist Los Angeles CA Chain Community Pharmacy Kyle Tadami Higuchi 2012 Safeway Pharmacy Pharmacy Manager Kailua Kona HI Richelle Yoshimi Hirata 2012 CVS/ Caremark Staff Pharmacist Keaau HI Chain Community Pharmacy Lee Quang Hoang 2012 Rite Aid Pharmacist Los Angeles CA Chain Community Pharmacy Daniel Hu 2012 FDA Office of Minority Health Health Disaprities FelloHilo HI Other Alice Hwang 2012 Walgreens Pharmacist Wahiawa HI Chain Community Pharmacy Brian Thomas Jacoway 2012 Kent's Pharmacy Pharmacist Brigham City UT Independent Community Pharmacy Peter Sungsu Jo 2012 Albertson's/Supervalu/Sav-on Pharmacist Seattle WA Chain Community Pharmacy Marisa J. Kaluhiokalani 2012 Kaiser Pharmacy Resident Honolulu HI Hospital Susan J. Kang 2012 CVS/Caremark Pharmacist San Diego CA Chain Community Pharmacy Daralynn M. Kawamoto 2012 Walgreens Grad intern/PharmacistBoise ID Chain Community Pharmacy Amanda J. Kelley 2012 CVS/Caremark Staff Pharmacist Dallas PA Chain Community Pharmacy Paul Sae-Hon Kim 2012 Diplomat Specialty Pharmacy Pharmacist, CHD Flint MI Other Christine Ann Knecht 2012 Albertson's Pharmacist Phoenix AZ Chain Community Pharmacy Kari Kimie Kurihara 2012 CVS/Caremark Pharmacist Honolulu HI Chain Community Pharmacy Paige Akiko Tejada Kurosawa 2012 Foodland Pharmacist HI Independent Community Pharmacy Kelly Pui Ling Kwok 2012 Walgreens Pharmacist Honolulu HI Chain Community Pharmacy Linh Ngoc Lieu 2012 CVS/Caremark Pharmacist San Diego CA Chain Community Pharmacy Alicia Loh 2012 Walgreens Pharmacist San Francisco CA Chain Community Pharmacy Daniel Loo 2012 Safeway Staff Pharmacist Hilo HI Chain Community Pharmacy Angelina Marie Lovell 2012 Walgreens Staff Pharmacist Anchorage AK Chain Community Pharmacy Denise Matsuoka 2012 Times Supermarket Pharmacist HI Independent Community Pharmacy David S. McBride 2012 Walgreens Staff Pharmacist Safford AZ Chain Community Pharmacy Meghan Ashley Mitchell 2012 North Memorial Pharmacist Robbinsdale MN Hospital Tanya Ann Moore 2012 CVS/Caremark Pharmacist Surprise AZ Chain Community Pharmacy Hugh Nguyen 2012 Rite Aid Pharmacist Chain Community Pharmacy Brian Kazumi Niimi 2012 Queen's Medical Center Pharmacy Resident Honolulu HI Hospital Soang Nong 2012 Rite Aid Pharmacist Bellevue WA Chain Community Pharmacy Craig Michael Nutter 2012 Rite Aid Pharmacist Norwalk OH Chain Community Pharmacy Ana Park 2012 CVS/Caremark Pharmacist Northridge CA Chain Community Pharmacy Alexandra Marie Perez 2012 The Queen's Medical Center Pharmacy Resident Honolulu HI Hospital Van-Quyn Thuy Phan 2012 CVS/Caremark Staff Pharmacist San Diego CA Chain Community Pharmacy Jeffrey Gene Retter 2012 CVS/Caremark Staff Pharmacist Roseville CA Chain Community Pharmacy Shantelle Renee Robinion 2012 5 Minute Pharmacy Pharmacist Waipahu Hi Independent Community Pharmacy Anthony Scott Rowley 2012 Rite Aid Pharmacist San Diego CA Chain Community Pharmacy Narges Shansab 2012 Davita Pharmacist TX Other Kelly Ann Sleeper 2012 CVS/Caremark Pharmacist Minneapolis MN Chain Community Pharmacy Roseann Holly Svec 2012 Kmart Pharmacy Manager El Paso TX Chain Community Pharmacy Chad Yasuo Tamashiro 2012 CVS/Caremark Pharmacist Los Angeles CA Chain Community Pharmacy Bryceson P. Tanaka 2012 CVS/Caremark Grad intern/PharmacistSan Diego CA Chain Community Pharmacy Anthony Thai 2012 Phoenix VA Medical Center Pharmacy Resident Phoenix AZ Hospital Sally Van 2012 Walgreens Part-time Pharmacist HI Chain Community Pharmacy Brian Khoi Vo 2012 Rite Aid Pharmacy Manager La Habra CA Chain Community Pharmacy Chee Vue 2012 Kaiser Pharmacist Fresno CA Hospital Jeremy Thomas Watson 2012 CVS/Caremark Pharmacist in Charge (Houston TX Chain Community Pharmacy Jessie Wong 2012 Walgreens Registered Pharmacist Corona CA Chain Community Pharmacy Wendy Ann Yamasaki-Herring 2012 Walgreens Pharmacist HI Chain Community Pharmacy Allison Akemi Yamashiro 2012 Kapiolani Women's and Children'sPharmacist Honolulu HI Hospital Jenna Mieko Yamashita 2012 CVS/Caremark Pharmacist Pahoa HI Chain Community Pharmacy Marina Yeh 2012 Walgreens Floater Pharmacist Honolulu HI Chain Community Pharmacy Jeffrey Ryan Abeyta 2013 Shopko Assistant Pharmacy MaMurray UT Chain Community Pharmacy Kurt William Adkins 2013 Fry's Pharmacy Pharmacist AZ? Chain Community Pharmacy Karen S. Darling 2013 Kmart Pharmacist in Charge The Dalles OR Chain Community Pharmacy Michael Deal 2013 Kmart Staff Pharmacist Hoffman Estate IL Chain Community Pharmacy William J. Engen 2013 Walgreens Pharmacist Fort Collins CO Chain Community Pharmacy Jackwayne Sayno Fernandez 2013 CVS/Caremark Staff Pharmacist Honolulu HI Chain Community Pharmacy Ryan Castillo Gaspar 2013 Costco Grad intern Kailua Kona HI Chain Community Pharmacy Nargis Hassan 2013 Walgreens Pharmacist Berkeley CA Chain Community Pharmacy Louis Duy Huynh 2013 Walmart Pharmacist San Diego CA Chain Community Pharmacy Christopher Akio Kamei 2013 CVS/Caremark Pharmacist Honolulu HI Chain Community Pharmacy Brendan Frank Iwao Katahara 2013 Safeway Pharmacist Honolulu HI Chain Community Pharmacy Cassie Leigh Kim 2013 VA Southern Nevada Healthcare SPharmacy Resident Las Vegas NV Clinic Based Pharmacy Todd H. Kitamori 2013 Kmart Grad intern/PharmacistEl Paso TX Chain Community Pharmacy Alison Lehua Kobayashi 2013 Walgreens Pharmacist Wailuku HI Chain Community Pharmacy Marcus Kouma 2013 Mann-Grandstaff VA Center Pharmacy Resident Spokane WA Hospital Christopher I. Lai Hipp 2013 Scripps Mercy Medical Center Pharmacy Resident San Diego CA Hospital Aaron Cody Lani 2013 Walgreens Grad intern/PharmacistHonolulu HI Chain Community Pharmacy Alexander E. Latif 2013 Northshore Pharmacy Pharmacist Kilauea HI Independent Community Pharmacy Diem Hong Le 2013 Walgreens Grad intern/PharmacistTorrance CA Chain Community Pharmacy Victor Wang Lin 2013 St. Luke's - Roosevelt Hospital CePGY1 Pharmacy ResidNew York NY Hospital Anqi Liu 2013 Safeway Floater Pharmacist Seattle WA Chain Community Pharmacy Wenbo Liu 2013 Walmart Grad Intern/Pharmacis Fresno CA Chain Community Pharmacy Cheryl Magbual Lopez 2013 Target Executive Pharmacist Los Angeles CA Chain Community Pharmacy Christine A.F. Lucas 2013 Walmart Pharmacist San Jacinto CA Chain Community Pharmacy Brynn Nicole Macumber 2013 Walgreens Staff Pharmacist Chandler AZ Chain Community Pharmacy Tina Marrie K. McDonald 2013 The Queen's Medical Center Pharmacy Resident Honolulu HI Hospital James Patrick Montague 2013 CVS/Caremark Staff Pharmacist Phoenix AZ Chain Community Pharmacy Ahmad Musheinesh 2013 CVS/Caremark Pharmacist Allen Park MI Chain Community Pharmacy Christine Nguyen 2013 VA Roseburg Pharmacy Resident Roseburg OR Hospital Jason Akira Okazaki 2013 Costco Pharmacist Honolulu HI Chain Community Pharmacy Kaylene Mariko Peric 2013 St. Vincent Indianapolis PGY1 Resident Indianapolis IN Hospital Mylan Thi Phan 2013 Walgreens Pharmacist Chain Community Pharmacy Tyler Jon Prescott 2013 Kinney Drugs Staff Pharmacist Morrisville VT Chain Community Pharmacy Brandon Kyle Reiss 2013 Target Pharmacist Oakland County MI Chain Community Pharmacy Nicole Lynn Schauer 2013 Walgreen's Staff Pharmacist Denver CO Chain Community Pharmacy Prabu Raman Segaran 2013 Providence St Peter Resident Olympia WA Hospital Jordan James Shibata 2013 Safeway Pharmacist Wailuku HI Chain CommunityPharmacy Shanele Shimabuku 2013 Hawaii Pacific Health Pharmacy Resident Lihue HI Hospital Adam Ross Stockdale 2013 Walmart Pharmacist Sequim WA Chain Community Pharmacy Michael E. Taylor 2013 Pharm2Pharm Hospital Community PhLihue HI Hospital Anh Quynh Truong 2013 Walgreens Pharmacist Fresno CA Chain Community Pharmacy Michael Setsuo Tsuji 2013 VA Pacific Islands Health Care SyPharmacy Resident Honolulu HI Clinic Based Pharmacy Robert Veilleux 2013 Walmart Pharmacist Richmond CA Chain Community Pharmacy Lindsay Vonotten 2013 Meijer Pharmacist floater Canton MI Chain Community Pharmacy William Joshua Walker 2013 Walgreen's Pharmacist Eugene OR Chain Community Pharmacy Melissa Kori Yoneda 2013 Hawaii Pacific Health - wilcox MemPharmacy Resident Lihue HI Hospital

Appendix B

Map of Program Outcomes Appendix B.xls

University of Hawaii – Hilo Pharmacy Professional Degree Outcomes

PHPP PHPP PHPP PHPS PHPS PHPS PHPS PHPS PHPP PHPP PHPS PHPP PHPS PHPS PHPP PHPP PHPP PHPP PHPS PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPP PHPS PHPP AmCare Hospita Medicin Retail Domain I. General Ability-Base Outcomes Drug 501 511 501 503 504 505 512 502 508 502 510 506 509 506 503 514 515 511 Comm. 504 516 520 523 598 505 517 522 525 518 521 591 524 540 l e 541 Info Competency A. Critical Thinking and Problem Solving P1 Fall P1 Spring Summer P2 Fall P2 Spring Summer P3 Fall P3 Spring P4 1. Identify, retrieve, and evaluate information to make 1233222 132 222 33322 3 23 2233 32 3222 2 4 4 4 4 informed decisions. 2. Solve complex problems within the context of Learning 21 312 1 22 222 1 322 1 2233 22 32 22 2 4 4 4 4 scientific, clinical, legal, social, cultural, ethical issues. Outcomes 3. Apply and integrate biomedical, pharmaceutical, and clinical science knowledge to solve pharmacy practice 12 312 3 121 13 122 3 2 31 32 32 22 4 4 4 4 related problems. Competency B. Communication 1. Demonstrate the ability to read and listen effectively. 1 2 1 2 2 2 2 1 2 2 2 2 2 2 3 2 2 2 3 2 3 2 2 4 3 3 2 2 2 3 2 2 4 4 4 4 2. Demonstrate speaking and writing communication Learning skills appropriate to the practice of pharmacy in various 2 2 3332 2 23 2 44 32 3233 4 4 4 4 Outcomes audiences and settings. 3. Use technology to effectively facilitate communication. 2 1 3 2 2 2 3 3 2 4 4 4 4 Competency C. Ethical Decision Making 1. Demonstrate respect for the values involved in the 2 2 33 2 13 2343 32 32 4 4 4 4 decision making of others. Learning 2. Make and defend rational, ethical decisions. 32211 23233232 24444 Outcomes 3. Apply ethical standards to decision-making as a 3323334444 pharmacist and a pharmacy leader. Competency D. Professional and Social Responsibility 1. Demonstrate sensitivity and tolerance within 22 2 2 23 1 23 32 3 3322 4 4 4 4 multicultural interactions and settings. 2. Demonstrate social skills required for professional 11232332333224444 effectiveness. 3. Apply cultural competencies in professional 2232332333224444 Learning behaviors. Outcomes 4. Demonstrate community responsibility through 22 134 4 4 community services. 5. Demonstrate leadership abilities through involvement 134 4 4 4 4 in health and human service initiatives. 6. Advocate improved professional approaches to meet 134 4 4 4 pharmacy-related needs. PHPP PHPP PHPP PHPS PHPS PHPS PHPS PHPS PHPP PHPP PHPS PHPS PHPS PHPS PHPP PHPP PHPP PHPP PHPS PHPP PHPP PHPP PHPP PHPP PHPS PHPP PHPP PHPP PHPP PHPP PHPP PHPS PHPP Hospita Medicin II. Professional Practice-Based Outcomes Drug AmCare Retail 501 511 501 503 504 505 512 502 508 502 507 506 509 506 503 514 515 511 Comm. 504 516 520 523 598 505 517 522 525 518 521 591 524 l e Domain Info Competency D. Professional and Social Responsibility P1 Fall P1 Spring Summer P2 Fall P2 Spring Summer P3 Fall P3 Spring P4 7. Promulgate a philosophy of caring within healthcare 22 2 1 2 3 2 134 3 3 2 4 4 4 4 Learning settings. Outcomes 8. demonstrate the ability to evaluate and modify 33 23 32 3 32 4 4 4 4 interpersonal behaviors for effective social interactions. Competency E. Self-Learning Abilities 1. Identify areas of deficiency and effective strategy for Learning 12332 2 2 222 2 22 2 3 2 2 1 2 3 43 3 3 2 2 4 4 4 4 improvement. Outcomes 2. Engage in active, self-directed, life-long learning. 2 3 2 2 2 2 2 2 2 2 2 2 3 2 2 1 4 3 3 3 2 2 4 4 4 4 Competency A. Provide Pharmaceutical Care 1. Gather and organize patient-specific data, scientific Learning literature, outcomes, and pharmaceutical products 21 2 2 2 33 222 3 13 2 11 32 32 22 2 4 4 4 4 Outcomes effectively. 2. Identify ongoing or potential drug-related problems 212 2 2 13 22 1 3 2 11 32 3222 4 4 4 4 and the root cause of the problems. 3. Interpret/evaluate data needed to prevent/resolve 23 22 13221 32113232224444 medication-related problems. 4. Implement changes in the pharmaceutical care plan 2 22 13 221 32 11 32 3222 44 44 based upon drug-related problems. 5. Formulate and implement a pharmaceutical care plan through collaboration with healthcare professionals and 222 1 21132 2 4444 the patient in a variety of healthcare settings. 6. Continuously reevaluate and adjust the pharmaceutical 22 1 2 11 32 2 4 4 4 care plan to ensure optimal outcomes. Appendix B.xls

7. Accurately and completely document pharmaceutical care activities in a medical record to facilitate 112211324444 collaboration among providers and serve as a record for billing pharmaceutical care service. 8. Display the attitudes, habits, and values required to 2 232113221122322 4444 render pharmaceutical care. 9. Apply knowledge and skills in the science and practice of pharmacy in order to function as a 2 2 22 2 1 3 22 1 3 2 21 2 2 32 2 2 4 4 4 4 professional pharmacist in a variety of pharmacy environments. 10.Demonstrate competencies of an entry-level practitioner to deliver pharmaceutical care to various 22 12 21 2411231224444 patient populations. PHPP PHPP PHPP PHPS PHPS PHPS PHPS PHPS PHPP PHPP PHPS PHPS PHPS PHPS PHPP PHPP PHPP PHPP PHPS PHPP PHPP PHPP PHPP PHPP PHPS PHPP PHPP PHPP PHPP PHPP PHPP HPS PHPP Hospita Medicin II. Professional Practice-Based Outcomes Drug AmCare Retail 501 511 501 503 504 505 512 502 508 502 507 506 509 506 503 514 515 511 Comm. 504 516 520 523 598 505 517 522 525 518 521 591 524 l e Domain Info Competency B. Management P1 Fall P1 Spring Summer P2 Fall P2 Spring Summer P3 Fall P3 Spring P4 1. Manage pharmacy operations, medication distribution 111233 and control systems. 2. Manage human resources. 11 2 3. Manage facilities and equipments. 1112333 4. Manage fiscal resources. 11 3 2 2 5. Manage and market change in response to professional 14 4 2 2 evolution. 6. Participate in the pharmaceutical care system's process Learning for: Outcomes a. reporting and managing medication errors and 111112211124444 adverse drug reactions. b. conducting drug use evaluations. 12 1 11 1 24444 7. Participate in the development, implementation, 113124 evaluation, and modification of a formulary system. 8. Apply principles of pharmacoeconomics and health outcomes research/quality assessment to evaluate 111123 pharmaceutical care plans and pharmacy services. Competency C. Promote Public Health 1. Provide emergency care within the scope of pharmacy 111 1 2 4 4 Learning practice. Outcomes 2. Promote public awareness of health, wellness, 22213211341213234444 prevention and disease management. Competency D. Provide Drug Information and Education 1. Provide evidence-based pharmaceutical and health- related information to health professionals and the 2222223234113224444 public. 2. Design , develop , and/or present educational material Learning 24113333443 to various audiences and settings. Outcomes 3. Provide education based upon applying the knowledge of social and behavioral sciences to address the human 2223234134444 responses to pharmaceutical and health-related therapeutics.

Appendix C

Staffing of the CoP UHH-COLLEGE OF PHARMACY PAYROLL PLAN 2010-2017 Department FY12 FY13 FY14 FY15 FY16 Administration Faculty 6 7 7 7 7 Staff 3 7 7 7 7 Temporary 3 4 4 4 4 Other 1 1 1 1 1 Research Faculty 2 2 2 2 2 Staff 4 4 4 4 4 Academic Affairs Faculty 2 2 2 2 2 Staff 5 5 5 5 5 Pharmacy Practice Faculty 19 24 25 25 25 Staff 2 3 3 3 3 Pharmaceutical Science Faculty 16 16 18 18 18 Staff 1 2 2 2 2 Student 10 10 10 10 10 Pre- Pharmacy Staff 1 1 1 1 1

TOTAL 75 88 91 91 91

SUMMARY BY GROUP FY12 FY13 FY14 FY15 FY16 Faculty 45 51 54 54 54 Staff 16 22 22 22 22 Temporary 3 4 4 4 4 Other 1 1 1 1 1 Student 10 10 10 10 10

Appendix D

Faculty Biographical Sketches Research Focus ‐ Department of Pharmaceutical Sciences

Natural Products Drug Discovery

Molecular and Cell Biology Medicinal Chemistry

Cancer ‐ Malaria ‐ Cardiovascular Disease Neurodegenerative Disorders ‐ Tuberculosis Department of Pharmaceutical Sciences

 André S. Bachmann Department Chair Associate Professor  Robert P. Borris Associate Dean for Research Associate Professor  Leng Chee Chang Assistant Professor  Mahavir B. Chougule Assistant Professor  Linda Connelly Assistant Professor  Jean Cruz Secretary  Edward Fisher Associate Dean for Academic Affairs Professor  Daniela Guendisch Assistant Professor  Aaron T. Jacobs Assistant Professor  Susan I. Jarvi Director, Pre-Pharmacy Program Associate Professor  Tamara P. Kondratyuk Assistant Specialist & Laboratory Manager  Dana-Lynn T. Koomoa-Lange Assistant Professor  Kenneth R. Morris Professor  Anthony J. Otsuka Instructor  Mimi F. Pezzuto Instructor  Dianqing Sun Assistant Professor  Ghee T. Tan Assistant Professor  Gary R. Ten Eyck Assistant Professor  Anthony D. Wright Associate Professor

Faculty André S. Bachmann

Department Chair and Associate Professor Pharmaceutical Sciences

[email protected]

André S. Bachmann, Associate professor and Chairman of the Department of Pharmaceutical Sciences, studies polyamine inhibitors and proteasome inhibitors that affect the proliferation of cancer. Much of his research is providing new insights into neuroblastoma and other pediatric forms of cancer. Bachmann has been studying ODC, a protein that often is over‐expressed in cancer. He has shown that this protein promotes neuroblastoma tumor growth, while a specific inhibitor of ODC called DFMO promotes cancer cell death.Bachmann's lab also is studying the molecular mechanisms of cell death in neuroblastoma, with the goal of trying to identify novel, natural product‐derived drugs that inhibit these processes. Bachmann has advanced his laboratory research with DFMO to the clinic which led to phase I (2010) and phase II (2012) clinical trials with relapsed neuroblastoma patients (ongoing), in collaboration with Giselle Sholler and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) at the Helen DeVos Children’s Hospital in Grand Rapids, MI.

Education  M.S., Microbiology, University of Zurich, Switzerland  Ph.D., Biology, University of Zurich, Switzerland  Postdoctoral Fellow with Karin Moelling, Molecular Oncology & Medical Virology, University of Zurich, Switzerland

Classes & Courses  PHPS 598 Cancer Prevention (Course Coordinator and Lecturer)  PHPS 703 Cancer Cell Biology (Lecturer)

Active Grants  R01 , National Cancer Institute (NCI), NIH  Hawaii Community Foundation (HCF)

Selected Peer‐Reviewed Publications  Oncogene, 2005, 24(36):5606‐18  Clinical Cancer Research, 2007, 13(21):6312‐9  Cancer Research, 2008, 68(23):9825‐31  Nature, 2008, 452(7188):755‐8  Molecular Cancer Therapeutics, 2009, 8(7):2067‐75  PNAS, 2009, 106(16):6507‐12  International Journal of Cancer, 2010, 126(9):2012‐24  Biochemical Pharmacology, 2010, 80(2):170‐8  Biochemistry, 2012, In press  International Journal of Oncology, 2012, In press

Awards and Honors  Swiss National Science Foundation Award, 1994  Siemens National Mentor Award, 2007  Inaugural Weinman Award for Translational Research, 2010

Selected News Releases  Star Bulletin, Honolulu, April 27, 2008  Star Advertiser, Honolulu, June 26, 2010  Tribune Herald, Hilo, August 31, 2010  Tribune Herald, Hilo, March 7, 2012 Faculty

Robert P. Borris

Associate Dean of Research and Associate Professor Pharmaceutical Sciences

[email protected]

Robert P. Borris, Associate Professor of Pharmaceutical Sciences and Associate Dean for Research, is a veteran natural products chemist with extensive experience in new drug discovery and development. His current research focuses primarily on the chemistry of terrestrial plants and microorganisms. A major focus of the Borris lab is an investigation of the changes in expression of plant metabolites in response to change in the local environment. The goal of this work is to develop a sensitive and non‐destructive means for monitoring environmental change before that change is manifest in decline of the local flora. A second major focus of the Borris lab is the discovery of new, biologically active, plant metabolites. In collaboration with Dennis Stevenson and Daniel Atha of the New York Botanical Garden, J.C.S.Pretorius of the University of the Free State (Bloemfontein, South Africa), P.C. Zietsman of the National Museum (Bloemfontein, South Africa), and Manana Khutsishvili of the Georgian Academy of Sciences (Tbilisi, Georgia), as well as other faculty members at UHH, this group is exploring terrestrial plants as a source of potential drug leads for a range of human and veterinary diseases. Within the lab, the chemotherapy of drug resistant microorganisms is a major interest. Education  B.S., Biology, Loyola University, Chicago, IL  B.S., Pharmacy, University of Illinois, Chicago, IL  Ph.D., Pharmacognosy, University of Illinois, Chicago, IL  Postdoctoral Fellow with Manfred Hesse, Organic Chemistry, University of Zurich, Switzerland

Classes & Courses  Pharmaceutical Calculations

Active Grants  Ecological Genomics and Metabolomics (ECOGEM), in EPSCoR‐III, NSF

Selected Publications  Journal of Natural Products 68 (8), 1247‐1252 (2005).  Journal of Natural Products 68, 617‐619 (2005).  Molecular Diversity 9, 123‐129 (2005).  Journal of Natural Products 67 (6), 1036‐1038 (2004).  Journal of Natural Products 67 (2), 228‐231 (2004).  Pure & Applied Chemistry 68 (12), 2325‐2332 (1996).

Selected Awards and Honors  President, American Society of Pharmacognosy, 1997.  Fellow, Linnean Society of London, 1995.  Board of Directors, Institute for Triple Helix Innovation, Honolulu, 2009‐present. Faculty

Leng Chee Chang

Assistant Professor Pharmaceutical Sciences

[email protected]

The research interests of Dr. Chang are on the isolation, identification, and biological evaluation of natural products of higher plant and microbial origin. She has worked on compounds with potential cancer chemotherapeutic, in particular, Raf Kinase inhibitors from Streptomyces species and endophytic fungi. Raf kinases are proto‐oncogenes that act as the entry point of the MAPK (mitogen‐activated protein kinase/ERK (extracellular signal‐regulated kinase) pathway. The role of MAPK/ERK signaling in tumorigenesis and metastasis has been well studied and is a validated chemotherapeutic target. Chang’s lab also is studying the identification of cancer chemopreventive agents from higher plants through exploration of ethnopharmacology and traditional medicine. Currently, her lab’s is studying Moringa oleifera (marunggay) and Morinda citrifolia (Noni). Marunggay is extensively eaten by the local Filipino population in Hawaii. Moringa oleifera showed significant inhibition of nitric oxide production with lipopolysaacharide (LPS)‐induced RAW 264.7 mouse macrophage cells. We hope the identification of bioactive compounds from Moringa oleifera will be used as lead in standardized dietary and nutritional development in the future. Education  M.S., Natural Products Chemistry, University of Malaysia, Sabah, Malaysia  Ph.D., Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, USA  Intramural Research Training Fellow with Carole A. Bewley, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland.

Classes and Courses  PHPS 501 Biochemistry I  PHPS 504 Immunology  PHPS 554 Herbal Medicines  PHPP 523 Wellness, Prevention and Disease Management  PHPS 599v Directed Studies

Active Grants  IDeA Networks for Biomedical Research Excellence (INBRE), NIH  Hawaii Community Foundation (HCF)  Cancer Research Center of Hawaii (CRCH)

Selected Publications  Bioorganic Medicinal Chemistry, 2010, 17:6598‐6602  Journal of Natural Product, 2010, 73:880‐884  Marine Drugs, 2010, 8:429‐437  Planta Medica 2008, 74:555‐559  Organic Letters, 2007, 9:3037‐3040

Awards and Honors  Van Doren Scholar Award, 1997  Cottrell College Science Award, 2005  D. John Faulkner Travel Award, 2006

Faculty Mahavir B. Chougule

Assistant Professor Pharmaceutical Sciences

[email protected]

Mahavir B. Chougule, Assistant Professor of the Department of Pharmaceutical Sciences, investigates the use of therapeutic agent and targeted nanotechnology based formulations for treatment of cancer and pulmonary disorders. His research work is focused on delivery of therapeutic agents, siRNA, and proteins using targeted nanocarriers for the treatment of cancer and pulmonary disorders to improve the efficacy and minimize the adverse side effects. Chougule has shown that the delivery of inhalation delivery of anticancer drug loaded nanoparticle significantly inhibits tumor growth compared to aerosolized solution. Chougule has also investigated the anticancer activity and molecular mechanism of Noscapine, a natural opium alkaloid against lung and breast cancer. He also developed the spray dried nano‐liposomal dry powder inhalers for management of pulmonary disorders and topical nanocarrier cream formulation for treatment of skin disorders. Chougule's research also focused on inhalation delivery of therapeutic agent and gene based nanocarriers for the treatment of pulmonary disorders. Chougule has 16 publications, 8 patents, 2 review article, one book chapter, and 45 scientific presentations to his credit.

Education  Diploma of Pharmacy, Bombay Technical Education Board, India  Bachelor of Pharmacy, Amravati University, India  Master of Pharmacy, Pharmaceutical Technology, The Maharaja Sayajirao U of Baroda,  Ph.D., Pharmacy, The Maharaja Sayajirao University of Baroda, India  Postdoctoral Research Fellow, Florida A & M University, USA

Classes & Courses  PHPS 505 Pharmaceutics  PHPS 512 Introduction to Pharmaceutical Sciences  PHPP 500 History of Pharmacy  PHPS 755 Advance Pharmaceutics  PHPS 750 Overview of the Pharmaceutical Sciences

Selected Publications  Eur. J. Pharm. Sci. 2012; 46(1‐2): 8‐16  PLoS One, 2011; 6(11): e27394  PLoS One, 2011; 6(3): e17733  Lung Cancer, 2011; 71(3): 271‐82  Molecular Cancer Therapeutics, 2010; 9(11): 3003‐14  J. Control. Release, 2010; 144(2): 233‐41.  Clin. Cancer Res. 2009, 15: 543‐552.  Cancer Chemother. Pharmacol., 2008, 63(1): 117‐26.  AAPS PharmSciTech. 2008, 9(1):47‐53  Int J Nanomedicine, 2007, 2(4):675‐88  J Nanosci Nanotechnol., 2006, 6(9‐10): 3001‐9.

Active Grants  Center for Magnesium Education & Research  Hawaii Community Foundation (HCF)  NSF outreach partnership  RCUH Seed Grant Faculty Linda Connelly

Assistant Professor Pharmaceutical Sciences

[email protected]

Linda Connelly, Assistant Professor of Pharmaceutical Sciences, studies the molecular basis of primary tumor growth and metastasis. Her current focus is on the role of osteoprotegerin in breast cancer using both in vitro techniques and the chick embryo metastasis model. Her lab is also investigating the role of the macrophages and inflammatory signaling molecules in tumor progression.

Education  BSc (Hons), First Class, Biochemistry with work placement, University of Glasgow, UK  Ph.D., Molecular Pharmacology, Wolfson Institute for Biomedical Research, University College London, UK  Postdoctoral Fellow in the Dept of Medical and Molecular Pharmacology, UCLA and the Dept of Cancer Biology, Vanderbilt University Medical Center

Classes & Courses  PHPS 703 Cancer Biology (Course Coordinator/Lecturer  PHPS 509 Pathophysiology (Physiology lecturer)  IS 201 Pre Pharmacy Orientation (Course Coordinator)  PHPS 202 Overview of Drug Classes (Course Coordinator/Lecturer)  Introduction to PCAT Preparation (lecturer/online course designer)

Active Grants  AREA R15 (NIH/NCI)

Selected Publications  Breast Cancer Research, 2011, 13(4):R83  Oncogene, 2011, 30 (12):1402‐12  J Cell Physiol, 2010, 222:72‐81  Cancer Research, 2008, 68(16):6762‐6769  PNAS, 2007, 104 (47): 18514‐9

Awards and Honors  Davidson Prize for Biochemistry, 1998  Wellcome International Prize Travelling Research Fellowship, 2002‐2005  Minority‐Serving Institution Faculty Scholar in Cancer Research, 2010  Excellence in teaching award for Pharmaceutical Sciences, 2010  Excellence in teaching award for Pharmaceutical Sciences, 2012

Faculty Edward Fisher

Associate Dean for Academic Affairs and Professor

[email protected]

Dr. Fisher has devised and presented many innovative continuing education seminars and NSF sponsored short courses. While serving as the founding Chair of the Department of Pharmaceutical Sciences, Midwestern University‐Glendale College of Pharmacy, he gained extensive experience starting up a new college of pharmacy. He now plays an integral role at UHH CoP in the evolution and implementation of the curriculum, in mentoring students and faculty, admissions, academic policies, strategic planning, student affairs, and professional accreditation. He is licensed as a pharmacist in Arizona and Pennsylvania, and has practiced in a variety of clinical settings. He is currently taking a leadership role in the CoP effort to expand academic programs. Education  B.A., Biology, Temple University, Philadelphia, Pennsylvania  B.S., Pharmacy, Temple University School of Pharmacy, Philadelphia, Pennsylvania  Ph.D., Pharmacology/Toxicology, Temple University, Philadelphia, Pennsylvania

Classes & Courses  Basic and Applied Toxicology (Course Coordinator)  Provide lectures in the area of nutrition and weight control

Active Grants/Contracts  Tripler Army Medical Center Psychopharmacology Instruction/Training Contract  U.S. Department of Education Clinical Pharmacy Training Program Grant

Selected Publications  The American Journal of Geriatric Pharmacotherapy, 2010, 8(2):21‐17  The Annals of Pharmacotherapy, 2006, 40:689‐693

Awards and Honors  Upjohn Pharmacy Award for Excellence in Research, 1987  National Rho Chi Advisor of the Year, 1996  APhA‐APPM Presentation Merit Award, 1997  Southwestern University School of Pharmacy Dean's Council of Students Teacher of the Year Award, 1991  AACP Teacher of the year (Midwestern University‐Glendale), 2005  Julius W. Sturmer Memorial Lecture Award, 2008

Selected News Release  The Wester, Sun City, Arizona, September 15, 2005.  Arizona Republic, Phoenix, Arizona, January 7, 2005.

Faculty

Daniela Gündisch (Guendisch)

Assistant Professor

Pharmaceutical Sciences [email protected]

We are developing novel ligands for ion channels with one emphasis on nicotinic acetylcholine receptors (nAChRs) (design, synthesis and structure‐activity relationship studies (SAR)) as potential therapeutics or as diagnostic tools for in vivo imaging (PET, SPECT). We have used natural products such as nicotine, cytisine, epibatidine, ferruginine, anatoxin‐a, and the endogenous ligands acetylcholine and choline as structural templates or as starting material in our synthesis projects. For example, in our cytisine‐based project we have developed a novel compound, which we have shown to be a partial agonist with subtype selectivity for 4/2* nAChRs and antidepressant activity in collaboration with Marina Picciotto (Yale University) and Roger Papke (University of Florida).

Education  Pharmacy, University of Tübingen, Germany  Ph.D., Pharmaceutical Chemistry, University of Tübingen, Germany  Postdoctoral Fellow with Edythe London, NIH/NIDA, Brain Imaging Center, Baltimore, U.S.A.  Habilitation, Pharmaceutical Chemistry/Medicinal Chemistry, University of Bonn, Germany

Classes & Courses  UHH/CoP: PHPS 506, 512, 553; PHPP 514, 515, 516, 517, 518, 521, 523, 594 (Medicinal Chemistry, Nuclear Pharmacy, PP, Therapeutics)  Germany/Europe: general, analytical, bio‐inorganic, organic, pharmaceutical, and medicinal chemistry; radiopharmacy; therapeutics; accompanying courses during rotation (pharmacy students); medicinal chemistry and radiopharmacy for Ph.D. students (also for the Erasmus/Sokrates program of the European Union); CE (diverse topics, e.g. for the German Chemical Society (GdCh))

Active Grants  University of Hawaii Hilo Research Council  INBRE, NIH  Hawaii Community Foundation (HCF), together with Leng Chee Chang (PI) and Supakit Wongwiwatthananukit

Selected Publications  Science, 2011, 332, 1330‐1332  JPET, 2009, 329, 377‐386  Synapse, 2005, 55, 89‐97  BMC, 2004, 12, 4953‐4962  J Med Chem, 2002, 45, 1064‐1072  Life Sci, 2000, 67, 463‐469  Mol Pharmacol, 2000, 57, 642‐649

Awards and Honors  Ph.D. Scholarship Award, University of Tübingen, Germany, 1992  Research Scholarship Award, University of Tübingen, Germany, 1994  Nomination for the Teaching Award, (Universities of Baden‐Württemberg), Germany, 1997  Fogarty International Fellow (NIH/NIDA), U.S.A., 1997‐1998  NIDA Director’s Award of Merit (Development of PET/SPECT Tracers), 1998  Habilitation Award, University of Bonn, Germany, 2001  Rottendorf Award (Pharmaceutical Sciences), Germany, 2007  Teaching Award for Pharmaceutical Sciences (UHH/CoP), 2009, 2011  Travel Grants (UHH), 2009, 2010

Faculty Aaron T. Jacobs

Assistant Professor Pharmaceutical Sciences

[email protected]

Aaron T. Jacobs, Assistant professor of Pharmaceutical Sciences, studies the activation of cellular stress responses and their effects on viability and function in relation to disease processes. A wide variety of reactive compounds, including antineoplastic drugs; xenobiotics; and endogenous metabolites are capable of inducing large‐scale adaptive responses at the cellular level. One aspect of his current research examines the role of electrophilic metabolites in the activation of the heat shock response. This response is regulated by the activation of heat shock factor‐1, which then drives the expression of numerous genes. Currently, his laboratory is investigating the role of specific heat shock‐induced genes in tumor cell growth and viability. His work also examines stress‐ mediated gene expression in neurons.

Education  B.S., Biology, University of California, Irvine  Ph.D., Pharmacology, University of California, Los Angeles  Postdoctoral Fellow, Vanderbilt University

Classes & Courses  Integrated Therapeutics II‐IV  Recent Advances in Drug Discovery

Active Grants  RCUH Seed Grant  P20, IDeA Networks of Biomedical Research Excellence (INBRE), NCRR

Selected Publications  Accounts of Chemical Research, 2010, 43(5):673‐683  Journal of Biological Chemistry, 2009, 284(14):9176‐9183  Chemical Research in Toxicology, 2008, 21(2):432‐444  Journal of Biological Chemistry, 2007, 282(46):33412‐33420  Chemical Research in Toxicology, 2007, 20(7):983‐985

Awards and Honors  Phi Beta Kappa, 1991  Excellence in Teaching, 2010 Faculty Susan I. Jarvi

Director, Pre‐pharmacy Program and Associate Professor Pharmaceutical Sciences

[email protected]

Susan I. Jarvi, Associate professor and Director of the Pre‐pharmacy Program, studies host‐parasite and parasite‐parasite interactions and influences on transmission and virulence of infectious disease. Jarvi is studying tolerance to infectious disease as evidenced through a recent population explosion of a low elevation native Hawaiian bird population despite high prevalence of Plasmodium infection. Her goal is to characterize and begin to define potentially novel mechanisms involved in tolerance to malaria in this relatively simple, geographically‐isolated, natural disease system. Jarvi’s lab is also interested in continued development of molecular‐based methods for the detection and evaluation of pathogen diversity, and development and implementation of vaccines.

Education  M.S., Veterinary and Animal Sciences (Genetics), University of Massachusetts, Amherst  Ph.D., Biology, Northern Illinois University, DeKalb  Postdoctoral Fellow at the Beckman Research Institute of the City of Hope National Medical Center Duarte, CA, and at the Molecular Genetics laboratory of the Smithsonian Institution, Washington DC.

Classes & Courses  PHPS 504 Pharmaceutical Immunology  PHPS 594 Genetics and Pharmacology of Malaria

Active Grants  INBRE 2010  Hawaii Community Foundation grant

Selected Publications  PLoS ONE 5(5) 2010: e10745. doi:10.1371/journal.pone.0010745  Molecular & Biochemical Parasitology 2009 163:114‐118  Biology Direct 2008 3:25  Conservation Genetics, 2008, 9, 339‐348  Vaccine 2008 Oct 26, 42. 5338‐44.  Molecular Ecology 2004, 13, 2157‐2168.

Awards and Honors  1982 Excellence in Student Teaching  1988 Outstanding Graduate Student, Northern Illinois University

Selected News Releases  2010 http://www.uhh.hawaii.edu/news/press/release/965  2010 http://pharmacy.uhh.hawaii.edu/documents/KawiliLaauSummer10.pdf  2010 http://www.uhh.hawaii.edu/news/press/release/926  2009 http://www.uhh.hawaii.edu/news/press/release/811  2008 http://www.uhh.hawaii.edu/news/press/view.php?release=739  2008 http://www.kaunana.com/CurrentIssue/SavingHawaiisEndangeredBirds/tabid/87/Default.aspx

Faculty

Tamara P. Kondratyuk

Assistant Specialist & Laboratory Manager

[email protected]

Dr. Kondratyuk research work related to search of natural product chemopreventive drugs and their important role in the treatment and prevention of cancer. Screening results led to the discovery of many biologically active compounds including phenazines from unexplored sea‐living species. The major cellular target for chemoprevention research is NFκB pathway. Dr.Kondratyuk showed that marine phenazines deregulate activity of NFkB pathway and activate protective mechanism against neoplastic transformation apoptosis. Variety of molecular mechanisms controlling apoptosis and cell cycle by NFkB inhibitors from natural products are under investigation. Education  M.S., Biochemistry, Kiev State University, USSR  Ph.D., Biochemistry, Moscow State University, USSR  Postdoctoral Fellow, Klinikum Der Friedrich‐Schiller University, Medicinal Chemistry, Germany  Postdoctoral Fellow, Department of Biochemistry Purdue University, Molecular Biology, USA

Classes & Courses  PHPS 505/L, Pharmaceutics I and II  Graduate Course PHPS 600 Natural Products and Cancer Chemoprevention

Active Grants  2P01 CA48112‐13 (PI Pezzuto), NIH/NCI

Selected Publications  J. Med.Chem., 2010, 53:5033‐43  Phytochemistry, 2010, 71: 641‐7  J.Nat.Product, 2010,72:396‐02  J. Nat. Prod.,2007, 70: 83‐8  J. Med. Chem.,2007, 50: 350‐5  Pharm. Biol.2004, 42: 46‐63  JBC, 1997, 272: 16978‐83  JBC, 1995, 270: 7750‐6

Faculty

Dana-Lynn T. Koomoa-Lange

Assistant Professor

Pharmaceutical Sciences [email protected]

Dr. Koomoa, Assistant Professor of the Department of Pharmaceutical Sciences, investigates the novel role of proteins in the malignant progression of cancer, and other pathophysiological processes. Much of her research is providing new insights into neuroblastoma and other types of cancers driven by myc expression (c-myc and N-myc). Koomoa’s lab investigates the ion channel proteins and channel regulatory proteins that are often over-expressed or down- regulated in cancer. Koomoa has shown that these proteins play a critical role in regulating neuroblastoma tumor growth, and metastasis, while inhibitors of these proteins inhibit these processes. In addition, Koomoa’s lab investigates the role of these proteins in other physiological and pathophysiological processes (e.g. Immune cell function, Central Nervous System disorders). This project involves using molecular biological, biochemical and biophysical techniques. Multi-plexed assays were established using the Perkin Elmer High-throughput Operetta imaging, live-cell ratio-metric calcium imaging and electrophysiological patch-clamp measurements, in order to correlate results from multiple assays.

Education  B.S., Cell and Molecular Biology, San Diego State University (San Diego, CA)  Ph.D., Molecular Pharmacology, Physiology and Biotechnology, Brown University (Providence, RI)  Postdoctoral Fellow, Laboratory of Cell and Molecular Signaling, Queen’s Medical Center/LCMS (Honolulu, HI)  Postdoctoral Fellow, Natural Products and Cancer Biology, UH Cancer Center (Honolulu, HI) Classes & Courses  Integrative Therapeutics IV (PHPP 518)  Biochemistry (PHPS 602) Active Grants  K01 , National Cancer Institute (NCI), NIH  Young Investigator’s Awarde (ALSF)  UH CoP start-up Funds Selected Publications  International Journal of Oncol., 2012, accepted  Biochem. Pharmacology, 2010, 80(2):170-8  Molecular Cancer Therapeutics, 2009, 8(7):2067-75  Cancer Research, 2008, 68(23):9825-31  Clinical Cancer Research, 2007, 13(21):6312-9  Current Biology, 2006, Vol. 16 (20): 2073-9  Nature Cell Biology, 2006, Vol. 8(7): 771-3  Science, 2006, Vol. 312 (5777): 1220-3 Awards and Honors  American Association for Cancer Research Minority Scholar in Cancer Research Award (2011)  Fellow, Keystone Symposium on Molecular and Cellular Biology (2009-2010)  University of Hawai’i Research Council Fellowship Award (2007 and 2008)  Carl Storm Fellowship (2007)  Helen F. Cserr Memorial Fellow, Outstanding Academic Achievement (2004-2005)  MDIBL Research Fellowship, Mt. Desert Island Biological Laboratory (2003) Selected News Releases  Star Advertiser, Honolulu, September, 2012  Tribune Herald, Hilo, September, 2012 Faculty

Kenneth R. Morris

Professor

Pharmaceutical Sciences

[email protected]

Ken Morris, professor in the Department of Pharmaceutical Sciences, studies pharmaceutical materials, dosage form design and processing. His research is widely recognized for its contributions to modernizing dosage form development in the pharmaceutical industry. Integration of advanced solids analytical techniques, with physical chemical and engineering principles to predict the response of pharmaceutical crystalline material to processing stress is used to systematically design dosage forms that perform as needed and are capable of being produced at scale. Current projects include measuring compaction properties of crystalline materials for the design and optimization of tableting processes and characterization of grape powders and the design of clinically viable delivery systems.

Education  M.S., Pharmaceutical Chemistry, University of Arizona  Ph.D., Pharmaceutics, University of Arizona  Solid State and Crystallographic internship, Cambridge, UK, Paul Raithby, advisor

Current Classes & Courses  Pharmaceutics I and II  Pharmacokinetics  Pharmaceutical Development

Active Grants  NSF‐ERC‐SOP, structured organic composites  CTGC, Grape commission

Selected Publications (since 2000)  Chemical Engineering Science, special issue in press  J. Nutrition, on‐line 7/22/2009  Crystal Growth & Design, 9 (8): 3359‐3366 Aug 2009  Journal of Computational Chemistry,30(5):733‐742 4‐15‐ 200  Journal of Electrostatics (2007), 95(12), 2645‐2656  Journal of Colloid and Interface Science. (2005), 209(2) 325‐335  Thermochimica Acta. 404:213‐226 (2003)  Journal of Physical Chemistry B. 104:2019‐2032 (2000)

Awards and Honors  2010 Professional achievement University of Arizona College of Pharmacy  2007 AAPS Fellow.  2006 AAPS Outstanding Manuscript Award in Analysis and Pharmaceutical Quality  2006 Best Paper Award in Informatics, International Journal of Computers and Chemical Engineering  1994 Fred Simon Award for Best Paper in the PDA Journal of Pharmaceutical Science and Technology  1987 EPA Research Paper of the Year  1983 Outstanding Research Award, Environmental Protection Agency, Environmental Research Laboratory

Faculty Anthony J. Otsuka

Instructor Pharmaceutical Sciences [email protected]

Anthony Otsuka came to the department after being an Assistant Professor in the Department of Genetics at UC Berkeley for 8 years and Associate and Full Professor of Genetics at Illinois State University for 21 years. Having been raised on Maui, one of his goals is to support higher education in the islands. There are three foci of the lab’s research: axon guidance mechanisms in the nematode, Caenorhabditis elegans, characterization of lipid‐accumulating mutants in C. elegans, and analysis of gene regulation in the bacterium, Escherichia coli. The axon guidance project focuses on a novel neural form of the cytoskeletal protein, ankyrin, which is required for proper synapse formation. This protein interacts with the B’‐regulatory subunits of the protein phosphatase, PP2A, and with the microtubule plus‐end protein, CLASP2. These components, along with CRMP (UNC‐33) and the GSK‐3beta signaling pathway, may be important for proper wiring of the nervous system. Using the single nucleotide polymorphism/restriction site cleavage (SNP‐Snip) technique, a number of lipid‐accumulating C. elegans mutants are being mapped. These mutants may help to elucidate the insulin pathway in this model organism and may have applications to the study of diabetes. E. coli produces its own biotin (vitamin H). The regulator for the biotin biosynthetic genes is a bifunctional protein that activates biotin and also represses transcription of the biotin operon. Structure/function studies of this protein have been previously carried out in the lab.

Education  B.S., Chemistry, Massachusetts Institute of Technology, 1972  M.S., Chemistry, University of California, San Diego, 1974  Ph.D., Chemistry, University of California, San Diego, 1979  Postdoctoral Fellow with Sydney Brenner, Medical Research Council Laboratory of Molecular Biology, Cambridge, England 1979‐1981

Classes & Courses  Genetics in Medicine (PHPS 550)  Molecular Biology (at ISU)  Molecular and Developmental Genetics (at ISU)  Biotechnology Laboratory (at ISU)  Advanced Neural Development (at ISU)  Selected Publications  Nature Immunol., 2006, 8:206‐13  Mol. Genet. Genom., 2002, 267:291‐302  J. Neurobiol. 2002, 50:333‐49  Gene, 2000, 252:147‐54  J. Cell Biol. 1995, 129:1081‐92  Neuron, 1991, 6:113‐22  Gene, 1986, 44:255‐61  Nature, 1978, 276:689‐94

Awards and Honors  N. I. H. Postdoctoral Fellowship, 1979‐81  Monbusho Fellowship for Study in Japan, 1996  Japanese Society for the Promotion of Science Fellowship for Study in Japan, 1997  ISU College of Arts and Sciences Outstanding College Service Award, 2001

Faculty Mimi F. Pezzuto

Instructor Pharmaceutical Sciences

[email protected]

Mimi F. Pezzuto, R.Ph., is an instructor in the Department of Pharmaceutical Sciences, responsible for the Pharmaceutics I, II Practice Laboratory. The lab course is designed to give students a practical understanding of pharmaceutical dosage forms and compounding techniques used in the practice of pharmacy. In addition to the laboratory course, Mimi also is responsible for courses including History of Pharmacy PHPP 550, Wellness and Prevention PHPP 523, Healthcare Systems PHPP 519, and Current Topics in Healthcare PHPP 598.

Education  B.S. Pharmacy, University of Illinois at Chicago College of Pharmacy

Selected Publications  Hana Hou! The magazine of Hawaiian Airlines, October/November 2010

Awards and Honors  Pharmacy of the Year, 1993, 1994 Walgreen Company

Selected News Releases  Tribune Herald, Hilo, May 20, 2010 Faculty Dianqing Sun

Assistant Professor Pharmaceutical Sciences

[email protected]

Research in my laboratory focuses on the design and synthesis of novel small molecule and natural product based anti‐infective and anti‐cancer agents. The chemical approaches include classical organic synthesis, parallel and high‐throughput chemistry, solid‐phase organic synthesis, followed by traditional medicinal chemistry optimization of the emerging lead compounds.

Education  Master, Organic Chemistry, East China University of Science and Technology, Shanghai, China  Ph.D., Organic Chemistry, The University of Memphis, TN, USA  Postdoctoral Fellow with Richard Lee, Medicinal Chemistry, University of Tennessee Health Science Center, TN, USA

Classes & Courses  Course Coordinator and instructor, Integrated Therapeutics I (PHPP 515)  Instructor, Integrated Therapeutics II‐IV (PHPP 516‐518)  Course Coordinator and instructor, Discovery and Development of Blockbuster Drugs (PHPS 562)  Instructor, Introduction to Pharmaceutical Sciences (PHPS 512)

Active Grants  Academic Research Enhancement Award (AREA) R15, NIAID/NIH  IDeA Networks for Biomedical Research Excellence (INBRE), NIH  Leahi Fund of the Hawaii Community Foundation (HCF)  UH Hilo Seed grant

Selected Publications  Org. Biomol. Chem., 2012, in press, DOI:10.1039/C2OB26456K.  ChemMedChem, 2012, in press, DOI:10.1002/cmdc.201200346.  ChemMedChem, 2012, 7(9): 1541‐1545.  Tetrahedron Lett., 2012, 53(32): 4173‐4178.  Bioorg. Med. Chem., 2011, 19(21): 6182‐6195.  Bioorg. Med. Chem., 2011, 19(18): 5585‐5595.  Tetrahedron Lett., 2011, 52(35): 4570‐4574.  Bioorg. Med. Chem., 2010, 18(2): 896‐908.  ChemMedChem, 2009, 4(10): 1649‐1656.  Antimicrob. Agents Chemother., 2009, 53(9): 4028‐4031.  Bioorg. Med. Chem., 2009, 17(10): 3588‐3594.  Eur. J. Med. Chem., 2009, 44(2): 460‐472.  J. Comb. Chem., 2007, 9(3): 370‐385.

Awards and Honors  Faculty Travel Grant, ACS Division of Organic Chemistry, 2012  Excellence in Teaching Award for Pharmaceutical Sciences, 2011  Gordon Research Conference on Combinatorial Chemistry Graduate Fellowship Award, 2005

Faculty Ghee Tan

Assistant Professor Pharmaceutical Sciences

[email protected]

Malaria is one of the major public health challenges undermining development in the poorest countries of the world. Disease control is hampered by the lack of an efficacious vaccine, and the occurrence of multidrug resistant strains of Plasmodium falciparum. A significant number of plant species have been identified by various cultures as having antimalarial properties, and current antimalarial therapy consists substantially of natural products and related derivatives. Artemisinin (ART) is a key ingredient in combination drug therapies recommended by the World Health Organization (WHO) for the treatment of multidrug resistant strains of falciparum malaria. However, the number of stereogenic centers present in the ART molecule makes total synthesis difficult and unadaptable to industrial production at acceptable costs. With a view to tackling global health challenges, my lab aims to discover and develop natural product‐ inspired antimalarial agents that are not only clinically efficacious, but also economical to synthesize in large scale making the drug affordable to low‐income countries. Established antimalarial lead compounds identified from natural sources will be synthesized and structurally modified to improve their antimalarial selectivity and potency against the erythrocytic, hepatic and gametocyte stages of P. falciparum. Studies will also be conducted to elucidate the mechanism(s) of action of these lead compounds as therapeutic and transmission blocking agents. Such efforts may ultimately lead to the identification of new molecular targets for malaria. In addition to the synthetic and analoging project described above, an equally important goal of the antimalarial drug discovery and development program at UH Hilo College of Pharmacy is to uncover biologically active molecules from nature as chemotherapeutic candidates for multidrug resistant malaria. To that end, endophytic fungi and the medicinal plants of various cultures around the world are being explored as potential sources of novel antimalarial agents.

Education  Ph.D., Molecular Pharmacology, University of Illinois at Chicago.  Postdoctoral Fellow, Public Health Research Institute/New York University.

Classes & Courses  PHPS 555 ‐ Geographic Medicine & Global Health  PHPS 502/752 ‐ Biochemistry‐Metabolism  PHPS 702 ‐ Bioassay Development: Principles and Practices in Drug Discovery

Selected Publications  N. Q. Chien, N. V. Hung, B. D. Santarsiero, A. D. Mesecar, N. M. Cuong, D. D. Soejarto, J. M. Pezzuto, H. H. S. Fong, and G. T. Tan (2004) New 3‐O‐acyl betulinic acids from Strychnos vanprukii Craib. J. Nat. Prod. 67(6), 994‐998.  H.‐J. Zhang, N. V. Hung, N. M. Cuong, D. D. Soejarto, J. M. Pezzuto, H. H. S. Fong, and G. T. Tan (2005) Sesquiterpenes and butenolides, natural anti‐HIV constituents from Litsea verticillata. Planta Med. 71, 446‐451.  C.‐Y. Ma, H.‐J. Zhang, G. T. Tan, N. V. Hung, N. M. Cuong, D. D. Soejarto, and H. H. S. Fong (2006) Antimalarial compounds from Grewia bilamellata. J. Nat. Prod., 69, 346‐350.  G. T. Tan, C. Gyllenhaal and D. Soejarto (2006) Biodiversity as a Source of Anticancer Agents. Curr. Drug Targets, 7(3), 265‐277.  S. F. Musoke, O. Odyek, W. W. Anokbonggo, J. Ogwal‐Okeng, E. J. Carcache‐Blanco, C.‐Y. Ma, J. Orjala, and G. T. Tan (2010) Antimalarial activity of Aspilia pruliseta, a medicinal plant from Uganda. Planta Med., 76: 1–3.  F. M. Sebisubi and G.T. Tan (2010) Natural Products with Promising Antimalarial Activity, in Natural Products, edited by J.M. Pezzuto and M.J. Kato, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK.  M. Pieroni, S. Girmay, D.‐Q. Sun, R. Sahu, B. L. Tekwani, and G. T. Tan (2012) Synthesis and structure–activity relationships of lansine analogs as antileishmanial agents. Chem.Med.Chem., in press.

Awards and Honorstan  Kilmer Prize for meritorious work on natural products, American Pharmaceutical Association and American Society for Pharmacognosy. Faculty Gary R. Ten Eyck

Assistant Professor Pharmaceutical Sciences

[email protected]

Gary R. Ten Eyck, Assistant Professor in the Department of Pharmaceutical Sciences, examines the neuroendocrinology of reproductive behaviors, particularly territoriality and paternal care, and communication utilizing neuropharmacological approaches. His lab also studies the evolutionary significance of direct development; particularly sensory systems. These investigations use the Puerto Rican coquí frog (Eleutherodactylus coqui). This amphibian differs from the “conventional" frog because it undergoes direct development, as oppose to metamorphosis, and exhibits paternal care. Investigations on reproductive behaviors, communication, and developmental biology are significant since the Puerto Rican coquí was recently introduced on the Island of Hawai‘i and its widespread distribution is a major environmental and economical concern.

Education  B.S., Biology, Central Michigan University  M.S., Biology, Central Michigan University  Ph.D., Biological Sciences (Neuroscience), University of South Dakota  Postdoctoral Fellow, NSF Developmental Neurobiology, University of Michigan

Classes & Courses  Neuropharmacology  Integrated Therapeutics (Course Coordinator)  Environmental Toxicology  Overview of Drug Classes

Selected Publications  Behavioral Brain Research, 2008, 193: 144‐147  Anatomy and Embryology, 2005, 210:221‐233  Neuroscience Letters, 2005, 388:100‐105  Hormones and Behavior, 2005, 47(2):223‐229  Journal of Morphology, 2004, 261: 225‐248

Awards and Honors  Office of the Vice President for Research, Research Award, University of Michigan, 2002  NSF Postdoctoral Fellowship, University of Michigan, 1997  Matthew A. Johnson Award, Doctoral Dissertation, University of South Dakota, 1997  National Science Foundation EPSCoR Graduate Research Fellowship, University of South Dakota, 1995

Selected News Releases  Statewide Interview: Island Issues Public Affairs Broadcast with Sherry Bracken, May 30, 2010  Big Island Buzz, UH Hilo is Joined by a Coqui Frog Expert, Jan 12, 2010  Honolulu Herald Tribute, Coquí Pro joins UH Hilo, Jan 6, 2010  UH Hilo Press Release, Coquí Expert joins College of Pharmacy, Jan 5, 2010  Big Island Chronicle, University News, Coquí expert joins UHH College of Pharmacy, Jan 05, 2010

Faculty Anthony D. Wright

Associate Professor Pharmaceutical Sciences

[email protected]

Tony, as well as being an Associate Professor in the Department of Pharmaceutical Sciences, is a world leader in marine natural products drugs discovery and a recognized expert in the area of structure elucidation using NMR. His academic career spanning over 30 years, including an interlude as a high school teacher of Mathematics, Chemistry and Physical Education, has been spent searching the natural world, mainly its oceans, for the chemical treasures it has to offer. His research group discovered the first compounds from the marine environment to have selective antimalarial activity and were also the first to isolate endophytic fungi from marine algae. His group was at the forefront in developing new methodologies for solving chemical structures of various natural products an area where they are still active. Here in Hawaii, Tony, his post doc, a senior in marine biology, various volunteers and collaborators are looking into the natural products chemistry and biological activity of niche macro‐ and micro‐organisms found on the Big Island of Hawaii, Guam and various other locations around the world.

Education  BSc Hons La Trobe University, Melbourne, Australia (1976)  Dip Ed La Trobe University, Melbourne, Australia (1977)  PhD James Cook University, Queensland, Australia (1988)  Post Doctoral Fellow, Department of Pharmacy, ETH, Zurich Switzerland (1989)

Classes & Courses

PharmD  Introduction to the Pharmaceutical Sciences  Pharmaceutics  History of Pharmacy  Toxicology and Substances of Abuse Graduate and Faculty  NMR application and theory

Active Grants  Since arriving in Hilo (2007) Tony has obtained a small amount of extramural funding. Currently, he has no external grants

Selected Publications  Journal of Medicinal Chemistry, 2002, 45, 3067‐3072  Chemosphere, 2006, 65, 604‐608  European Journal of Organic Chemistry, 2007, 2268‐2275  Marine Biotechnology, 2008, 10, 64‐74  Marine Ecology Progress Series, 2009, 385, 137‐149  Marine Drugs, 2009, 7, 565‐575

Awards and Honors  ETH Zurich, Switzerland, Post Doctoral Scholarship, 1989  American Society of Pharmacognosy Young Investigator Awardee, 1995

Selected News Releases  Dive into your imagination October 2008: http://www.diveintoyourimagination.com/cool‐scientists‐you‐should‐ know/cool‐scientists/dr.‐anthony‐d.‐wright‐303.html ACPE Self Study: Appendix 25-1 Biographical Sketches

Department of Pharmacy Practice

Julie Adrian, Assistant Professor: Dr. Adrian received her B.S. with High Honors in Agriculture with specialty in Animal Science from the University of Hawai`i at Hilo in 2000 and her Doctorate of Veterinary Medicine from Oklahoma State University in 2004 graduating within the top 10% of her class and as a member of Phi Zeta. She is licensed to practice veterinary medicine and has also maintained both National (Federal) and State Drug Enforcement Agency (DEA) licensures. She has veterinary accreditation recognized by the USDA, APHIS, and the Bureau of Animal Industry. She has privately practiced veterinary medicine from 2004, and professed undergraduate students in pre-veterinary medicine since 2006 and pharmacology students since 2010. Her scholarly interests and publications include veterinary toxicology, drug-induced euthanasia and psychological effects of euthanasia of pets to owners, zoonotic diseases, and the benefits and detriments of guava tree part consumption for nutritional and medicinal purposes. Her work has also been featured in the New York Times and the Honolulu Star Advertiser. Dr. Adrian is an editorial board member of the Journal of Veterinary Science and Technology, reviewer for the Journal of Biotech Research, and editorial board member of the International Journal of Livestock Production. She is a member of the American Veterinary Medical Association (AVMA) and the Hawaii Island Portuguese Chamber of Commerce.

Katherine Anderson, Pharm.D., Assistant Professor: Dr. Anderson received a Doctor of Pharmacy degree from Washingon State University College of Pharmacy and completed an ASHP-accredited specialty geriatric pharmacy residency at the Department of Veterans Affairs Medical Center in Boise, ID. She is a Certified Geriatric Pharmacist (CGP) and a Fellow of the American Society of Consultant Pharmacists (FASCP). Dr. Anderson is a member of the Hawai'i Pharmacists Association, American Pharmacists Association, American Society of Consultant Pharmacists, American Association of Colleges of Pharmacy, and American Society of Diabetes Educators. She has a background in independent geriatric consultancy and holds licenses in HI, Comment [C1]: Cut? WA, OR, ID, UT, AK, AR, and AZ. Dr. Anderson’s research focuses on the development and validation of culturally-sensitive tools to assess cognition, prescription literacy, pillbox organization, and barriers to disease state management for populations with high incidence of diabetes. Dr. Anderson received the Foundation of the American Society of Consultant Pharmacists Innovative Practice Award in 2007 for the development of the “Medi-Cog”, a cognitive/pillbox skills screen developed to aid clinicians in assessing patients’ ability to appropriately self-manage medications. In 2010 she received Clinical Pharmacy Services Improvement and Patient Safety Pharmacist Collaborative Life Saving Patient Safety Awards for achieving improved health outcomes in a rural, underserved population. Dr. Anderson is a student advisor for APhA and the Pacific Islander Mobile Screening Clinic, a UHH CoP student- led outreach serving ethnically diverse population island-wide to achieve adequate access to medical care and educate regarding safe and effective use of medications.

Forrest Batz, Pharm.D., Assistant Professor: Dr. Batz received a Doctor of Pharmacy degree from the University of California, San Francisco (UCSF) School of Pharmacy and completed an ASHP–accredited pharmacy residency at the Department of Veterans Affairs Medical Center in Tucson, AZ. Dr. Batz has worked in drug information, conducted research in community pharmacy practice, and helped develop a model for integrative pharmacy practice. As a writer

January 3, 2011 Page 1

ACPE Self Study: Appendix 25-1 Biographical Sketches and speaker, he has worked since 1997 supporting health professionals to integrate natural medicines information into daily practice. Dr. Batz served as a founding assistant editor of the Natural Medicines Comprehensive Database and continues to serve as a contributing editor. He is a co-author of the A-Z Guide to Drug-Herb-Vitamin Interactions and co-editor of the Herb- Drug Interaction Handbook. He is actively involved in programs to remove pharmaceuticals from the waste stream and waterways, and serves on the Green Pharmacy Advisory Board of Teleosis Institute. Dr. Batz is a member of the Hawai'i Pharmacists Association, American College of Clinical Pharmacy, American Pharmacists Association, American Society of Health System Pharmacists, and American Association of Colleges of Pharmacy.

Ben Chavez, PharmD, Assistant Professor: Dr. Chavez received his Doctor of Pharmacy degree from the University of Florida in 2004. He completed a psychopharmacology residency in 2005 at Nova Southeastern University in conjunction with the South Florida State Hospital and the Oakland Park Veterans Affair psychiatric outpatient clinic. He is a Board Certified Psychiatric Pharmacist (BCPP) and a licensed practicing pharmacist. He was a Clinical Assistant Professor at Rutgers University, Ernest Mario School of Pharmacy from 2005-2010, where he served as a course coordinator for their Neuropsychiatric Therapeutic course, as well as for the Advanced Neuropsychiatry elective. He taught several lectures, including schizophrenia, depression, attention-deficit hyperactivity disorder, anxiety disorders, and many more. His practice site during his time at Rutgers was the inpatient psychiatric unit at Monmouth Medical Center. There he worked as an integral part of the treatment team with direct patient contact and also precepted pharmacy students. He also coordinated students from different disciplines there, including pharmacy, medical, and physician assistant students. He has served on several committees at Rutgers University Monmouth Medical Center, as well as for the College of Psychiatric and Neurologic Pharmacists (CPNP), a national pharmacy organization. He was the chair of the Continuing Education committee for two years at the Ernest Mario School of Pharmacy. He was on both behavioral health and pharmacy committees at Monmouth Medical Center. He has been very involved in CPNP on both the Mentoring committee for two years, and currently serving in the Recertification Committee helping to develop continuing education content for board certified psychiatric pharmacists. He also was an Adjunct Assistant Professor at Drexel School of Medicine in Philadelphia where he gave lectures to medical students. He has also lectured at the University of Medicine and Dentistry of New Jersey for physician assistants. He is also on the Board of Editors for the Annals of Pharmacotherapy and has been published in several peer-reviewed journals.

Anita E. Ciarleglio, Ph.D., Assistant Professor: Dr. Ciarleglio received her B.S. in pharmacy from St. Louis College of Pharmacy, and her Ph.D. in Pharmacology at St. Louis University School of Medicine. She is licensed as a registered pharmacist in Hawaii. She subsequently performed postdoctoral work at St. Louis and at the University of Miami School of Medicine. She has held many professional and instructional positions, notably conducting in-depth continuing education programs for pharmacists through Pacific Seminars Inc. and serving as an ambulatory care clinical pharmacist at Kaiser Permanente. Dr. Ciarleglio has instructed hundreds of students each semester through statewide distance-learning programs, as well as being highly active in several community education programs the pharmacy technology programs for the education of pharmacy technicians.

January 3, 2011 Page 2

ACPE Self Study: Appendix 25-1 Biographical Sketches

Lara Gomez, Pharm.D., Assistant Specialist, Clinical Education Coordinator: Dr. Gomez received her Doctor of Pharmacy degree at the University of New Mexico College of Pharmacy in 2001. Following an Infectious Disease residency at UNM/Health Sciences Center in 2002, she joined the Lovelace Sandia Women’s Hospital as a staff and clinical pharmacist. She has had teaching experience in the University of New Mexico Doctor of Pharmacy program and is certified in APhA Immunization Therapy, Diabetes, and Tobacco Treatment programs. She has been with KTA Pharmacy since she returned home to Hilo in 2005. Dr. Gomez holds professional licensure in the States of Hawaii and New Mexico.

Roy Goo, Pharm.D., Assistant Professor: Dr. Goo received his Doctor of Pharmacy Degree at the University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences in 2007 and completed a PGY-1 residency at Tripler Army Medical Center in 2008. Following the completion of his residency Dr. Goo developed the first Emergency Department Clinical Pharmacy Program for the Department of Defense while serving as a clinical pharmacist for both the Emergency Department and the Progressive Care Wards. Dr. Goo currently serves as an officer in the United States Army Reserve and joins the faculty of the University of Hawai`i at Hilo after working briefly as a long-term care consultant pharmacist on the islands of Kauai and Maui.

Patricia Jusczak, RPh, BPharm, Assistant Specialist, Clinical Education Coordinator: Pat Jusczak received her B.S. in Pharmacy from the Massachusetts College of Pharmacy and is licensed as a registered pharmacist in Massachusetts and New Hampshire. Her background includes work in community pharmacy practice, but most extensively in hospital pharmacy, for more than 30 years. Working in various practice models in acute care community hospital settings, she was Director of Pharmacy Services for over 13 years, Clinical Coordinator for over 8 years, and has practiced as a consulting pharmacist for an outpatient surgery center. During this time she developed, implemented, and managed drug formularies, drug distribution systems, drug therapy protocols, clinical intervention programs, pharmacy computer systems, and quality improvement programs. She has been preceptor to pharmacy students and adjunct faculty with colleges of pharmacy for more than 20 years. Her areas of specialty include medication safety, pain management, Joint Commission Standards for Hospitals, and medication management practice standards.

Eryn Kishimoto, PharmD., Assistant Specialist: Dr. Kishimoto received her Doctor of Pharmacy degree at the University of the Pacific and completed her post-graduate first year residency at The Queens Medical Center in Honolulu, Hawaii. Previous to her joining the college in June 2012, she was a clinical pharmacist at Hawaii Medical Center – Liliha. Dr. Kishimoto currently practices at Straub Hospital in Acute Medicine.

Carolyn S.J. Ma, Pharm.D., BCOP, CHTP/I, Associate Professor and Chair : Dr. Ma received her Doctor of Pharmacy degree from the University of California at San Francisco and completed a Clinical Pharmacy Residency at Thomas Jefferson University Hospital and second year Oncology Pharmacy Specialty Residency at The Hospital of the University of Pennsylvania. Dr. Ma practiced as a Board Certified Oncology Pharmacist at the Queens Medical Center in Honolulu for many years with subspecialty and program development experience in autologous bone marrow transplant, pain management and oncology drug

January 3, 2011 Page 3

ACPE Self Study: Appendix 25-1 Biographical Sketches research trials. She subsequently became Vice President for Clinical Programs for Am Med International in Hong Kong, a start up company that builds cancer clinics in China. Prior to her return to Hawaii in 2007, she was a management consultant for Stanford Hospitals and Clinics with expertise in JCAHO Medication Management as well as pharmacy and ambulatory care clinic workflow change management. Dr. Ma is also a certified practitioner and instructor of Healing Touch, an energy based bioenergy field complementary modality. She currently sits on the Board of Pharmacy and is current President for the Hawaii Pharmacists Association. In 2011, Dr. Ma was recipient of the Bowl of Hygeia award.

Christina Mnatzaganian, Pharm.D., Junior Specialist, Clinical Track Faculty: Dr. Mnatzaganian received her Bachelor’s of Science in Business Administration (2003) and Doctor of Pharmacy (2011) degrees from University of Arizona in Tucson. She completed the ASHP-accredited University of Hawaii-Hilo PGY1 Community Pharmacy Practice Residency in 2012 on the island of Maui. She is licensed as a pharmacist in Hawaii and Arizona and is a current member of the American Pharmacists’ Association, the American Society of Health- System Pharmacists, the American Association of Colleges of Pharmacy, and the Hawaii Pharmacists’ Association.

Yaw B. Owusu, Pharm.D., Assistant Professor: Yaw Owusu received his PharmD degree from Temple University School of Pharmacy, Philadelphia, PA in 2007. He completed a postgraduate pharmacy practice residency at Baylor University Medical Center, Dallas, TX in 2008. In July 2008, Owusu entered a postgraduate year 2 Ambulatory Care residency at The University of Texas at Austin and the Blackstock Family Health Center (University of Texas Southwestern - -Austin Family Medicine). From summer 2008 to summer 2010, he completed a Master of Science program at the University of Texas at Austin specializing in health outcomes research with the Divisions of Pharmacy Practice and Administration. Owusu has been a licensed pharmacist since 2007.

Candace Tan, Assistant Professor: Dr. Tan received her Doctor of Pharmacy Degree from the University of Southern California in 2009. Following this, she completed a primary care focused PGY-1 residency also at the University of Southern California and then joined the College of Pharmacy immediately after completion of the program. Dr. Tan is also a Board Certified Ambulatory Care Pharmacist (BCACP).

Sheri Tokumaru, Pharm.D., BCPS, Assistant Professor: Dr. Tokumaru received her Doctor of Pharmacy degree from the University of Michigan and completed a pharmacy practice residency at the University of California at San Francisco where she solidified her interest in critical care. She subsequently completed a specialized pharmacy residency in critical care at the University of Kentucky. After her training, Dr. Tokumaru worked as a clinical pharmacist at Cedars-Sinai and at the University of California San Diego Medical Center in various intensive care units. She most recently taught at the University of Illinois at Chicago College of Pharmacy where she precepted and mentored both students and pharmacy residents in the Neurosciences Intensive Care Unit and the Medical Surgical Intensive Care Unit. Dr. Tokumaru regularly taught throughout the pharmacy curriculum through lecturing in critical care topic areas, serving as a recitation leader and being a course coordinator. Her current practice site is in the Neurosciences Intensive Care Unit at The Queen’s Medical Center on Oahu. She

January 3, 2011 Page 4

ACPE Self Study: Appendix 25-1 Biographical Sketches lectures in the areas of infectious diseases, critical care and cardiology and enjoys teaching in both the didactic and clinical settings.

Peyton Wong, Pharm.D., Associate Specialist: Dr.Wong received his Pharm.D. degree from the University of California, San Francisco. He completed a Pharmacy Practice Residency at Boston University Medical Center. After his training, Dr. Wong practiced Clinical Pharmacy for next 13 years in areas of internal medicine and primary care, with an emphasis in anticoagulation, and served as an Adjunct Professor of Clinical Pharmacy at the University of the Pacific, School of Pharmacy. Prior to joining the faculty at the University of Hawaii, Hilo College of Pharmacy, Dr. Wong took on a more administrative role working as an Inpatient Anticoagulation Clinical Coordinator for a 1000-bed medical center in the San Francisco Bay area.

Supakit Wongwiwatthananukit, Pharm.D., Ph.D., Associate Professor: Dr. Wongwiwatthananukit received his B.S. in Pharmacy with First-class Honors from the Prince of Songkhla University, Thailand. He obtained his Pharm.D. with High Honors from College of Pharmacy, University of Illinois at Chicago. Subsequently, he earned his M.Sc. and Ph.D. in Pharmacy Practice from College of Pharmacy, Purdue University. Prior to joining the University of Hawaii at Hilo College of Pharmacy Dr. Wongwiwatthananukit was an assistant professor and graduate program coordinator of clinical pharmacy program at Chulalongkorn University, Bangkok, Thailand. He has been a graduate student advisor for more than 30 students and an active member of many academic committees. He received the Purdue Research Foundation Fellowship Award and the Jenkins-Knevel Award for Excellence in Research. He was also a winner of the Nagai Award for Pharmacy Practice Research, a recipient of 2010 Excellence in Teaching Award for Pharmacy Practice University of Hawaii at Hilo College of Pharmacy, and recently a 2010 winner of Outstanding Poster Presentation Award for Pharmacy Practice in the Research Conference in Pharmaceutical Sciences, Bangkok, Thailand. Dr. Wongwiwatthananukit’s research focuses on four research themes which include: (1) development and validation of an instrument to assess humanistic outcomes (e.g., health- related quality of life, self-efficacy, life-long learning); (2) applying state of the art pharmacoeconomic analysis and health outcomes research to conduct translational comparative effectiveness and cost-effectiveness research, which compares different interventions and strategies to prevent, diagnose, treat and monitor health conditions. The goal is to inform patients, providers, and decision-makers about which interventions, especially medication therapy, are most clinically and cost-effective for specific patients under specific circumstances and ultimately serve to improve community healthcare practices with larger and more diverse populations; (3) evaluation of the patient-oriented pharmacy services, medication therapy management, and clinical trials in the areas of tobacco cessation, dyslipidemia, obesity, diabetes, self-care, self-medication/herbals and dietary supplements; (4) characterization of components within natural products on their safety, efficacy and quality profiles using analytical tools to acquire molecular spatial data on minimally processed relevant natural products. He is the recipient of over a dozen grants and has published more than 30 articles in peer-reviewed research journals, six books, and other publications.

January 3, 2011 Page 5

ACPE Self Study: Appendix 25-1 Biographical Sketches

January 3, 2011 Page 6

Appendix E

Five Year Pro Forma Appendix E UHH-COLLEGE OF PHARMACY BUDGET PLAN 2011-2017 FY12 FY13 FY14 FY15 FY16

OPERATING BUDGET PERSONNEL FTE FTE FTE FTE FTE Faculty 45 $ 5,068,133 51 $ 5,590,652 54 $ 6,111,402 54 $ 6,111,402 54 $ 6,111,402 Staff 22 $ 1,020,378 16 $ 790,879 22 $ 1,000,290 22 $ 1,000,290 22 $ 1,000,290 Temporary 5 $ 182,284 7 $ 319,630 3 $ 111,423 3 $ 111,423 3 $ 111,423 PostDoctoral/Residents/Graduate Students 23 $ 1,021,864 19 $ 834,333 19 $ 834,333 19 $ 834,333 19 $ 834,333 Student 6 $ 26,113 5 $ 20,000 5 $ 20,000 5 $ 20,000 5 $ 20,000 Total Personnel $ 7,318,773 $ 7,555,494 $ 8,077,447 $ 8,077,447 $ 8,077,447 OPERATIONS Materials and Supplies $ 435,381 $ 316,298 $ 401,298 $ 401,298 $ 401,298 Travel $ 112,500 $ 112,500 $ 127,500 $ 127,500 $ 127,500 Printing $ 16,000 $ 16,000 $ 16,000 $ 16,000 $ 16,000 Library $ 90,000 $ 86,000 $ 86,000 $ 86,000 $ 86,000 Student Activity $ 90,000 $ 90,000 $ 90,000 $ 90,000 $ 90,000 Facility Forestry-Hilo(Utilities,Lease) $ 77,000 $ 77,000 $ 77,000 $ 77,000 $ 77,000 Gold Bond-Honolulu(Utilities, Lease) $ 246,000 $ 246,000 $ 246,000 $ 246,000 $ 246,000 Waiakea Research Station-Hilo(R&M) $ 120,000 $ 35,000 $ 35,000 $ 35,000 $ 35,000 Lihue, Kauai(Utilities, Lease) $ 102,000 $ 102,000 $ 102,000 $ 102,000 Modulars-Hilo(R&M) $ 10,000 $ 10,000 $ 10,000 $ 10,000 $ 10,000 Annex-Hilo(R&M) $ 5,000 $ 5,000 $ 5,000 $ 5,000 $ 5,000 Equipment/Maintenance Contracts $ 411,000 $ 397,000 $ 550,000 $ 400,000 $ 400,000 Utilities/Communications $ 75,000 $ 75,000 $ 75,000 $ 90,000 $ 90,000 Miscellaneous** $ 3,884,263 $ 5,962,983 $ 6,734,144 $ 6,249,782 $ 352,507 R&M $ 142,000 $ 142,000 $ 142,000 $ 100,000 $ 240,000 Total Operations $ 5,714,144 $ 7,672,780 $ 8,696,942 $ 8,035,580 $ 2,278,305 $3M Revenue Bond(Modulars) $ 205,500 $ 205,500 $ 205,500 $ 205,500 $5M Revenue Bond(New Building $ 315,000 $ 315,000 Total Operating Costs $ 13,032,917 $ 15,228,274 $ 16,979,889 $ 16,633,527 $ 10,670,752

REVENUE In-State Tuition Rates $ 17,364 $ 18,432 $ 18,432 $ 18,432 $ 18,432 Out-of State Tuition Rates $ 34,729 $ 35,784 $ 35,784 $ 35,784 $ 35,784

P1 Number of Students 90 (41/49) 88 (46/42) 90 (45/45) 90 (45/45) 90 (45/45) In-State Tuition Revenue $ 711,924 $ 847,872 $ 829,440 $ 829,440 $ 829,440 Out-of State Tuition Revenue $ 1,701,721 $ 1,502,928 $ 1,610,280 $ 1,610,280 $ 1,610,280

P2 Number of Students 90 (41/49) 94 (41/53) 88 (46/42) 90 (45/45) 90 (45/45) In-State Tuition Revenue $ 711,924 $ 755,712 $ 847,872 $ 847,872 $ 847,872 Out-of State Tuition Revenue $ 1,701,721 $ 1,896,552 $ 1,502,928 $ 1,502,928 $ 1,502,928

P3 Number of Students 87 (44/43) 84 (42/42) 94 (41/53) 88 (46/42) 90 (45/45) In-State Tuition Revenue $ 764,016 $ 774,144 $ 755,712 $ 755,712 $ 755,712 Out-of State Tuition Revenue $ 1,493,347 $ 1,502,928 $ 1,896,552 $ 1,896,552 $ 1,896,552

P4 Number of Students 89 (49/40) 86 (45/41) 84 (42/42) 94 (41/53) 88 (46/42) In-State Tuition Revenue $ 850,836 $ 829,440 $ 774,144 $ 774,144 $ 774,144 Out-of State Tuition Revenue $ 1,389,160 $ 1,467,144 $ 1,502,928 $ 1,502,928 $ 1,502,928

Tuition Revenue - PharmD $ 9,324,649 $ 9,576,720 $ 9,719,856 $ 9,719,856 $ 9,719,856 Tuition Revenue - PHD &MS $ 215,000 $ 245,000 $ 265,000 $ 265,000 Scholarship Fees $ (1,344,017) $ (1,246,734) $ (1,295,431) $ (1,298,031) $ (1,298,031) Admin/Operational Fees $ (489,586) $ (498,243) $ (499,243) $ (499,243) State Allocation $ 2,460,770 $ 2,460,770 $ 2,460,770 $ 2,460,770 $ 2,460,770 State Reduction $ (1,183,880) $ (1,429,956) $ (370,000) $ (370,000) $ (370,000) Application Fee $ 38,700 $ 43,900 $ 40,000 $ 40,000 $ 40,000 RTRF(est 6% from year prior grants) $ 51,609 $ 216,577 $ 319,987 $ 372,383 $ 352,507 Extramural Grants/Contracts $ 3,213,872 $ 5,333,124 $ 6,206,375 $ 5,875,118 Gifts $ 618,782 $ 413,282 $ 207,782 $ 2,282 Carry Over from the year before $ 147,568 $ 12,391 $ 68,598 $ 3,205 Total Revenue $ 13,180,485 $ 15,240,665 $ 17,048,487 $ 16,636,732 $ 10,674,064

Difference $ 147,568 $ 12,391 $ 68,598 $ 3,205 $ 3,313 **Expenditures are based on operating costs associated with grants and contracts, including subcontracts, personnel, equipment, supplies, travel, etc.

Appendix F

Tuition for the CoP ATTACHMENT 1 Page 2 of 6

University of Hawai'i Tuition1 SELECT ADVANCED PROFESSIONAL PROGRAMS PER-CREDIT-HOUR AND FULL-TIME SEMESTER TUITION SCHEDULE

Academic Years 2012-2013 2013--2014 2014-2015 2015--2016 2016-2017 Resident Nonresident Resident Non reside nt Resident Nonresident Resident Nonresident Resident Nonresident 2 UH MANOA Per SH I FT Per SH I FT Per SH I FT Per SH I FT Per SHI FT Per SH I FT Per SH I FT PerSH I FT Per SH I FT Per SH I FT

3 Graduate Susiness 733 I 8796 1239 I 14868 764 I 9168 1311 I 15732 B02 I 9624 1400 I 16800 843 I 10116 1496 I 17952 887 I 10644 1598 I 19176 I I I I I I I 1 I I I I I I I I I I I Graduate Education (EdD) 532 I 6384 1222 I 14664 566 I 6792 1297 I 15564 608 I 7296 1390 I 16680 653 I 7B36 1489 17868 701 I 8412 1595 I 19140 I I I I I I I I I I I I I I I I , I Graduate Nursing 763 I 9156 1453 I 17436 B11 I 9732 1542 I 18504 870 I 10440 1652 I 19824 933 I 11196 1770 21240 1001 I 12012 1896 I 22752 I I I I I I I I I Law I I I I I I I I I I I I I I I I I I JD 726 I 8712 1409 I 16908 764 I 9168 1510 I 18120 811 I 9732 1633 I 19596 870 I 10440 1766 21192 933 I 11196 1909 I 22908· I I I I I I I I I I I I I I I I I I LLM 1455 I 17460 1455 I 17460 1529 I 18348 1529 I 18348 1622 I 19464 1622 I 19464 1737 I 20844 1737 20844 1860 I 22320 1860 I 22320 I I I I I I I I I I I I I I I I I I Medicine 1253 I 15036 2638 I 31656 1317 I 15804 2718 I 32616 1384 I 16608 2800 I 33600 1454 I 17448 2885 34620 1528 I 18336 2972 I 35664

2 UH HIL0 I I I I I I I I I I I I I I I I I I I I Graduate Nursing 598 I 7176 1196 I 14352 635 I 7620 1269 I 15228 680 I 8160 1359 I 16308 729 I 8748 1455 I 17460 781 I 9372 1558 I 18696 I I I I I I I I I I I I I I I I I I I I Pharmacy 768 I 9216 1491 I 17892 815 I 9780 1536 I 18432 865 I 10380 1583 I 18996 918 I 11016 1631 I 19572 974 ' 11688 1680 I 20160 I I I I I I I I I I

1 All students are subject to campus-based student fees not shown here.

2 Full-time (FT) tuition applies to students enrolling for 12 or more credits. In accordance with University concurrent enrollment policy, students enrolling at multiple institutions/campuses during the same term pay the applicable tuition at each campus. Unless a special tuilion schedule applies. regular day tuition applies to any credit course offered throughout the year for which a General Fund appropriation is authorized.

3 The CSA master's degrees offered in executive format charge the resident tuition established here plus additional fees delegaled \0 and approved by the President.

Approved by the Board of Regents: October 26, 2011

Appendix G

Faculty Funding PI Name Title Award Sponsor Award Amount Award Start Date Award End Date Andre Bachmann Development of Neuroblastoma Therapeutics by Optimization of Polyamine Inhibitor Strategy University of Hawaii Foundation 40,488 9/1/10 5/31/12 Andre Bachmann In Vivo Efficacy of Novel Proteasome Inhibitors in Neuroblastoma Hawaii Community Foundation (HCF) 47,372 9/1/10 11/5/12 Andre Bachmann CA-111419-04 Polyamines NIH 91,243 9/1/10 6/30/12 Anthony Wright CA143727-03ArecaNut Chemistry UHH-JABSOM Cancer Center 45,795 9/1/11 8/31/12 Anthony Wright CA143727-03Pre-Pilot Project UHH-JABSOM Cancer Center 37,312 9/1/11 8/31/12 Anthony Wright CA143727-04 Guam 54 Pilot Project III UHH-JABSOM Cancer Center 29,391 9/1/12 8/31/13 Anthony Wright CA143727-04 Guam 54 Pre Pilot Project I UHH-JABSOM Cancer Center 24,606 9/1/12 8/31/13 Carolyn Ma Hawaii State Asthma Initiative State of Hawaii - Dept of Health 9,500 3/20/12 12/31/12 Dana-lynn Koomoa MYCN-induced calcium and magnesium signaling regulates Neuroblastoma progression NIH 134,922 9/12/12 8/31/17 Dana-lynn Koomoa ALSF DFMO-Based NIH 44,404 6/16/10 12/31/12 Deborah Juarez Reducing Cost-Related Medication Nonadherence in Persons with Diabetes Pacific Health Research & Education Institute 23,823 9/1/11 8/31/12 Dianqing Sun Development of Novel Natural Product-inspired Antibacterial Agents for Treating Pulmonary Tuberculosis HAWAII COMMUNITY FOUNDATION (HCF) 50,000 8/16/12 2/15/14 Dianqing Sun Development of Piperidinois and Engelhardiones as Novel Antituberculosis Agents NIH 406,257 9/1/11 8/31/14 Edward Fisher Instruction in Clinical Psychopharmacology at Tripler Army Medical Center DEFENSE, DEPT-ARMY TRIPLER MEDICAL CTR 752,192 9/30/12 9/29/13 Eugene Konorev Inhibition of cardiac vascular network formation by targeted anticancer drug sorafenib HAWAII COMMUNITY FOUNDATION MED RSCH FUNDS 49,993 5/16/12 11/15/13 John Pezzuto "Pharm2Pharm" Service Innovation in Rural Hawaii HEALTH & HUMAN SVC, DEPT-CTR FOR MEDICARE & MEDICAID S 14,346,043 7/1/12 6/30/15 John Pezzuto Clinical Pharmacy Training Program Fy 2011 Education, Dept - FED 1,500,000 9/1/10 8/31/12 John Pezzuto INBRE NIH 3,244,858 6/1/10 5/31/13 Karen Pellegrin Beacon -Sub award (Jacobs, M Pezzuto, Heffernan) 35,296 Karen Pellegrin 90BC0012/01 HI CTY Beacon Commconst NIH 14,522,189 4/1/10 5/31/13 Kenneth Morris UHH Outreach Partner Proposal for the NSF-ERC-SOPS RUTGERS, STATE UNIVERSITY OF NEW JERSEY 50,000 7/1/11 6/30/12 Kenneth Morris materials and dosage form characterization GLAXOSMITHKLINE 78,688 7/1/12 6/30/13 Kenneth Morris UHH Outreach Partner Proposal for the NSF-ERC-SOPS RUTGERS, STATE UNIVERSITY OF NEW JERSEY 80,000 7/1/11 6/30/13 Lara Gomez Rural East Hawaii Workforce Development Network Bay Clinic, Inc. 120,000 9/1/10 8/31/13 Leng Chee Chang BRIDGES-Potential of Physalis peruviana(poha) in the Treatment of Breast UHH-JABSOM Cancer Center 25,000 9/1/12 7/31/13 Linda Connelly Osteoprotegerin in breast cancer cells: role in tumor growth and metastasis NIH 410,100 9/1/12 8/31/15 Linda Connelly Role of Endogenous Osteoprotegerin Expression in Breast Cancer Metastasis Hawaii Community Foundation (HCF) 50,000 5/18/11 11/18/12 Mahavir Chougule Transdermal Permeation of Magnesium Supplement Cream Formulations Across Skin Center for Magnesium Education and Research, LLC 16,347 10/25/11 4/25/12 Mahavir Chougule Targeted Nanocarriers of siRNA for the Treatment of Asthma HCF-Leahi Fund 35,000 8/18/11 2/18/13 Robert Borris EPSCOR NSF 979,510 9/1/09 8/31/14 Susan Jarvi A statewide targetedgp pathofen surveillance study:y Diversityy of Avipoxvirusp and avian malaria in native Hawaiian forest birds INTERIOR,, DEPT-FISH & WILDLIFE SVC 58,414, 9/1/12 3/1/14 Susan Jarvi Efficacy of a vaccine against Angiostrongylus costaricensis to A. cantonensis in rats (Rattus rattus) from Hawaii. HAWAII COMMUNITY FOUNDATION MED RSCH FUNDS 40,000 7/20/12 1/20/14 Susan Jarvi Evaluation of a vaccine for rat lung-worm (Angiostrongylus cantonesis) Agriculture, Dept - Animal and Plant Health Inspection Service 33,550 9/10/12 9/9/13 Overall - Total 37,412,293

Appendix H

Major Equipment

Large Equipment

• Two (2) Bruker Avance DRX 400MHz multinuclear NMR spectrometers • Varian MS500-IT LC-MSn system with ESI and APCI interfaces • Agilent 6530 LC-qTOF mass spectrometer with ESI and APCI interfaces • Agilent 7000B GC-QQQ mass spectrometer • Bruker powder X-ray diffractometer • Mettler Toledo TGA/DSC1 • Shimadzu UV-1800 and UV-Mini 1240 UV/Vis spectrophotometers • Nicolet iS10 FTIR with Centaurus microscope • Jasco J815 CD spectropolarimeter • Rudolph Research Autopol IV multiwavelength polarimeter • Buchi B540 melting point instrument • Beckman Quanta MPL flow cytometer • Accuri C6 flow cytometer • Sorvall WX90 Ultracentrifuge • Perkin Elmer Cyclone Plus Phosphor Scanner • Perkin Elmer Geliance 1000 gel imager • Perkin Elmer Wizard beta counter • Perkin Elmer 2480 gamma counter • Perkin Elmer Tricarb 2910 TR liquid scintillation counter • Perkin Elmer Microbeta Trilux Microplate Liquid Scintillation Counter • Beckman Coulter LS6500 multipurpose liquid scintillation counter • Perkin Elmer Microbeta Filterman-96 cell harvester • Stratagene Mx3005P realtime QPCR system • Applied Biosystems StepOne realtime QPCR system • BioRad CFX-96 realtime QPCR systems BioRad C1000 thermal cyclers • Agilent 2100 Bioanalyzer • Licor Odyssey infrared imager • Biotek Synergy 2, Synergy MX, MicroQuant and ELx800 microplate readers • Perkin Elmer Victor-X5 microplate reader • Lumistar luminescence plate readers • Perkin Elmer Operetta High Content Screening System with integrated CO-2 incubator, Columbus Data Manager, and Volocity 3D image analysis software • Leica TCS-SPE laser confocal microscope • Zeiss, Leica and Olympus upright, inverted, stereo, and fluorescence microscopes • Patchclamp electrophysiology system • New Brunswick I24 and E24R shakers • Fisher Isotemp and NAPCO CO2 incubators and forced air incubators • Thermo Excelsior ES tissue processor • Thermo Microm 360 microtome • Thermo Microm HM550 cryostat microtome • Several Mettler-Toledo and Shimadzu analytical and toploading balances • Cahn Analytical C-35 microbalance • Several Buchi and Heidolph rotary evaporators with Lauda recirculating chillers • Heidolph LR20 20 liter rotary evaporator • 4 Savant SpeedVac concentrators • Genevac EZ2plus evaporator system • 2 Labconco Freezone Plus lyophilizers • Yamato, Market Forge and Tuttnauer autoclaves • Sorvall Legend XTR and Micro 21R centrifuges • Numerous pH meters (Orion and Mettler), hotplates, stirrers and vortex mixers • CEM Discover and Biotage Initiator microwave reactors • Ten (10) analytical HPLC systems (Beckman Series Gold, Shimadzu Prominence, Dionex Ultimate 3000, PE Series 200, Waters 600e), Agilent 1220 Infinity with PDA or UV/Vis detectors, Shimadzu and Varian ELSD detectors, Waters Fluorescence detector, ESA Coulochem III electrochemical detector and a Dionex Corona ultra CAD detector • Two (2) preparative HPLCs (Shimadzu) • Two (2) Biotage Isolera flash chromatography systems • Two (2) MPLC system (Buchi), LPLC pumps (FMI), with a variety detectors and other components • Kromaton HPCPC system with 50ml, 200ml and 1L rotors and a multiwavelength detector • Numerous Refrigerators, -20C freezers, -80 freezers and liquid nitrogen storage systems • Rigaku LN40 liquid nitrogen generator • BT Industries spinning band distillation system • SG-Water Glass Contour solvent purification system • New Brunswick CelliGen BLU mammalian cell bioreactor • Eppendorf bench top centrifuges (5810R, 5702, 5424, 5424R, 5430R)

Appendix I

Faculty Publications University of Hawai`i at Hilo College of Pharmacy Publishing Report 2007-2012

Julie Ann Luiz Adrian, DVM, Assistant Professor/Veterinary Pharmacy, Pharmacy Practice

1. Adrian JAL, Arancon N, Mathews B, Carpenter. Proximate analysis, in vitro organic matter digestibility, and energy content of common guava (Psidium guajava L.) and yellow, strawberry guava (Psidium cattleianum var. lucidum) tree parts and fruits as potential forage. Journal of Agricultural and Food Chemistry, in press. 2. Adrian JA, Vu T, Hayashi K. The new cooperative medical system in China: a cure for all? International Journal of Healthcare Information Systems and Informatics, 7(3), 2012. 3. Vu T, Adrian JA. Pharmacy and veterinary pharmacy education – facts and forecast. Journal of Global Business Development, 3(1):15-19, 2011. 4. Adrian JAL, Arancon NQ. Effect of high forage oxalate and calcium consumption on goat urine characteristics. International Journal of Livestock Production, 2(3):31-39, 2011. 5. Duponte M, Adrian J, Cleveland E. A feeding trial of fortified dehydrated garbage for growing swine in Hawaii. Pacific Agriculture and Natural Resources, 1(1):36-40, on-line November 2009. 6. Cleveland E, Arancon N, Adrian J. Treating foot rot in goats using a zinc sulfate foot bath. Pacific Agriculture and NaturalResources, 1(1):49-51, on-line November 2009. 7. Luiz-Adrian JA, Deliramich AN, Frueh BC. Complicated grief and posttraumatic stress disorder in humans’ response to the death of pets/animals. The Bulletin of the Menninger Clinic, 73(3):176-187, 2009. 8. Luiz JA, Heseltine J. Five common toxins ingested by dogs and cats. Compend Contin Educ Pract Vet, 30(11):578-588, 2008. 9. Luiz-Adrian JA. Leptospirosis: identification and treatment in companion animals. J. Hawaiian Pacific Agric, 15, 2008. 10. Luiz JA. Giant marine toad, Bufo marinus L., poisoning in Hawaii: symptoms and treatment. J. Hawaiian Pacific Agric, 14:67-68, 2007. 11. Luiz JA. Clinical snapshot: 2 year-old, female, miniature Dachshund. Compend Contin Educ Pract Vet, 29(4):192-194, 2007. 12. Luiz JA. Clinical snapshot: 2 year-old, castrated, mixed breed dog. Compend Contin Educ Pract Vet, 29(6):336-338,2007. 13. Luiz JA. Diagnostic challenge, hermaphrodite. Vet Pract News, 19(6):19- 21,2007.

PUBLICATION UNDER REVIEW 1. Cleveland E, Adrian J. Treatment of goat dermatitis using raw honey. American Holistic Veterinary Medical Association.

André S. Bachmann, PhD, Chair and Associate Professor, Pharmaceutical Sciences

1. Yco LP, Geerts D, Koster J, Bachmann AS*. PRAF2 mediates cell proliferation and metastasis in neuroblastoma, International Journal of Oncology, In Press (2012).

2. Koomoa DT, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS*. DFMO inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. International Journal of Oncology, In Press (2012).

3. Archer CR, Groll M, Stein M, Schellenberg B, Clerc J, Kaiser M, Kondratyuk TP, Pezzuto JM, Dudler R, Bachmann AS*. Activity enhancement of synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells. Biochemistry, 51(34):6880-6888 (2012).

4. Gawecka JE1, Geerts D1, Koster J, Caliva MJ, Sulzmaier FJ, Opoku- Ansah J, Wada RK., Bachmann AS, Ramos JW*. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma, International Journal of Cancer, 131:1556-1568 (2012).

5. Opoku-Ansah J, Ibarra-Rivera TR, Pirrung MC*, Bachmann AS*. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma. Pharmaceutical Biology, 50: 25-29 (2012).

6. Ibarra-Rivera TR, Opoku-Ansah J, Bachmann AS*, Pirrung MC*. Syntheses and cytotoxicity of syringolin B-based proteasome inhibitors. Tetrahedron, 67: 9950-9956 (2011).

7. Clerc J, Li N, Krahn D, Groll M, Bachmann AS, Florea BI, Overkleeft HS, Kaiser M*. The natural product hybrid of syringolin A and glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chemical Communications, 47: 385-387 (2011).

8. Geerts D, Koster J, Albert D, Koomoa DT, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS*. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 are prognostic markers for aggressive neuroblastoma independent of MYCN amplification status. International Journal of Cancer, 126: 2012-2024 (2010).

9. Archer CR, Koomoa DT, Clerc J, Shimizu M, Kaiser M, Schellenberg B, Dudler R, Bachmann AS*. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy involves p53 accumulation as well as Akt/PKB activation in neuroblastoma cells. Biochemical Pharmacology, 80: 170- 178 (2010).

10. Borsics T, Lundberg E, Geerts D, Koomoa DT, Koster J, Wester K, Bachmann AS*. Subcellular localization and expression of PRAF2 in malignant glioma: influence on cell survival and migration. Cancer Science, 101: 1624-1631 (2010).

11. Clerc J, Schellenberg B, Groll M, Bachmann AS, Huber R, Dudler R, Kaiser M*. Convergent synthesis and biological evaluation of Syringolin A and derivatives as eukaryotic 20S proteasome inhibitors. European Journal of Organic Chemistry, 2010: 3991-4003 (2010).

12. Clerc J, Groll M, Illich DJ, Bachmann AS, Huber R, Schellenberg B, Dudler R, Kaiser M*. Synthetic and structural studies on Syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proceedings of the National Academy of Sciences USA, 106: 6507-6512 (2009).

13. Koomoa DT, Borsics T, Feith DJ, Coleman CS, Wallick CJ, Gamper I, Pegg AE, Bachmann AS*. Inhibition of S-adenosylmethionine decarboxylase by the competitive inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/PKB regulation and apoptotic cell death in neuroblastoma, Molecular Cancer Therapeutics, 8: 2067-2075 (2009).

14. Clerc J, Florea BI, Kraus M, Groll M, Huber R, Bachmann AS, Dudler R, Driessen C, Overkleeft HS, Kaiser M*. Syringolin A selectively labels the 20S proteasome in murine EL4 and wildtype and bortezomib-adapted leukemic cell lines, Chembiochem, 10: 2638-2643 (2009).

15. Groll M1, Schellenberg B1, Bachmann AS*, Archer CR, Huber R, Lindow S, Kaiser M*, Dudler R*. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature, 452: 755-758 (2008).

16. Koomoa DT, Go RV, Wester K, Bachmann AS*. Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles. Neuroscience Letters, 436: 171-176 (2008).

17. Koomoa DT, Yco LP, Borsics T, Wallick CJ, Bachmann AS*. Ornithine decarboxylase inhibition by DFMO activates opposing signaling pathways via phosphorylation of both Akt/PKB and p27Kip1 in neuroblastoma. Cancer Research, 68: 9825-9831 (2008).

18. Bachmann AS*, Archer CR, Schellenberg B, Dudler R. Profiling of cancer cell signaling pathways activated by a novel proteasome inhibitor class (syrbactins) in human neuroblastoma. European Journal of Cancer, Supplements, 6(12): 72-73 (2008).

19. Bachmann AS*. Proteasome Inhibitors in Pediatric Cancer Treatment. Hawaii Medical Journal, 67: 247-249 (2008).

20. Geerts D1, Wallick CJ1, Koomoa DT, Koster J, Versteeg R, Go RV, Bachmann AS*. Expression of PRA1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clinical Cancer Research, 13: 6312-6319 (2007).

Book Chapters:

1. Bachmann AS Levin VA. Clinical applications of polyamine-based therapeutics In: Woster P, Casero Jr R (eds), Polyamine Drug Discovery (Chapter 11). Royal Society of Chemistry, London, p. 257-276 (2012). 2. Bachmann AS, Geerts D, Sholler G. Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention In: Hayat E (ed), Pediatric Cancer: Diagnosis, Therapy, and Prognosis: Neuroblastoma (Volume 1, Chapter 9). Springer Company, Germany, p. 91-103 (2012).

Robert P. Borris, PhD, Associate Dean for Research and Associate Professor

1. Cheenpracha, S., Borris, R.P., Tran, T.T., Jee, J.M., Seow, H.F., Cheah, H.- Y., Ho, C.C., and Chang, L.C. (2011). 2. Three New Amides from Streptomyces sp. H7372.J. Braz. Chem. Soc. 22 (2), 223-229. Published online 21 September 2010 3. Clark, B.R., Suzuki, J.Y., Bliss, B.R., and Borris, R.P. (2012) Flavone C- glycosides from Anthurium andreanum. Nat. Prod. Commun. 7 (6) 747-748. 4. Youn, U.-J., Park, E.-J., Kondratyuk, T.P., Simmons, C.J., Borris, R.P., Tanamatayarat, P., Wongwiwatthananukit, S., Toyama, O., Songsak, T., Pezzuto, J.M., and Chang, L.C. (2012) 5. Anti-inflammatory Sesquiterpene Lactones from the Flower of Vernonia cinerea. Bioorg. Med. Chem. Lett. In press. Published online 14 July 2012 (http://dx.doi.org/10.1016/j.bmcl.2012.07.010)

Leng Chee Chang, PhD, Assistant Professor, Pharmaceutical Sciences

1. Ul-Haq I, Youn UJ, Park E-J, Chai X-Y, Kondratyuk TP, Marler LE, Mirza B, Pezzuto JM, Chang LC. (2012). Biologically Active Withanolides from Withania coagulans Dunal. J. Nat. Prod. Submitted. 2. Youn UJ, Park E-J, Kondratyuk TP, Simmons CJ, Borris R, Wongwiwatthananukit S, Tanama tayarat, P, Toyama O, Songsak T, Pezzuto JM, Chang LC. (2012). Anti-inflammatory sesquiterpene lactones from the flower of Vernonia cinerea. Bioorganic and Medicinal Chemistry Letters. 22, 5559-5562. 3. Eun-Jung Park, Cheenpracha S, Chang LC, Pezzuto JM. (2011). Suppression of of cyclooxygenase-2 and inducible nitric oxide synthase expression by epimuqubilin A via IKK/IκB/NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells. Phytochem Lett. 4, 426-431. 4. Eun-Jung Park, Cheenpracha S, Chang LC, Pezzuto JM. (2011). Inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression and inducible nitric oxide synthase by 4-[(2′-O-acetyl-α-L-rhamnosyloxy]benzyl]isothiocyanate from Moringa oleifera. Nutr and Cancer. 63, 971-82. 5. Yip, WK, Cheenpracha S, Chang LC, Ho CC, Seow HF. (2010). Anti- proliferative and anti-invasive properties of a purified fraction from Streptomyces sp. H7372. Int J of Oncol. 37, 1229-1241. 6. Yao GM, Sebisubi FM, Voo LK, Ho CC, Tan GT, Chang LC. (2011). Citrinin Derivatives from the Soil Filamentous Fungus Penicillium sp. H9318. J. Braz. Chem. Soc. 22, 1125-1129. 7. Cheenpracha S, Borris RP, Tran TT, Jee JM, Seow HF, Cheah HY, Ho CC, Chang LC. (2011) Three new amides from Streptomyces sp. H7372. J. Braz. Chem. Soc. 22, 223-229. 8. Cheenpracha S, Park E-J, Yoshida WY, Barit C, Wall M, Pezzuto JM, Chang LC. (2010) Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. Bioorg. Med. Chem. 17, 6598-6602. 9. Cheenpracha S, Park E-J, Rostama B, Pezzuto JM, Chang LC. (2010) Inhibition of Nitric Oxide (NO) Production in Lipopolysaccharide (LPS)- activated Murine Macrophage RAW 264.7 Cells by the Norsesterterpene Peroxide, Epimuqubilin A. Marine Drugs. 8, 429-437. PMCID: PMC2857364 10. Cheenpracha S, Vidor NB, Yoshida WY, Davies J, Chang LC. (2010) Coumabiocins A-F, Aminocoumarins from an Organic Extract of Streptomyces sp. J. Nat. Prod. 73, 880-884. NIHMSID: NIHMS195876 11. Cheenpracha S, Zhang H, Mar MNA, Foss AP, Foo SK, Lai NS, Jee JM, Seow HF, Ho CC, Chang L C. (2009). Yeast Glycogen Synthase Kinase-3β Pathway Inhibitors from an Organic Extracts of Streptomyces sp. J. Nat. Prod. 72, 1520-1523. 12. Yao GM, Kondratyuk TP, Tan GT, Pezzuto JM, Chang LC. (2009). Bioactive Sulfated Sesterterpene Alkaloids and Sesterterpene Sulfates from the Marine Sponge Fasciospongia sp. J. Nat. Prod. 72, 319-323. 13. Ghufran MA, Qureshi RA, Batool A, Kondratyuk TP, Guilford JM, Marle LE, Chang LC, Pezzuto J M. (2009). Evaluation of Selected Indigenous Medicinal Plants from the Western Himalayas for Cytotoxicity and as Potential Cancer Chemopreventive Agents. Pharm. Biol. 47, 533-538. 14. Ankudey FJ, Kiprof P, Stromquist ER, Chang LC. (2008). New Bioactive Bromotyrosine-Derived Alkaloid from a Marine Sponge Aplysinella sp. Planta Med. 74, 555-559. 15. Zhang H, Skildum A, Stromquist E, Hellekant T-R, Chang LC. (2008). Bioactive Polybrominated Diphenyl Ethers from the Marine Sponge Dysidea sp. J. Nat. Prod. 71, 262-264. 16. Yao GM, Chang LC. (2007). Novel Sulfated Sesterterpene Alkaloids from the Marine Sponge Fasciospongia sp. Org. Lett. 9, 3037-3040. 17. Grüschow S, Chang LC, Mao Y, Sherman DH. (2007). Hydroxyquinone O- Methylation in Mitomycin Biosynthesis. J. Am. Chem. Soc. 129, 6470-6476. 18. Shao N, Yao GM, Chang LC. (2007). Bioactive Constituents from the Marine Crinoid Himerometra magnipinna. J. Nat. Prod. 70, 869-871. 19. Barker L,Lien BA, Brun O, Schaak DD, McDonough KA, Chang LC. (2007). A Mycobacterium marinum Zone of Inhibition Assay as a Method for Screening Potential Antimycobacterial Compounds from Marine Extracts. Planta Medica. 73, 1-5. 20. Yao GM, Vidor NB, Foss AP, Chang LC. (2007). Lemnalosides A-D: Decalin- Type Bicyclic Diterpene Glycosides from the Marine Soft Coral Lemnalia sp. J. Nat. Prod. 70, 901-905.

Benjamin Chavez, PharmD, Assistant Professor, Pharmacy Practice

1. Chavez B. The role of second generation antipsychotics in autism disorder. Mental Health Clinician. Sept 2012. 2. Fuller RA, Chavez B. Ticagrelor (Brillinta), an antiplatelet drug for acute coronary syndrome. P & T. 2012;37(10). 3. Chavez B, Gilliam EH, Pathak R, Volino LR. Popular game shows as educational tools in the pharmacy classroom. Currents in Pharmacy Teaching and Learning 2012;4:146-149. 4. Chavez B, Hughes F. The Use of Short Downloadable Lectures to Supplement Didactic Lectures. Currents in Pharmacy Teaching and Learning 2012;4(1):16-18. 5. Ornellas T, Chavez B. Naltrexone SR/ Bupropion SR (Contrave): A new approach to weight loss in obese adults. P&T 2011;36(5).:255-62. 6. Chavez B, Reilly T. Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history. J Clin Psych 2010;71(12):1696-98. 7. Sopko MA, Caberwal H, Chavez B. The safety and efficacy of methylphenidate and dexmethylphenidate in adults with attention deficit/hyperactivity disorder. Journal Central Nervous System Disease 2010;2: 9-14. 8. Chavez B, Gilliam EH, Patel RP, Pathak R. Use and Assessment of Debate Instructional Method in a Pharmacy Elective. [abstract] American Journal of Pharmacy Education 2010; 74(5):66. 9. Chavez B, Volino LR, Gilliam EH, Pathak R. Fun with Pharmacy: Game Show Activities in the Classroom. [abstract] American Journal of Pharmacy Education 2010; 74(5):64. 10. Chavez B, Hughes F. Downloadable Audio Lectures to Enhance Learning in the Pharmacy Curriculum. [abstract] American Journal of Pharmacy Education 2010; 74(5):60. 11. Chavez B, Reilly T. Leuprolide-induced mania with psychotic symptoms in a male patient with no prior psychiatric history. [abstract] J Pharm Practice 2010; 23(2):151. 12. Chavez B, Zaidi S, Barone JA. Collaborative Practice Between a Psychiatric Pharmacist and a Child and Adolescent Psychiatrist in a Private Outpatient Clinic. [abstract] J Pharm Practice 2010; 23(2): 13. Huang MH, Chavez B. Improving Patient Medication Adherence after Pharmacist Counseling upon Discharge from a Mental Health Facility. [abstract] J Pharm Practice 2010; 23(2):178 14. Gerhard T, Chavez B, Olfson M, Crystal S. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharm 2009;29(3):307-10. 15. Chavez B, Sopko M, Ehret M, et al. An Update on CNS Stimulant Formulations in Children and Adolescents with ADHD. Ann 16. Reilly T and Chavez B. Tolvaptans (Samsca®) for hyponatremia: Is it worth its salt? P & T 2009;34(10):543-47. 17. Bogart GT and Chavez B. Safety and efficacy of quetiapine in bipolar depression. Ann Phamacother 2009; 43(11):1848-56. 18. Chavez B, Rynn K, Zaidi S. Dextromethorphan and chlorpheniramine overdose during first-trimester pregnancy in an adolescent [abstract]. J Pharm Practice 2009;22(2):264. 19. Chavez B and Wagner M. Real-Time Student Evaluations of Faculty Teaching Using a Web-Based Course Management Program [abstract]. Am J Pharm Ed. 2008;72(3):49. 20. Chavez B, Chavez-Brown M, Sopko MA, Rey JA. A Review of the Literature on Atypical Antipsychotics in Children With Pervasive Developmental Disorders. Pediatric Drugs 2007;9(4):249-66. 21. Chavez B, Sherwood DA, McCue M. Extended-release Paliperidone (Invega®): The First Controlled-Release Atypical Antipsychotic. P & T 2007; 32(11).

22. Chavez B, Chavez-Brown M, Rey JA. Role of Risperidone in Children with Autism Spectrum Disorder. Ann Pharmacother 2006;40:909-16. 23. Chavez B and Poveda R. Efficacy With High-Dose Aripiprazole After Olanzapine Related Metabolic Disturbances. Ann Pharmacother 2006;40:2265-2268 24. Chavez B. Review of Posttraumatic Stress Disorder. US Pharm. 2006;11:31-38. 25. Ehret M and Chavez B. A Review of the STAR*D Trial. Journal of Pharmacy Practice. 2006;19(6):353-60. 26. Chavez B. Pharmacotherapy in Managing Insomnia: Assessing Patient Needs and Outcome. US Pharm 2005;30(2): HS23-26. 27. Chavez B and Rey JA. Eszopiclone (Lunesta®): A New Non- benzodiazepine Sedative-Hypnotic. P & T. 2005.;30(7):388-391. 28. Publications – Book Chapters 29. Chavez B. Pediatric Psychiatric Issues or Disorders Usually First Diagnosed in Childhood or Adolescence. Board Certification in Psychiatric Pharmacy Review Book 2012-2013. 30. Chavez B. Pediatric Psychiatric Issues or Disorders Usually First Diagnosed in Childhood or Adolescence. Board Certification in Psychiatric Pharmacy Review Book 2010-2011.

Mahavir Chougule, Assistant Professor, Pharmaceutical Sciences

1. Chougule M, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of Amiloride Hydrochloride. J Nanosci Nanotechnol 2006, 6(9-10):3001-9. 2. Chougule M, Padhi B, Misra A., Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int J Nanomedicine, 2007, 2(4):675-88. 3. Chougule M, Padhi B, Misra A, Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone, AAPS PharmSciTech. 2008, 9(1):47-53 4. Jackson T., Chougule M., Ichite N., Patlolla R., and Singh M. Antitumor activity of Noscapine in Human Non-small cell lung cancer xenograft model. 2008, Cancer Chemother Pharmacol. 63(1):117-26. 5. Ichite, N., Chougule, M, Jackson, T., Fulzele, S., Safe, S. and Singh, M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin. Cancer Res. 2009, 15:543-552. 6. Padhi B, Chougule M, Misra A, Aerosol performance of large respirable particles of amikacin sulfate produced by spray and freeze drying techniques, Curr Drug Deliv. 2009, 6(1):8-16 7. Chougule M., Ichite N., Patel AR, Jackson T., Safe S.and Singh M., Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer, Molecular Cancer Therapeutics, 2010 Nov;9(11):3003-14. 8. Patlolla R., Chougule M., Patel AR., Jackson T., and Singh M, Celecoxib encapsulated nanostructured lipid carrier system for pulmonary delivery, J. Control. Release, 2010; 144(2), 233-41. 9. Chougule M.,Patel AR, Sachdeva P., Jackson T., and Singh M., Anti-cancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer, Lung Cancer, 2010 Jul 29. [Epub ahead of print] (PMID 20674069) 10. Chougule M., A. R. Patel, T. Jackson, and M Singh, Antitumor activity of noscapine in combination with Doxorubicin in triple negative breast cancer, , PLoS One. 2011 6(3):e17733. 11. Chougule M., A. R. Patel, T. Jackson, and M Singh, "Enhanced anticancer activity of Gemcitabine in combination with Noscapine via antiangiogenic and apoptotic pathway against Non-Small Cell Lung Cancer", PLoS One. 2011;6(11):e27394 12. Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and In Vitro-In Vivo Correlation (IVIVC) of novel methylene- substituted 3,3' diindolylmethane (DIM)., Eur J Pharm Sci. 2012 May 12;46(1- 2):8-16. 13. Chougule M, Tekade R, Current Scene and Prospective Potentials of siRNA in Cancer Therapy, J Pharmacogenom Pharmacoproteomics 2012, 3(6), e125

Peer-reviewed Book Chapter

Nanoliposomal dry powder formulations, G. Patel, M. Chougule, M Singh, and Misra A, Methods Enzymol. Elsevier Inc. 2009, 464, 167-91

Peer-reviewed Reviews 1. M. Chougule M, B. Padhi, K. Jinturkar, A. Misra, Development of dry powder inhalers, Recent Pat Drug Deliv Formul., 2007, 11-21 2. Recent advances in liposomal dry powder formulations: preparation and evaluation. A. Misra A, K. Jinturkar, D. Patel, J. Lalani, M. Chougule, Expert Opin Drug Deliv. 2009, 6(1), 71-89

Linda Connelly, PhD, Assistant Professor, Pharmaceutical Sciences and Office of Pre-Pharmacy

1. Connelly L., Robinson-Benion C., Chont M., Saint-Jean L., Li H., Polosukhin V.V., Blackwell T.S., Yull F.E. (2007). A transgenic model reveals important roles for the NF-kappaB alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J. Biol. Chem., 282 (13), 10028-10035 2. Stathopoulos G.T., Sherrill T.P., Cheng D.S., Scoggins R.M., Han W., Polosukhin V.V., Connelly L., Yull F.E., Fingleton B., Blackwell T.S. (2007) Epithelial Nuclear Factor-kappaB Activation Promotes Urethane-Induced Lung Carcinogenesis. Proc. Natl. Acad. Sci. USA, 104 (47), 18514-9 3. Jin R., Lho Y., Connelly L., Wang Y., Yu X., Saint-Jean L., Case T.C., Ellwood-Yen K., Sawyers C.L., Bhowmick N.A., Blackwell T.S., Yull F.E., Matusik R.J. (2008) The NF-kappa B Pathway Controls Progression of Prostate Cancer to Androgen Independent Growth. Cancer Research, 68 (16), 6762-6769 4. Connelly L., Barham W., Pigg R., Saint-Jean L., Sherrill T., Cheng D.S., Chodosh L.A., Blackwell T.S., Yull F.E. (2010) Activation of nuclear factor- kappa B in mammary epithelium promotes milk loss during mammary development and infection. Journal of Cellular Physiology, 222: 72-81 5. Connelly L., Barham W., Onishko, H. Sherrill T., Chodosh L.A., Blackwell T.S., Yull F.E. (2011) Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene, 30 (12):1402-12 6. Connelly, L., Barham, W., Onishko, H.M., Chen, L., Sherrill, T., Zabuawala, T., Ostrowski, M.C., Blackwell, T.S. and Yull, F.E. (2011) NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model. Breast Cancer Research, 13(4):R83 7. Zaynagetdinov, R., Stathopoulos, G., Sherrill, T., Cheng, D.S., McLeod, A.G., Ausborn, J.A., Polosukhin, V.V., Connelly, L., Zhou, W., Fingleton, B., Peebles, R.S., Prince, L.S., Yull, F.E., Blackwell T.S. (2012) Epithelial nuclear factor-kappaB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene, 31(26):3164-76 8. Barham, W., Sherrill, T., Connelly, L., Blackwell, T.S., Yull F.E. (2012) Intraductal injection of LPS as a mouse model of mastitis: signaling visualized via an NF-kappaB reporter transgenic. J Vis Exp, Sep 4;(67)

Edward Fisher, PhD, Associate Dean for Academic Affairs

1. Russ S. Muramatsu, Mark H.J. Litzinger, Edward Fisher, and Junji Takeshita, Alternative Formulations, Delivery Methods, and Administrative Options for Psychotropic Medications in Elderly Patients with Behavioral and Psychological Symptoms of Dementia, the American Journal of Geriatric Pharmacotherapy, 8(2), 21-17, April 2010.

2. Mohammad Tafreshi, Edward Fisher and Earnest L Bowling, Treatment of Dry Eye, Pharmacy Times: 75(4), 97-105, April 2009.

Roy Goo, Assistant Professor, Pharmacy Practice

D. Juarez, R. Goo, S. Tokumaru, T. Sentell, J. Davis, M. Mau, PDB41 Impact of “Sustained Hemoglobin A1C Control on Health Care Costs Among Patients With Diabetes in Hawaii.” Value in Health - June 2012 (Vol. 15, Issue 4, Pages A177- A178, DOI: 10.1016/j.jval.2012.03.962

Daniela Guendisch, Assistant Professor, Pharmaceutical Sciences

1) Bucerius J, Manka C, Schmaljohann J, Mani V, Gündisch D, Rudd JHF, Bippus R, Mottaghy FM, Wüllner U, Fayad ZA, Biersack HJ. (2012). Feasibility of [18F]‐2‐Fluoro‐A85380‐PET for Imaging of Human Vascular Nicotinic Acetylcholine Receptors in vivo. JACC Cardiovasc Imaging 5:528- 536. 2) Turcanu DS, Kirtok N, Eibl C, Guendisch D, La Gamma EF, Nankova BB. Nicotinic receptor partial agonists alter catecholamine homeostasis and response to nicotine in PC12 cells. (2012). Neuroscience Letters 516:212- 216. 3) Perez EG, Cassels BK, Eibl C, Gündisch D. Synthesis and evaluation of N1‐alkylindole‐3‐ylalkylammonium iodides as nicotinic acetylcholine receptor ligands. (2012). Bioorg Med Chem. 20:3719-3727.

4) Gündisch D, Eibl C. Nicotinic acetylcholine receptor ligands, a patent review (2006 -- 2011). (Invited review). Expert Opin Ther Patents 2011;21:1867-1896. 5) Mineur YS, Abizaid A, Rao Y, Salas R, DiLeone RJ, Gündisch D, Diano S, De Biasi M, Horvath TL, Gao XB, Picciotto MR. Nicotine decreases food intake through activation of POMC neurons. Science 2011; 332(6035):1330-2.

6) Papke LR, Trocme´-Thibierge C, Guendisch D, Al Rubaiy SA, Bloom SA. Electrophysiological Perspectives on the Therapeutic Use of Nicotinic Acetylcholine Receptor Partial Agonists. JPET 2011; 337:1–13.

7) Shen L, Park EJ, Kondratyuk TP, Guendisch D, Marler L, Pezzuto JM, Wright AD, Sun D. Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg Med Chem 2011; 19(21):6182-95.

8) Tomassoli I, Eibl C, Wulf M, Papke RL, Picciotto MR, Gündisch D. The twin drug approach for novel nicotinic acetylcholine receptor (nAChR) ligands: synthesis and structure-affinity relationships. Biochem Pharmacol 2011; 82:1023.

9) Elsinghorst PW, Härtig W, Gündisch D, Mohr K, Tränkle C, Gütschow M. A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins. Curr Topics Med Chem 2011; 11:2731-2748.

10) Gündisch D, Eibl C. From acetyl bispidine to an extended bispidine amide framework: Synthesis and structure-affinity relationships for nicotinic acetylcholine receptors (nAChRs). Biochem Pharmacol 2009; 78:905.

11) Mineur Y, Eibl C, Young G, Kochevar C, Papke RL, Gündisch D, Picciotto, MR. Cytisine-based nicotinic partial agonists as novel antidepressant compounds. JPET 2009; 329:377-386.

12) Wüllner U, Gündisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schütz C, Reinhardt M, Eschner W, Klockgether T, Schmaljohann J. Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 2008; 430:34-37.

13) Patt M, Solbach C, Wüllner U, Blocher A, Stahlschmidt A, Gündisch D, Kovar KA, Machulla HJ. Synthetic Approaches and Biodistribution Studies of [11C]Methylphenidate. J Pharm Pharm Sci 2007; 10:312s-320s.

Elizabeth Heffernan, MA, Director of Student Services

1. Heffernan, L., Kalvaitis, D., Segaran, P., Fisher, E. (2012). An innovative exploration of Kalaupapas distinctive history impacts the cultural perspectives of Student Pharmacists in relation to patient care. 2012 Hawaii Pharmacist Association Annual Meeting. Published as an abstract in the Hawaii Journal of Medicine & Public Health, 71 (6): 149.

2. Shimabuku, S. Kim, C., Lai Hipp, C., Heffernan, E. (2012). Marshallese Mobile Screening Clinic. 2012 Hawaii Pharmacist Association Annual Meeting. Published as an abstract in the Hawaii Journal of Medicine & Public Health, 71 (6):148.

3. Heffernan, L., Nakamura, K. Suefuji, C., Kalvaitis, D. (2012). Applicant Trends in Seat Deposit Forfeits for Colleges and Schools of Pharmacy. 113th Annual Meeting of the American Association of Colleges of Pharmacy, Kissimmee, FL, July 14-18, 2012. Published to the website of American Journal of Pharmaceutical Education (www.ajpe.org) 76 (5) Article 99.

4. Chong, M., Shimabuku, S., LaiHipp, C., Kim, C., Heffernan, L. Marshallese Mobile Screening Clinic Project. American Pharmacist Association (APhA) Annual Meeting & Exposition. (March 2012). Published as an abstract in the Journal of the American Pharmacists Association (JAPhA) March/April 2012.

Susan Jarvi, PhD, Director, Pre-Pharmacy Program and Associate Professor

1. Jarvi ,S.I., Lieberman, M.M., Hofmeister, E., Nerkurkar, V.R., Wong, T., & Weeks-Levy, C. (2008) Protective efficacy of a recombinant subunit West Nile virus vaccine in Domestic geese (Anser anser). Vaccine Oct 26, 42. 5338-44. 2. Jarvi, S.I.,Triglia, D., Giannoulis, A., Farias, M.E.M., Bianchi, K., & Atkinson, C.T. (2008) Diversity, origins and virulence of Avipoxviruses in Hawaiian Forest Birds. Conservation Genetics, 9, 339-348. 3. Jarvi ,S.I., Farias M.E.M. and Atkinson CT. (2008) Genetic characterization of Hawaiian isolates of Plasmodium relictum reveals mixed-genotype infections. Biology Direct 3:25. 4. Farias, M.E.M., and Jarvi ,S.I., (2009) A nucleotide-constrained single base extension method for improved detection of minority alleles in Plasmodium. Molecular & Biochemical Parasitology 163:114-118. 5. Farias, Margaret E.M., Dennis A. LaPointe, Carter T. Atkinson, Christopher Czerwonka, Rajesh Shrestha, Susan I. Jarvi. (2010) Taqman Real-Time PCR detects Avipoxvirus DNA in blood of Hawaii Amakihi (Hemignathus virens). PLoS ONE 5(5): e10745. doi:10.1371/journal.pone.0010745 6. Atkinson, C.T., K.C. Wiegand, D. Triglia, and S.I. Jarvi. 2011. Efficacy of a commercial canarypox vaccine for protecting Hawaiì Àmakihi from field isolates of Avipoxvirus. Hawaiì Cooperative Studies Unit Technical Report HCSU-019. University of Hawaiì at Hilo. http://hilo.hawaii.edu/hcsu/documents/TRHCSU- 019Atkinson_Avian_Pox.pdf 7. Jarvi S.I., D. Hu, K. Misajon, B.A. Coller, T. Wong, M. Lieberman 2012.Vaccination of captive Nene against West Nile Virus using a protein- based vaccine (WN-80E). In press: J of Wildlife Diseases. 8. Jarvi S.I., Farias MEM, Howe K, Jacquier S, Hollingsworth R, W Pitt. Quantitative PCR estimates Angiostrongylus cantonensis infection levels in semi-slugs (Parmarion martensi). 2012 Molecular & Biochemical Parasitology 185 (2012) 174– 176. 9. Atkinson, C.T., K.C. Wiegand, D. Triglia, and S.I. Jarvi. 2012. Reversion to virulence and efficacy of an attenuated canarypox vaccine in Hawaiì Amakihi (Hemignathus virens). In press J of Zoo and Wildlife Medicine 43(4):807-818 10. Jarvi S.I., D. Hu, K. Misajon, B.A. Coller, T. Wong, M. Lieberman 2012.Vaccination of captive Nene against West Nile Virus using a protein- based vaccine (WN-80E). In Press J of Wildlife Diseases. 11. Farias, M.E.M. C.T. Atkinson, and S.I. Jarvi. 2012. Distribution of trap alleles of Plasmodium relictum in infected hatch-year amakihi (Hemignathus virens) on the east side of Hawaii Island. In press Malaria Journal 11:305.

Book Chapters 1. LaPointe, D.A., Atkinson, C.T. & Jarvi ,S.I., (2009) Management of mosquito-borne disease in Hawaiian forest bird populations. In: Hawaiian Forest Birds: Their Biology and Conservation, T.K. Pratt, C.T. Atkinson, P.C. Banko, J. Jacobi, and B.L. Woodworth, Editors. Yale University Press, New Haven. 405-424. 2. Jarvi ,S.I., Fleischer, R.C. & Eggert, L.S. (2009) Genetics and conservation of native Hawaiian forest birds. In: Hawaiian Forest Birds: Their Biology and Conservation, T.K. Pratt, C.T. Atkinson, P.C. Banko, J. Jacobi, and B.L. Woodworth, Editors. Yale University Press, New Haven. 253-273.

Deborah Juarez, ScD, Associate Professor, Pharmacy Practice

1. Taira DA, Gelber RP, Davis J, Gronley K, Chung RS, Seto TB. Anti- hypertensive Adherence and Drug Class among Asian Pacific Americans. Ethnicity and Health, 2007;12(3):265-281. 2. Berthiaume J, Davis J, Taira DA, Thein KK. A managed care organization’s use of integrated health management to improve secondary prevention of coronary artery disease. Am J Manag Care. 2007;13(3):142-7. 3. Gilmore AS, Zhao Y, Kang N, Ryskina, Legorreta, Taira DA, Chung RS. Patient Outcomes and Evidence-Based Medicine in a PPO Setting: A Six- Year Evaluation of a Physician Incentive Program. Health Services Research. 2007;42(6):2140-2159. 4. Breton A, Taira D, Burns E, O’Leary J, Chung RS. Follow-up Services after an Emergency Department Visit for Substance Abuse. Am J Manag Care. 2007;13(9):497-505. 5. Halliday T, Taira DA, Davis H, Chan H. Socioeconomic Disparities in Breast Cancer Screening in Hawai’i. Preventing Chronic Disease 2007 Oct;4(4):A91. Epub 2007 Sep 15. 6. Davis J, Fujimoto RY, Juarez DT, Hodges K, Asam K. Major Depression Associated with Rates of Transition Between Cardiovascular Diseases. Am J Manag Care. 2008;14(3):125-129. 7. Kretzer K, Taira Juarez D, Davis J. Initial Antihypertensive Prescriptions, Switching Patterns and Adherence Among Insured Patients in Hawai‘i. Hawaii Med J. 2008;67(4):96-100. 8. Juarez DT, Osheroff W. Patient Perceptions of Inter-Provider Coordination of Care. Hawaii Med J. 2008;67(5):121-125. 9. Davis J, Fujimoto R, Chan H, Taira Juarez D. Factors affecting the influenza vaccination of high risk adults in Hawai’i. Hawaii Med J. 2009;68(3): 50-55. 10. Maskarinec G, Erber E, Grandinetti A, Verheus M, Oum R, Hopping B, Schmidt MM, Uchida A, Juarez DT, Hodges K, Kolonel LN. Diabetes Incidence Based on Linkages with Health Plans: The Multiethnic Cohort. Diabetes. 2009;58:1732-1738. 11. Chen J; Kang N; Juarez DT; Hodges K; Chung, RS. The Effect of a PPO Pay- for-Performance Program on Patients with Diabetes. Am J Manag Care. 2010;16(1):e11-e20. 12. Chen J; Kang N; Juarez DT; Hodges K; Chung, RS. Impact of a Pay-for- performance Program on Low Performing Physicians. Journal for Health Care Quality. 2010;32:13-22. 13. Juarez DT, Samoa RA, Chung RS, Seto TB. Disparities in Health, Obesity and Access to Care Among An Insured Population of Asian and Pacific Islander Americans in Hawaii. Hawaii Medical Journal. Hawaii Med J. 2010 Feb;69(2):42-6. 14. Schwartz SM, Ireland C, Strecher V, Nakao D, Wang C, Juarez D. The Economic Value of a Wellness and Disease Prevention Program. Popul Health Manag. 2010 Dec;13(6):309-17. 15. Saito E, Davis J, Mau M, Harrigan R, Juarez DT. Copayment Level and Drug Switching: Findings for Type 2 Diabetes. American Journal of Pharmacy Benefits. Am J Pharm Benefits. 2010;2(6):412-420. 16. Davis J, Fujimoto R, Chan H, Juarez DT. Identifying characteristics of patients with low urgency emergency department visits in a managed care setting. Manag Care. 2010 Oct;19(10):38-44. 17. Chen JY, Kang N, Juarez DT, Yermilov I, Braithwaite RS, Hodges KA, Legorreta A, Chung RS. Heart Failure Patients Receiving ACEIs/ARBs Were Less Likely To Be Hospitalized Or To Use Emergency Care In The Following Year. Journal for Health Care Quality. 2011 Jul;33(4):29-36. 18. Davis J, Fujimoto R, Chan H, Juarez DT. Adherence with lipid-lowering, antihypertensive, and diabetes medications singly and together. Am J Pharm Benefits. 2011;3(3):173-179. 19. Chen JY, Tian H, Juarez DT, Yermilov I, Braithwaite RS, Hodges KA, Legorreta A, Chung RS. Does Pay-for-Performance improve cardiovascular care in a “real world” setting? Am J Med Qual. 2011 Sep-Oct;26(5):340-8. 20. Davis JW, Chung RS, Juarez DT. Prevalence of Comorbid Conditions with Aging Patients with Diabetes and Cardiovascular Disease. Hawaii Med J. 2011;70(10):209-14. 21. Ashby J, Juarez DT, Berthiaume J, Sibley P, Chung RS. The Relationship of Hospital Quality and Cost Per Case in Hawaii. Inquiry. 2012;49:65-74. 22. Juarez DT; Davis JW; Brady SK; Chung RS. Prevalence of Coronary Heart Disease and Its Risk Factors Related to Age in Asian, Pacific Islanders, and Caucasians in Hawai‘i. Journal of Healthcare for the Poor and Underserved. 2012; 23(3):1000-10. 23. Juarez DT, Sentell T, Tokumaru S, Goo R, Davis J, Mau M. Factors Associated with Three Years of Poor Glycemic Control or Wide Glycemic Variability Among Diabetic Patients in Hawaii. Prev Chronic Dis. 2012;9:120065. 24. Juarez DT, Goo R, Tokumaru S, Sentell T, Davis JW, Mau MM. Association Between Sustained Hemoglobin A1c Control and Health Care Costs. Am J Pharm Ben (in press) 25. Davis J, Juarez DT, Hodges K. Relations of ethnicity and body mass index with the development of hypertension and hyperlipidemia. Ethnicity and Disease. (in press)

Eugene Konorev, MD, Assistant Professor, Pharmaceutical Sciences

1. Konorev, E.A., Vanamala, S., Kalyanaraman, B. Differences in doxorubicin- induced apoptotic signaling in adult and immature cardiomyocytes. Free Rad Biol Med. 45, 1723-1728 (2008). 2. Chandran, K., Aggarwal, D., Migrino, R.Q., Joseph, J., McAllister, D., Konorev, E.A., Antholine, W.E., Zielonka, J., Srinivasan, S., Avadhani, N.G., Kalyanaraman, B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by mitoQ. Biophys J. 96, 1388-1398 (2009). 3. Kumar SN, Konorev EA, Aggarwal D, Kalyanaraman B. Analysis of proteome changes in doxorubicin-treated adult cardiomyocyte. J. Proteomics. 74, 683- 697 (2011). 4. Anna Leychenko, Eugene Konorev, Mayumi Jijiwa, Michelle L. Matter. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. PLoS ONE. 6, e29055 (2011).

Tamara P. Kondratyuk, PhD, Laboratory Manager and Assistant Specialist

1. Mayhoub, A.S., Marler, L., Kondratyuk,T.P., Park,E-J., Pezzuto, J.M., and Cushman, M. Optimization of thiazol analogues of resveratrol for induction of NAD(P)H: quinone reductase 1(QR1) JBMC, 2012, accepted

2. Yu, X., Park, E-J., Kondratyuk,T.P., Pezzuto, J.M., and Sun, D. Discovery, Synthesis, and Evaluation of 2-Phenylindoles as Nitric Oxide Synthase Inhibitors and Potential Cancer Preventive Agents. Org. Biomol. Chem. 10, 8835-8847, 2012.

3. Ul-Haq, I., Mirza, B., Kondratyuk, T.P., Park, E-J., Burns, B.E., Marler, L.E., and Pezzuto, J.M. Preliminary evaluation of the cancer chemopreventive and cytotoxic potential of naturally growing ethnobotanically selected plants from Pakistan Pharm. Biol., 1–13, 2012.

4. Luqman, S., Meena, A., Singh, P., Kondratyuk,T.P., Marler, L.E., Pezzuto, J.M., Negi, A.S. Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents. Chem. Biol. Drug. Des, 80, 616- 624, 2012.

5. Archer,C.R. ,Groll, M., Stein, M.L., Schellenberg,B., Clerc, J., Kaiser, M., Kondratyuk, T.P., Pezzuto,J.M., Dudler, R., Bachmann, A.S. Activity Enhancement of Synthetic Syrbactin Proteasome Inhibitor Hybrid and Biological Evaluation in Tumor Cells. Biochemistry, 51:6880-6888, 2012.

6. Youn, U.J., Park,E-J., Kondratyuk,T.P., Simmons, C.J., Borris, R., Tanamatayarat,P., Wongwiwatthananukit, S., Toyama, O., Songsak,T., Pezzuto, J.M., and Chang, L.C. Anti-inflammatory sesquiterpene lactones from the flowers of Vernonia cinerea. Bioorg.Med. Chem.Let., 22: 5559– 5562, 2012.

7. Chen, L., Conda-Sheridan, M., Reddy,P.V.N., Morrell, A., Park,E- J., Kondratyuk, T.P., Pezzuto, J.M., van Breemen, R.B. Cushman, M., Identification, Synthesis, and Biological Evaluation of the Metabolites of 3- Amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents. J.Med. Chem., 55:5965-5981, 2012.

8. Mayhoub, A.S., Marler,L., Kondratyuk,T.P., Park, E-J., Pezzuto, J.M. and Cushman, M. Optimization of the Aromatase Inhibitory Activities of Pyridylthiazole Analogues of Resveratrol. Bioorg. Med.Chemistry,20: 2427-2434, 2012.

9. Kondratyuk, T.P., Park, E-J., Yu, R., van Breemen, R.B., Asolkar, R.A., Murphy, B.T., Fenical, W., and Pezzuto, J.M. Novel Marine Phenazines as Potential Cancer Chemopreventive and Anti-Inflammatory Agents. Mar. Drugs, 10:451-464, 2012.

10. Mayhoub,A.S., Marler,L., Kondratyuk,T.P., Park, E-J., Pezzuto, J.M. and Cushman, M. Optimization of thiadiazole analogues of resveratrol versus three chemopreventive targets. Bioorg. Med.Chemistry, 20:510-520, 2011.

11. Luqman,S., Meena,A., Marler,L.E., Kondratyuk,T.P., and Pezzuto, J.M. Suppression of NFκB activation and aromatase activity by capsaicin and its analogue capsazepine. J. Med. Food, 14: 1344-1351, 2011. 12. Shen,L., Eun- Park, Kondratyuk,T.P., Guendisch, D., Marler, L., Pezzuto, J.M., Wright, A.D., and Sun, D. Design, synthesis, and biological evaluation of callophycin A analogues as potential chemopreventive and anticancer agents. Bioorg. Med. Chem. 19: 6182-95, 2011. 13. Park, E-J., Cheenpracha, S., Chang, L.C., Kondratyuk, T.P., and Pezzuto, J.M. Inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression and inducible nitric oxide synthase by 4-[(2′-O-acetyl-α-L- rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutr. Cancer, 63:971-82, 2011. 14. Kondratyuk, T.P., Park, E-J., Marler,L.E., Ahn, S.,Yuan, Y., Choi, Y., van Breemen, R.B., Sun, B., Hoshino, J.,Cushman, M., Jermihov, K.C., Mesecar,A.D.,Grubbs, C.J. and Pezzuto, J.M. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity, Mol. Nutr. Food Res.55: 1249-1265, 2011. 15. Zou, J., Pan, L., Li, Q., Zhao,J., Pu, J., Yao, P., Gong, N., Lu, Y., Kondratyuk, T.P., Pezzuto, J.M., Fong, H.H.S., Hongjie Zhang, and Sun, H. Xuehuanins A and B: Novel Diterpenoids from Isodon rubescens. Org. Lett.13:1406-1409, 2011.

16. Park, E-J, Kondratyuk,T.P., Morrell, A., Kiselev,E., Conda-Sheridan, M., Cushman, M., Ahn, S., Choi, Y., White, J.J., van Breemen, R.B., and Pezzuto, J.M. Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells. Cancer Prev Res (Phila),4:592-607, 2011.

17. Yang, J., Kondratyuk, T., Jermihov, K., Marler, L.,Qiu, X., Choi, Y., Cao, H., Yu, R., Sturdy, M., Liu, Y., Wang, L., Mesecar, A., van Breemen, R., Pezzuto, J., Fong, H., Chen, Y., and Zhang, H. Bioactive compounds from the fern Lepisorus contortus. J.Nat. Prod., 74:129-136, 2011.

18. Martin Conda-Sheridan, Laura Marler, Eun-Jung Park, Tamara P. Kondratyuk, Katie Jermihov, Andrew D. Mesecar, John M. Pezzuto,William Fenical, and Mark Cushman Potential Chemopreventive Agents Based on the Structure of Lead Compound 2-Bromo-1- hydroxyphenazine Isolated from Streptomyces sp., Strain CNS284, J. Med. Chem.,53:8688-99 , 2010.

19. Nam, S.J., Gaudêncio, S.P., Maloney, K.N., Kauffman, C.A., Jensen, P.R., Kondratyuk, T.P., Marler, L.E., Pezzuto, J.M., and Fenical, W. Fijiolides A and B, Chlorinated Aminoglycoside from a Marine-Derived Bacterium of the Genus Nocardiopsis: the chemistry and preliminary pharmacology. J.Nat. Prod., 73:1080-1086, 2010.

20. Asolkar, R.N., Jensen, P.R., Fenical, W., Kondratyuk, T.P., Park, E-J, and Pezzuto, J.M.. Arenamides A-C, inhibitors of NFκB from the marine Actinomycete Salinispora arenicola. J.Nat.Prod., 72:396-402, 2010.

21. Yang, J., Kondratyuk, T.P. , Marler, L.E., Qiu, X., Choi,Y., Cao,H., Sturdy, M., Pegan, S., Liu ,Y., Wang ,L.Q., Mesecar , A.D., Van Breemen,R.B., Pezzuto, J.M., Fong , H.H.S., Chen,Y.G., Zhang, H.J. Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata. Phytochemistry, 71: 641-647, 2010.

22. Hoshino, J., Park , E.J., Kondratyuk, T.P. , Marler, L., Pezzuto,J.M., van Breemen, R.B., Mo, S., Li, Y., and Cushman, M. Selective Synthesis and Biological Evaluation of Sulfate-Conjugated Resveratrol Metabolites. J. Med.Chem., 53:5033-5043, 2010.

23. Morais, M.C.C., Luqman, S., Kondratyuk,T.P., Petronio,M.S., Regasini,L/O., Silva,D.H.S., Bolzani, V.S., Soares,C.P., and Pezzuto, J.M. Suppression of TNF-α induced NFκB activity by gallic acid and its semi-synthetic esters: possible role in cancer chemoprevention. Nat. Prod. Res., 24:1758-1765, 2010.

24. Schupp, P., Kohlert-Schupp, C., Whitefield, S., Engemann, A ., Hemscheidt, T., Pezzuto, J.M., Kondratyuk, T.P ., Park, E-J., Marler, L ., Rostama, B and Wright, A.D. Cancer Chemopreventive and Anticancer Evaluation of Extracts and Fractions from Marine Macro- and Micro- organisms Collected from Twilight Zone Waters Around Guam. Nat. Prod. Commun.,4: 1717-1728, 2009.

25. Yao, G., Kondratyuk, T.P., Tan, G.T., Pezzuto, J.M., and Chang, L.C. Bioactive sulfated sesterterpene alkoloids and sesterterpene sulfates from the marine sponge Fasciopongia sp. J. Nat. Prod., 72: 319-323, 2009.

26. Ghufran, M.A., Qureshi, R.A., Batool, A., Kondratyuk, T.P., Guilford, J., Marler, L., Chang, L.C. and Pezzuto, J.M. Evaluation of Selected Indigenous Medicinal Plants from Western Himalayas for Cytotoxicity and as Potential Cancer Chemopreventive Agents". Pharm. Biol., 47:533-538, 2009.

27. Endringer, D.C., Guimarães, K.G., Kondratyuk, T., Pezzuto, J.M., and Braga, F.C.. Selective inhibition of aromatase by dihydroisocoumarin from Xyris pterygoblephara. J. Nat. Prod., 71: 124-130, 2008.

28. Williams, P.G., Asolkar, R.N., Kondratyuk, T., Pezzuto, J.M., Jensen, P.R., and Fenical, W. Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicola. J. Nat. Prod., 70: 83-88, 2007.

29. Maiti, A., Cuendet, M., Kondratyuk, T.P., Croy, V., Pezzuto, J.M., and Cushman, M. Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis . J. Med. Chem., 50: 350-355, 2007.

Dana Koomoa-Lange, PhD, Assistant Professor, Pharmaceutical Sciences

1. Borsics T, Lundberg E, Geerts D, Koomoa DK, Koster J, Wester K, Bachman AS. Expression and subcellular distribution of monomeric and dimeric PRAF2 in malignant glioma, Cancer Sci, 101(7): 1624-31, 2010. 2. Archer CR, Koomoa DL, Mitsunaga EM, Clerk J, Shimizu M, Kaiser M, Schellenberg B, Dudler R, Bachmann AS. Syrbactin Class of proteasome- inhibitor induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma, Biochem Pharmacol, 80(2): 170-8, 2010. 3. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification, Int J Cancer. 126 (9): 2012-24, 2010. 4. Koomoa DL, Borsics T, Feith DJ, Coleman CC, Wallick CJ, Gamper I, Pegg AE and Bachmann AS. Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/PKB regulation and apoptosis in neuroblastoma, Mol Cancer Ther. Vol. 8 (7): 2067-75, 2009. 5. Koomoa DL, Yco L, Wallick C, Borsics T, Bachmann AS. Ornithine Decarboxylase Inhibition by DFMO Activates Opposing Signaling Pathways via Phosphorylation of both Akt/PKB and p27Kip1 in Neuroblastoma, Cancer Res. Vol. 68 (23), 2008. 6. Koomoa DL, Go RC, Wester K, Bachmann AS. Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles, Neurosci Lett. Vol. 436(2):171-6, 2008 7. Geerts D, Wallick CJ, Koomoa DL, Koster J, Versteeg R, Go RC, Bachmann AS. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation, Clin Cancer Res. Vol. 13(21):6312-9, 2007. 8. Koomoa DL, Mark MW, Goldstein L. The Activation Pathway of the Volume- Sensitive Organic Osmolyte Channel in Xenopus laevis Oocytes Expressing Skate Anion Exchanger 1 (AE1), J Membr Biol Vol. 208: 241 - 250, 2006 9. Vig M, Beck A, Billingsley JM, Lis A, Parvez S, Peinelt C, Koomoa DL, Soboloff J, Gill DL, Fleig A, Kinet JP, Penner R. CRACM1 multimers form the ion-selective pore of the CRAC channel. Curr Biol. Vol.16(20):2073-9, 2006. 10. Peinelt C, Vig M, Koomoa DL, Beck A, Nadler MJ, Koblan-Huberson M, Lis A, Fleig A, Penner R, Kinet JP. Amplification of CRAC current by STIM1 and CRACM1 (Orai1). Nat Cell Biol. Vol. 8 (7):771-3, 2006. 11. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, Koblan-Huberson M, Kraft S, Turner H, Fleig A, Penner R, Kinet JP. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science. Vol. 312(5777):1220-3, 2006. 12. Koomoa DL, Musch MW, Goldstein L. Osmotic Stress stimulates the organic osmolyte channel in Xenopus laevis oocytes expressing skate (Raja erinacea) AE1. J.Exp.Zool. Vol. 303(4):319-22. 2005 13. Musch MW, Koomoa DL , Goldstein L. Hypotonicity-induced Exocytosis of the skate anion exchanger, skAE1: role of lipid raft regions. J. Biol.Chem. 279: 39447-39453, 2004. 14. Koomoa DL , Musch MW, Myers DE, Goldstein L. Expression of the Skate (Raja erinacea) AE1 Osmolyte Channel in Xenopus laevis Oocytes: Monovalent cation permeability J.Membr.Biol. 198: 23-29, 2004. 15. Goldstein, Koomoa DL , Musch MW. ATP Release From Hypotonically Stressed Skate RBC: Potential Role in Osmolyte Channel Regulation J.Exp.Zool. 296A: 160-163, 2003. 16. Koomoa DL, Musch MW, Goldstein L. Comparison of the Osmolyte Transport Properties Induced by trAE1 versus Iclswell in Xenopus oocytes J.Membr.Biol. 185: 57-63, 2002. 17. Koomoa DL, Musch MW, MacLean AV, Goldstein L. Volume-activated trimethylamine oxide efflux in red blood cells of spiny dogfish (Squalus acanthias) Am.J.physiol.281: R803-R810, 2001.

Kenneth R. Morris, PhD, Professor, Pharmaceutical Sciences

1. Daniel Hu, Rahul V. Haware, Mazen L. Hamad, Kenneth R. Morris*, Characterization of Critical Physical and Mechanical Properties of Freeze- Dried Freeze Dried Grape Powder for Development of a Clinical Patient Delivery System, Journal of Nutrition, Pharm Dev Technol online Feb 15, 2012. 2. Rahul V. Haware, Paul Kim, Lauren Ruffino, Brian Nimi, Catherine Fadrowsky, Michael Doyle, Stephan X.M. Boerrigter, Alberto Cuitino, Ken Morris*, Anisotropic Crystal Deformation Measurements Determined using Powder X-Ray Diffraction and a New in situ Compression Stage, International Journal of Pharmaceutics, special issue on predictive methods in Pharmaceutical development. , in press. Volume 418, Issue 2, Pages 199- 206 (14 October 2011) 3. Jennifer Wang, Martha Davidovich, Devikant Desai, D Bu, M. Hussain, and Kenneth R. Morris, "Solid State Interactions of a Drug Substance and Excipients and their Impact on Tablet Dissolution: A Thermal-Mechanical Facilitated Processed-Induced Transformation or PIT", Journal of Pharmaceutical Sciences, 99(9): 3849-3862 SEP 2010 4. Mazen L. Hamada, Keith Bowman, Nathan Smith, Xiaohong Sheng, Abhay Gupta, and Kenneth R. Morris, “Multi-Scale Pharmaceutical Process Understanding: from Particle to Powder to Dosage Form”, Chemical Engineering Science, special issue entitled “Pharmaceutical Engineering Science – A Key for Tomorrow’s Drug”, Vol. 65 Issue: 21 Sp. Iss. SI p. 5625- 5638, Nov 1 2010. 5. Xiaoming Chen, Joseph G. Stowell, Kenneth R. Morris, Stephen R. Byrn, 6. “Quantitative study of solid-state acid–base reactions between polymorphs of flufenamic acid and magnesium oxide using X-ray powder diffraction”, J. Pharm. And Biomed. Analysis, 51(2010) 866-874 Sept 2009 7. John M. Pezzuto, Venkat Venkatasubramanian, Mazen Hamad, and Kenneth R. Morris, “Unraveling the Relationship between Grapes and Health”, J. Nutrition, on-line 7/22/2009. 8. Joshi, Vidya, Morris, Kenneth R., Byrn, Stephen R., Carvajal, M. Teresa, “Evaluation of the Use of E-a (Activation Energy) as a Quantitative Indicator of Physical Stability of Indomethacin Solvates: Methanolate and Tertiary Butyl Alcohol Solvate”, Crystal Growth & Design, 9 (8): 3359-3366 Aug 2009. 9. Tan, Jeffrey S., Boerrigter, Stephan X.M., Scaringe, Raymond P., Morris, Kenneth R., “Application of Error-Ranked Singular Value Decomposition for the Determination of Potential-Derived Atomic-Centered Point Charges”, Journal of Computational Chemistry,30(5):733-742 4-15- 2009. 10. Hilden, Jon, Bowman, Keith, Morris, Ken, Wang, Steve, Sprockel, Omar, Ennis, Bryan, “Note on the Interpretation of powder shear test data”, Powder Technology (2008), 182, 486-492. 11. Hailemariam, L., Suresh, P., Akkisetty, V. P. K., Joglekar, G., Hsu, S-H., Jain, A., Morris, K., Reklaitis, G. V., Basu, P., and Venkatasubramanian, V. “Excipient Interaction Prediction: Application of the Purdue Ontology for Pharmaceutical Engineering (POPE)”. In B. Braunscweig and X. Joulia (ed.), 18th European Symposium on Computer Aided Process Engineering, Computer Aided Chemical Engineering Series, Vol. 23, 85-90. Elsevier, Amsterdam (2008). 12. Wen, Hong, Morris, Kenneth R., Park, Kinam, “Synergic Effects of Polymeric Additives on Dissolution and Crystallization of Acetaminophen”, Pharmaceutical Research (2008), 25(2), 349-358. 13. Soh, Josephine, L.P., Boersen, Nathan, Carvajal, M. Teresa, Morris, Kenneth R., Peck, Garnet E., Pinal, Rodolfo, “Importance of Raw Material Attributes for Modeling Ribbon and Granule Properties in Roller Compaction: Multivariate Analysis on Roll Gap and NIR Spectral Slope as Process Critical Parameters” Journal of Pharmaceutical Innovation (2007), 2(3-4), 106-124. 14. Engers, David A., Fricke, Molly N., Newman, Ann W., Morris, Kenneth R., “Triboelectric charging and dielectric properties of pharmaceutically relevant mixtures” Journal of Electrostatics (2007), 95(12), 2645-2656. 15. Wildfong, P.L., Morris K.R., Anderson, C.A., Short, S.M. “Demonstration of a shear-based solid-state phase transformation in a small molecular organic system: chlorpropamide” Journal of Pharmaceutical Sciences (2007), 96(5):1100-13. 16. Li H, Stowell, J.G., He, X., Morris, K.R., Byrn, S.R., “Investigations on solid- solid phase transformation of 5-methyl-2-[(4-methyl-2-nitrophenyl) amino]-3- thiophenecarbonitrile” Journal of Pharmaceutical Sciences (2007), 96(5):1079-89.

Book Chapters 1. K. Morris, R. McCann, “Concepts in Quality by Design for Drug Development and Manufacture” Pre-approval Inspections, Ch. 7, Drugs and the Pharmaceutical Sciences series Vol. 181, Dekker, 2nd Ed, 2008 2. F. Muzzio, K.R. Morris, J.L.P. Soh, R.J. McCann, “General Issues in the Scale-up of Solid Oral Dosage Form Manufacturing”, Pharmaceutical Dosage Forms, ED. Hoag and Augsburger, Marcel Dekker, in press. 3. G.E. Peck, J. L. P. Soh, K.R. Morris “Dry Granulation”, Pharmaceutical Dosage Forms, ED. Hoag and Augsburger, Marcel Dekker, in press. 4. S.M. Carl, D.L. Lindley, G.T. Knipp, K.R. Morris, E. Oliver, G.W. Becker and R.A. Arnold. Biotechnology Drug Product Development. Pharmaceutical Manufacturing Handbook, Editor S.H. Gad, John Wiley & Sons, New York, NY, Ch. 1.1, 2008. 5. E. Oliver, S.M. Carl, K.R. Morris, G.W. Becker and G.T. Knipp.Regulatory Considerations in the Approval of Follow-On Protein Drug Products. Pharmaceutical Manufacturing Handbook, John Wiley & Sons, New York, NY, Ch. 1.2, 2008.

Karen Pellegrin, PhD, Director of Continuing/Distance Education and Strategic Planning 1. Pellegrin KL. A brief survey to identify priorities for improving clinician recruitment and retention: Results from Hawaii Island physicians. Hawaii Journal of Medicine & Public Health (April 2012, Vol 71, No 4, Supplement 1, 41-45). 2. Pellegrin KL, Pezzuto JM. Strategic direction for high demand degrees: An analysis of the U.S. pharmacy degree competitive market. International Journal of Management in Education special issue on “Quest for a Competitive Edge in Higher Education”, 2011; Vol. 5 (No. 2/3):285-300. 3. Pellegrin KL, Currey HS. Demystifying and improving organizational culture in healthcare. In: Wolf JA, Hanson H, Moir MJ, Friedman L, Savage GT (ed.). Organization Development in Healthcare: Conversations on Research and Strategies (Advances in Health Care Management, Volume 10). Emerald Group Publishing Limited, 2011: 3-23. 4. Pellegrin, KL. Commentary: Healthcare Improvement on Two Levels. West Hawaii Today, January 26, 2009, p. 7A.

John M. Pezzuto, PhD, Dean and Professor

1. Williams, P.G., Asolkar, R.N., Kondratyuk, T., Pezzuto, J.M., Jensen, P.R., and Fenical, W. Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicola. J. Nat. Prod., 70: 83- 88, 2007. 2. Maiti, A., Cuendet, M., Kondratyuk, T., Croy, V.L., Pezzuto, J.M., and Cushman, M. Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J. Med. Chem., 50: 350-355, 2007. 3. Murillo, G., Hirschelman, W.H., Ito, A., Moriarty, R.M., Kinghorn, A.D., Pezzuto, J.M., and Mehta, R.G. Zapotin, a phytochemical present in a Mexican fruit, prevents colon carcinogenesis. Nutr. Cancer, 57: 28-37, 2007. 4. Maiti, A., Cuendet, M., Croy, V.L., Endringer, D.C., Pezzuto, J.M., and Cushman, M. Synthesis and biological evaluation of (±)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J. Med. Chem., 50: 2799-2806, 2007. 5. Jutiviboonsuk, A., Zhang, H.-J., Kondratyuk, T.P., Herunsalee, A., Chaukul, W., Pezzuto, J.M., Fong, H.H.S., and Bunyapraphatsara, N. Isolation and characterization of cancer chemopreventive compounds from Barringtonia maunwongyathiae. Pharm. Biol., 45: 185-194, 2007. 6. Liu D, Guo J, Luo Y, Broderick DJ, Schimerlik MI, Pezzuto JM, Breemen RB. Screening for ligands of human retinoid X receptor-alpha using ultrafiltration mass spectrometry. Anal. Chem., 79: 9398-9402, 2007. 7. Endringer, D.C., Pezzuto, J.M., Soares, C.M., and Braga, F.C. L-(+)- Bornesitol. Acta Crystallogr. Sect. E Struct. Rep. Online, 63: 1067- 1068, 2007. 8. Guo J, Liu D, Nikolic D, Zhu D, Pezzuto JM, van Breemen RB. In vitro metabolism of isoliquiritigenin by human liver microsomes. Drug Metab. Dispos., 36: 461-468, 2008. 9. Guo, J., Liu, A., Cao, H., Luo, Y., Pezzuto, J.M., and van Breemen RB. Biotransformation of the chemopreventive agent isoliquiritigenin by UDP-glucuronosyltransferases. Drug Metab. Dispos., 36: 2104-2112, 2008. 10. Endringer, D.C., Guimarães, K.G., Kondratyuk, T.P., Pezzuto, J.M., and Braga, F.C. Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. J. Nat. Prod., 71: 1082-1084, 2008. 11. Pezzuto, J.M. Grapes and human health: A perspective. J. Agric. Food Chem., 56: 6777-6784, 2008. 12. Guilford, J.M. and Pezzuto, J.M. Natural products as inhibitors of carcinogenesis. Expert Opin. Investig. Drugs. 17: 1341-1352, 2008. 13. Cuendet, M., Oteham, C.P., Moon, R.C., Keller, W.J., Peaden, P.A., and Pezzuto, J.M. Dietary administration of Asimina triloba (paw paw) extract increases tumor latency in N-methyl-N-nitrosourea-treated rats. Pharm. Biol., 46: 3-7, 2008. 14. Topcu, G., Turkmen, Z., Schilling, J.K., Kingston, D.G.I., Pezzuto, J.M., and Ulubelen, A. Cytotoxic activity of some anatolian Salvia extracts and isolated abietane diterpenoids. Pharm. Biol., 46: 180-184, 2008. 15. Francy-Guilford, J. and Pezzuto, J.M. Mechanisms of cancer chemopreventive agents: A perspective. Planta Med., 74: 1644-1650, 2008. 16. Cuendet, M., Oteham, C.P., Maiti, A., Craig, B.A., Cushman, M., Moon, R.C., and Pezzuto, J.M. Zapotin prevents mouse skin tumorigenesis during the stages of initiation and promotion. Anticancer Res, 28: 3705-3709, 2008. 17. Pezzuto, J.M. Resveratrol as an Inhibitor of Carcinogenesis. Pharm. Biol., 46: 443-573, 2008. 18. Pezzuto, J.M., Venkatasubramanian, V., Hamad, M., and Morris, K.R. Unraveling the relationship between grapes and health. J. Nutr., 139: 1783S-1787S, 2009. 19. Asolkar, R.N., Freel, K.C., Jensen, P.R., Fenical, W., Kondratyuk, T.P., Park, E.J., and Pezzuto, J.M. Arenamides A-C, cytotoxic NFkappaB inhibitors from the marine actinomycete Salinispora arenicola. J. Nat. Prod., 72: 396-402, 2009. 20. Kang, S.S., Cuendet, M., Endringer. D.C., Croy, V.L., Pezzuto, J.M., and Lipton, M.A. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB. Bioorg. Med. Chem., 17:1044-1054, 2009. 21. Deng, Y., Balunas, M.J., Kim, J.A., Lantvit, D.D., Chin, Y.W., Chai, H., Sugiarto, S., Kardono, L.B.S., Fong, H.H.S., Pezzuto, J.M., Swanson, S.M., Carcache de Blanco, E.J., and Kinghorn, A.D. Bioactive 5,6- Dihydropyrone Derivatives from Hyptis brevipes. J. Nat. Prod., 72: 1165-1169, 2009.

22. Maiti, A., Reddy, P.V., Sturdy, M., Marler, L., Pegan, S.D., Mesecar, A.D., Pezzuto, J.M., and Cushman, M. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J. Med. Chem., 52: 1873-1884, 2009. 23. Ghufran, M.A., Qureshi, R.A., Batool, A., Kondratyuk, T.P., Guilford, J.M., Marler, L.E., Chang, L.C., and Pezzuto, J.M. Evaluation of selected indigenous medicinal plants from the Western Himalayas for cytotoxicity and as potential cancer chemopreventive agents. Pharm. Biol., 47: 533-538, 2009. 24. Yao, G., Kondratyuk, T.P., Tan, G.T., Pezzuto, J.M., and Chang, L.C. Bioactive sulfated sesterterpene alkaloids and sesterterpene sulfates from the marine sponge Fasciospongia sp. J. Nat. Prod., 2009 Jan 29. [Epub ahead of print] 25. Mi, Q., Pezzuto, J.M., Farnsworth, N.R., Wani, M.C., Kinghorn, A.D., and Swanson, S.M. Use of the in vivo hollow fiber assay in natural products anticancer drug discovery (#). J. Nat. Prod., 72: 573-580, 2009. 26. Endringer, D.C., Pezzuto, J.M., and Braga, F.C. NF-κB inhibitory activity of cyclitols isolated from Hancornia speciosa. Phytomedicine, 16: 1064-1069, 2009. 27. Balunas, M.J., Su, B., Riswan, S., Fong, H.H., Brueggemeier, R.W., Pezzuto, J.M., and Kinghorn, A.D. Isolation and characterization of aromatase inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett., 2: 29-33, 2009. 28. Schupp, P.J., Kohlert-Schupp, C., Whitefield, S., Engemann, A., Rohde, S., Hemscheidt, T., Pezzuto, J.M., Kondratyuk, T.P., Park, E.J., Marler, L., Rostama, B., and Wright, A.D. Cancer chemopreventive and anticancer evaluation of extracts and fractions from marine macro- and microorganisms collected from Twilight Zone waters around Guam. Nat Prod Commun., 4: 1717-1728, 2009. 29. Endringer, D.C., Valadares, Y.M., Campana, P.R., Campos, J.J., Guimarães, K.G., Pezzuto, J.M., and Braga, F.C. Evaluation of Brazilian plants on cancer chemoprevention targets in vitro. Phytother. Res., 29: 928-933, 2010. 30. Yang, J.H., Kondratyuk, T.P., Marler, L.E., Qiu, X., Choi, Y., Cao, H., Yu, R., Sturdy, M., Pegan, S., Liu, Y., Wang, L.Q., Mesecar, A.D., van Breemen, R.B., Pezzuto, J.M., Fong, H.H., Chen, Y.G., and Zhang, H.J. Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata. Phytochemistry, 71: 641-647, 2010. 31. Cuendet, M., Guo, J., Luo, Y., Chen, S., Oteham, C.P., Moon, R.C., van Breemen, R.B., Marler, L.E., and Pezzuto, J.M. Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res., 3: 221-232, 2010. 32. Morais, M.C., Luqman, S., Kondratyuk, T.P., Petronio, M.S., Regasini, L.O., Silva, D.H., Bolzani, V.S., Soares, C.P., and Pezzuto, J.M. Suppression of TNF-alpha induced NFkappaB activity by gallic acid and its semi-synthetic esters: Possible role in cancer chemoprevention. Nat. Prod. Res., 24: 1758-1765, 2010. 33. Calamini, B., Ratia, K., Malkowski, M., Cuendet, M., Pezzuto, J.M., Santarsiero, B.D., and Mesecar, A.D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J., 429: 273- 282, 2010. 34. Cheenpracha, S., Park, E.J., Rostama, B., Pezzuto, J.M., and Chang, L.C. Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. Mar. Drugs, 8: 429-437, 2010. 35. Nam, S-J, Gaudêncio, S.P., Maloney, K.N., Kauffman, C.A., Jensen, PR., Kondratyuk, T.P., Marler, L.E., Pezzuto, J.M., and Fenical, W. Fijiolides A and B, inhibitors of TNF-alpha-induced NFkappaB activation, from a marine-eerived sediment bacterium of the genus Nocardiopsis. J. Nat. Prod., 73: 1080-1086 2010. 36. Luqman, S. and Pezzuto, J.M. NFκB: A promising target for natural products in cancer chemoprevention. Phytother. Res., 24: 949-963, 2010 (invited review). 37. Sun, B., Hoshino, J., Jermihov, K., Marler, L., Pezzuto, J.M., Mesecar, A.D., and Cushman, M. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg. Med. Chem., 18: 5352-5366, 2010. 38. Hoshino, J., Park, E.J., Kondratyuk, T.P., Marler, L., Pezzuto, J.M., and Cushman, M. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem., 53: 5033- 5043, 2010. 39. Gullett, N.P., Ruhul Amin, A.R., Bayraktar, S., Pezzuto, J.M., Shin, D.M., Khuri, F.R., Aggarwal, B.B., Surh, Y.J., and Kucuk, O. Cancer prevention with natural compounds. Semin. Oncol., 37: 258-281, 2010. 40. Cheenpracha, S., Park, E.J., Yoshida, W.Y., Barit, C., Wall, M., Pezzuto, J.M., and Chang, L.C. Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. Bioorg. Med. Chem., 18: 6598-6602, 2010. 41. Conda-Sheridan, M., Marler, L., Park, E.J., Kondratyuk, T.P., Jermihov, K., Mesecar, A.D., Pezzuto, J.M., Asolkar, R.N., Fenical, W., and Cushman, M. Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, Strain CNS284. J. Med. Chem., 53: 8688- 8699, 2010. 42. Marler, L., Conda-Sheridan, M., Cinelli, M.A., Morrell, A.E., Cushman, M., Chen, L., Huang, K., van Breemen, R., and Pezzuto, J.M. Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives. Anticancer Res., 30: 4873-4882, 2010. 43. Choi, Y., Jermihov, K., Nam, S.J., Sturdy, M., Maloney, K., Qiu, X., Chadwick, L.R., Main, M., Chen, S.N., Mesecar, A.D., Farnsworth, N.R., Pauli, G.F., Fenical, W., Pezzuto, J.M., and van Breemen, R.R. Screening natural products for inhibitors of quinone reductase-2 using ultrafiltration LC-MS. Anal. Chem., 83: 1048-1052, 2011. 44. Yang, J.H., Kondratyuk, T.P., Jermihov, K.C., Marler, L.E., Qiu, X., Choi, Y., Cao, H., Yu, R., Sturdy, M., Huang, R., Liu, Y., Wang, L.Q., Mesecar, A.D., van Breemen, R.B., Pezzuto, J.M., Fong, H.H., Chen, Y.G., and Zhang, H.J. Bioactive compounds from the fern Lepisorus contortus. J. Nat. Prod., 2011 Jan 24. [Epub ahead of print] 45. Pezzuto, J.M. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann. NY Acad. Sci., 1215: 123-130, 2011. 46. Zou, J., Pan, L., Li, Q., Zhao, J., Pu, J., Yao, P., Gong, N., Lu, Y., Kondratyuk, T.P., Pezzuto, J.M., Fong, H.H., Zhang, H., and Sun, H.. Rubesanolides A and B: Diterpenoids from Isodon rubescens. Org. Lett., 13: 1406-1409, 2011. 47. Park, E-J, Kondratyuk, T.P., Morrell, A., Kiselev, E., Conda-Sheridan, M., Cushman, M., Ahn, S., Choi, Y., White, J.J., van Breemen, R.B., and Pezzuto, J.M. Induction of retinoid X receptor activity and consequent up-regulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells. Cancer Prev. Res., 4: 592-607, 2011. 48. Park, E.J., Cheenpracha, S., Chang, L.C., Kondratyuk, T.P., and Pezzuto, J.M. Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression by 4- [(2'-O-acetyl-α-L-rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutr. Cancer, 63: 971-982, 2011. 49. Kondratyuk, T.P., Park, E.J., Marler, L.E., Ahn, S., Yuan, Y., Choi, Y., Yu, R., van Breemen, R.B., Sun, B., Hoshino, J., Cushman, M., Jermihov, K.C., Mesecar, A.D., Grubbs, C.J., and Pezzuto, J.M. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol. Nutr. Food Res., 55: 1249- 1265, 2011. 50. Vang, O., Ahmad, N., Baile, C.A., Baur, J.A., Brown, K., Csiszar, A., Das, D.K., Delmas, D., Gottfried, C., Lin, H.Y., Ma, Q.Y., Mukhopadhyay, P., Nalini, N., Pezzuto, J.M., Richard, T., Shukla, Y., Surh, Y.J., Szekeres, T., Szkudelski, T., Walle, T., and Wu, J.M. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 6: e19881, 2011. 51. Luqman, S., Meena, A., Marler, L.E., Kondratyuk, T.P., and Pezzuto, J.M. Suppression of tumor necrosis factor-α-induced nuclear factor κB activation and aromatase activity by capsaicin and its analog capsazepine. J. Med. Food, 2011 Jun 11. [Epub ahead of print] 52. Park, E.J., Kiselev, E., Conda-Sheridan, M., Cushman, M., and Pezzuto, J.M. Induction of apoptosis by 3-amino-6-(3-aminopropyl)- 5,6-dihydro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline via modulation of MAPKs (p38 and c-Jun N-terminal kinase) and c-Myc in HL-60 human leukemia cells. J. Nat. Prod. 2011 Dec 7. [Epub ahead of print] PubMed PMID: 22148260. 53. Park, E.J., Cheenpracha, S., Chang, L.C., and Pezzuto, J.M. Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by epimuqubilin A via IKK/IκB/NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells. Phytochem. Lett., 4: 426-431, 2011. 54. Shen, L., Park, E.J., Kondratyuk, T.P., Guendisch, D., Marler, L., Pezzuto, J.M., Wright, A.D., and Sun, D. Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg. Med. Chem., 19: 6182-6195, 2011 55. Mayhoub, A.S., Marler, L., Kondratyuk, T.P., Park, E.J., Pezzuto, J.M., and Cushman, M. Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets. Bioorg. Med. Chem. 2011 Sep 25. [Epub ahead of print] 56. Guilford, J.M. and Pezzuto, J.M. Wine and health: A review Am. J. Enol. Vitic. 62: 471-486, 2011. 57. Guilford, J.M. and Pezzuto, J.M. (2011). Cancer Chemoprevention, in Phytochemistry and Pharmacognosy, edited by M.J. Kato and J.M. Pezzuto, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK [http://www.eolss.net] 58. Kato, M.J. and Pezzuto, J.M. (2011). Phytochemistry and Pharmacognosy, in Phytochemistry and Pharmacognosy, edited by M.J. Kato and J.M. Pezzuto, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK [http://www.eolss.net] 59. Tamara P. Kondratyuk, T.P., Park, E.-J., Yu, R., van Breemen, R.B., Asolkar, R.N., Murphy, B.T., Fenical, W., and Pezzuto, J.M. Novel marine phenazines as potential cancer chemopreventive and anti- inflammatory agents Mar. Drugs 2012, 10(2), 451-464; doi:10.3390/md10020451. 60. Mayhoub, A.S., Marler, L., Kondratyuk, T.P., Park, E.-J., Pezzuto, J.M., and Cushman, M. Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol. Bioorg. Med. Chem., 20: 2427-2434, 2012. 61. Park, E.-J., Pezzuto, J.M., Jang, K.W., Nam, S.-J., Bucarey, S.A., and Fenical, W. Suppression of nitric oxide synthase by thienodolin in lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells. Nat. Prod. Commun., 6: 789-794, 2012. 62. Park, E-J and Pezzuto, J.M. Flavonoids in cancer prevention. Anti- Cancer Agents Med. Chem., in press. 63. Chen, L., Conda-Sheridan, M., Reddy, P.V.N., Morrell, A., Park, E.-J., Kondratyuk, T.P., Pezzuto, J.M., van Breemen, R.B., and Cushman, M. Identification, Synthesis, and Biological evaluation of the metabolites of 3-amino-6-(3′-aminopropyl)-5H-indeno[1,2- c]isoquinoline-5,11-(6H)dione (AM6−36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents. J. Med. Chem., 55: 5965-5981, 2012. 64. Youn, U.J., Park, E.-J., Kondratyuk, T.P., Simmons, C.J., Borris, R.P., Tanamatayarat, P., Wongwiwatthananukit, S., Toyama, O., Songsak, T., Pezzuto, J.M., and Chang, L.C. Anti-inflammatory sesquiterpene lactones from the flowers of Vernonia cinerea Bioorg. Med. Chem. Lett. 22: 5559-5562, 2012. 65. Kondratyuk, T.P. and Pezzuto, J.M. (2012). Chemistry and biological activity of grapes, in Nutraceuticals and Functional Foods, edited by G. K. Jayaprakasha, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK [http://www.eolss.net] 66. Archer, C.R., Groll, M., Stein, M.L., Schellenberg, B. Clerc, J., Kaiser, M., Kondratyuk, T.P., Pezzuto, J.M., Dudler, R., and Bachmann, A.S. Activity enhancement of the synthetic syrbactin proteasome 2 inhibitor hybrid and biological evaluation in tumor cells. Biochemistry, 51: 6880- 6888, 2012. 67. Yu, X., Park, E.-J., Kondratuk, T.P., Pezzuto, J.M., and Sun, D. Synthesis of 2-arylindole derivatives and evaluation as nitric oxide synthase and NFκB inhibitors. Org. Biomol. Chem. 10: 8835-8847, 2012. 68. Luqman, S., Meena, A., Singh, P., Kondratyuk, T.P., Marler, L.E., Pezzuto, J.M., Negi. A.S. Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents. Chem. Biol. Drug Des., in press. 69. Park, E.-J. and Pezzuto, J.M Antioxidant marine products in cancer chemoprevention Antiox. Redox. Signaling (forum issue on “Antioxidants in Cancer Prevention”), in press. 70. Sun, D., Hurdle, J.G., Lee, R.E., Lee, R.E., Cushman, M., Pezzuto, J.M. Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead. Chem. Med. Chem., in press. 71. Chen, L., Conda-Sheridan, M., Reddy, P.V.N., Park, E.-J., Kondratyuk, T.P., Morrell, A., Pezzuto, J.M., Cushman, M., and van Breemen, R.B. In vitro and in vivo metabolism of 3-amino-6-(3-aminopropyl)-5,6- dihydro-5, 11-dioxo-11H-indeno[1,2-c] isoquinoline dihydrochloride (AM6-36), a promising lead for cancer chemopreventive agents. J. Med. Chem., in press. 72. Ihsan-ul-Haq, Mirza, B., Kondratyuk, T.P., Park, E.-J., Burns, B.E., Marler, L.E., and Pezzuto, J.M. Preliminary evaluation of the cancer chemopreventive and cytotoxic potential of naturally growing ethnobotanically selected plants from Pakistan. Pharm. Biol., in press.

Book Chapters

1. Cuendet, M. and Pezzuto, J.M. Antitumor alkaloids in clinical use or in clinical trials. In: E. Fattorusso, O. Taglialatela-Scafati (eds.), Modern Alkaloids-Structure, Isolation, Synthesis and Biology. Hoboken, New Jersey: Wiley-VCH., pp. 25-52, 2008. 2. Cuendet, M. and Pezzuto, J.M. Molecular targets of botanicals used for chemoprevention. In: D.I. Abrams, A. Weil (eds.), Integrative Oncology. New York, New York: Oxford University Press, pp. 41-56, 2009. 3. Pezzuto JM, Park EJ, and Park EJ. Autoxidation and antioxidants, Encyclopedia of Pharmaceutical Science and Technology, 4th Edition (EPST4), edited by J. Swarbrick, 2011. 4. Park, E.-J. and Pezzuto JM. Flavonoids in cancer prevention. Anticancer Agents Med Chem. 2012 Jan 31. [Epub ahead of print] PubMed PMID: 22292763. 5. Marler, M. and Pezzuto, J.M. Nutritional Phytochemicals and the Management of Chronic Inflammation. In: Inflammation and Cancer: Mechanisms and Dietary Approaches for Cancer Prevention. A.-N. T. Kong (ed.), Taylor & Francis, in press.

Book Edited

Topics in Current Chemistry. Vol. 329. Natural Products in Cancer Prevention and Therapy. J.M Pezzuto and N. Suh (Eds.), pp. 254, Springer, New York / Heidelberg, 2013 (ISBN 978-3-642-34574-6). The book is available in electronic form and the hardcover is due Dec. 31,

Perspective

Suh, N. and Pezzuto, J.M. Strawberry Fields Forever? Cancer Prev Res; 5; 30–33, 2012 (Perspective).

Dianqing Sun, Assistant Professor, Pharmaceutical Sciences

1. X. Yu, E.-J. Park, T. P. Kondratyuk, J. M. Pezzuto, D. Sun*, Synthesis of 2- Arylindole Derivatives and Evaluation as Nitric Oxide Synthase and NFκB Inhibitors, Org. Biomol. Chem., 2012, 10(44), 8835-8847. 2. M. Pieroni, S. Girmay, D. Sun, R. Sahu, B. L. Tekwani, G. T. Tan, Synthesis and Structure–Activity Relationships of Lansine Analogs as Antileishmanial Agents, ChemMedChem, 2012, in press, DOI:10.1002/cmdc.201200346. 3. D. Sun*, J. G. Hurdle, R. Lee, R. Lee, M. Cushman, J. M. Pezzuto, Evaluation of Flavonoid and Resveratrol Chemical Libraries Reveals Abyssinone II as a Promising Antibacterial Lead, ChemMedChem, 2012, 7(9), 1541-1545. 4. L. Shen, C. J. Simmons, D. Sun*, Microwave-assisted Synthesis of Macrocycles via Intramolecular and/or Bimolecular Ullmann Coupling, Tetrahedron Lett., 2012, 53(32), 4173-4178.

5. L. Shen, E.-J. Park, T. P. Kondratyuk, D. Guendisch, L. Marler, J. M. Pezzuto, A. D. Wright, D. Sun*, Design, Synthesis, and Biological Evaluation of Callophycin A and Analogues as Potential Chemopreventive and Anticancer Agents. Bioorg. Med. Chem., 2011, 19(21), 6182-6195. 6. L. Shen, D. Sun*, Total Synthesis and Structural Revision of Engelhardione, Tetrahedron Lett., 2011, 52(35), 4570-4574. 7. J. R. Brown, E. J. North, J. G. Hurdle, C. Morisseau, J. S. Scarborough, D. Sun, J. Korduláková, M. S. Scherman, V. Jones, A. Grzegorzewicz, R. M. Crew, M. Jackson, M. R. McNeil, R. E. Lee, The Structure Activity Relationship of Urea Derivatives as Anti-Tuberculosis Agents, Bioorg. Med. Chem., 2011, 19(18), 5585-5595. 8. S. Sivendran, V. Jones, D. Sun, Y. Wang, A. E. Grzegorzewicz, M. S. Scherman, A. Napper, J. A. McCammon, R. E. Lee, S. L. Diamond, M. McNeil, Identification of Triazinoindol-Benzimidazolones as Nanomolar Inhibitors of The Mycobacterium tuberculosis Enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3,5- epimerase (RmlC), Bioorg. Med. Chem. 2010, 18(2), 896-908.

Anthony D. Wright, PhD, Associate Professor, Pharmaceutical Sciences

1. Acetylated Sesterterpenes from the Great Barrier Reef Sponge Luffariella variabilis, P. Ettinger-Epstein, C. A. Motti, R. de Nys, A. D. Wright, C. N. Battershill, D. M. Tapiolas, J. Nat. Prod. 2007, 70, 648-651. 2. Antimycobacterial Activity of a Bis-Sulfonamide, B. L. Wilkinson, L. F. Bornaghi, A. D. Wright, T. A. Houston, S-A. Poulsen, Bioorg. Med. Chem. Lett. 2007, 17, 1355-1357. 3. Novel Sorbicillin Derivatives with an Unprecedented Carbon Skeleton from the Sponge-Derived Fungus Trichoderma sp. K Neumann, A. Abdel-Lateff, A. D. Wright, S. Kehraus, A. Krick, G. M. König, Eur. J. Org. Chem. 2007, 2268-2275. 4. New Iantherans from the Marine Sponge Ianthella quadrangulata: the first natural secondary metabolites acting as P2Y11 receptor agonists,H. Greve, S. Kehraus, A. Krick, G. M. König, S. Meis, M. Kassack, A. D. Wright, J. Med. Chem. 2007, 50, 5000-5007. 5. NF-KB-Inhibiting Naphthopyrones from the Fijian Echinoderm Comanthus parvicirrus, F. Folmer, W. T. A. Harrison, J. N. Tabudravu, M. Jaspars, W. Aalbersberg, K. Feussner, A. D. Wright, M. Dicato, M. Diederich, J. Nat. Prod. 2008, 71, 106-111. 6. Production of Manoalide and its Analogues by the Sponge Luffariella variabilis is Hardwired, P. Ettinger-Epstein, D. M. Tapiolas, C. A. Motti, A. D. Wright, C. N. Battershill, R. de Nys, Mar. Biotechnol. 2008, 10, 64-74. 7. Cytotoxic Bastadin 24, from the Australian Sponge Ianthella quadrangulata, H. Greve, S. Kehraus, A. Krick, G. Kelter,A. Maier, H.-H. Fiebig, A. D. Wright, G. M. König, J. Nat. Prod. 2008, 71, 309-312. 8. Steroids from an Australian Sponge Psammoclema sp., I. P. Holland, A. McCluskey, J. A. Sakoff, N. Chau, P. J. Robinson, C. A. Motti, A. D. Wright, I. A. van Altena, J. Nat. Prod. 2009, 72, 102–106. 9. Three New Spongian Diterpenes from the Fijian Marine Sponge Spongia sp., H. Gross, A. D. Wright, G. M. König, Nat. Prod. Comm., 2009, 4, 315- 322. 10. Direterpene Formamides from the Tropical Marine Sponge Cymbastela hooperi, and their Antimalarial Activity in Vivo, A. D. Wright, N. Lang- Unnasch, J. Nat. Prod., 2009, 72, 492-495. 11. Trichopyrone and other constituents from the Marine Sponge-Derived Fungus Trichoderma sp., A. Abdel-Lateff, K. Fisch, A. D. Wright, Z. Naturforsch., 2009, 64c, 186-192. 12. Eusynstyelamides A, B and C, nNOS Inhibitors, from the Ascidian Eusynstyela latericus, D. M. Tapiolas, B. F. Bowden, E. Abou-Mansour, R. H. Willis, J. R. Doyle, A. N. Muirhead, C. Liptrot, L. E. Llewellyn, C. W. W. Wolff, A. D. Wright, C. A. Motti, J. Nat. Prod., 2009, 72, 1115-1120. 13. Chemical antifouling defences of tropical sea stars: Effects of the surface- associated compounds hexadecanoic acid, cholesterol, lathosterol and sitosterol, J. Guenther, A. D. Wright, K. Burns, Rocky de Nys, Mar. Ecol. Prog. Ser., 2009, 385, 137-149. 14. Detailed NMR, Including 1,1-ADEQUATE, and Anticancer Studies of Compounds from the Echinoderm Colobometra perspinosa, A. D. Wright, J. L. Nielson, D. M. Tapiolas, C. A. Motti, S. P. B. Ovenden, P. S. Kearns, C. H. Liptrot, Mar. Drugs, 2009, 7, 565-575. 15. Cancer Chemopreventive and Anticancer Evaluation of Extracts and Fractions from Marine Macro- and Micro-organisms Collected from Twilight Zone Waters Around Guam, P. Schupp, C. Kohlert-Schupp, S. Whitefield, A. Engemann, T. Hemscheidt, J. M. Pezzuto, T. P. Kondratyuk, E.-J. Park, L. Marler, B. Rostama, A. D. Wright, Nat. Prod. Comm., 2009, 4, 1717-1728. 16. Screening for Anticancer activity of Fungi Derived from Indonesian Marine Sponges, E. Chasanah, H. I. Januar, D. Bourne, C. Liptrot, A. D. Wright, Journal of Marine and Fisheries Post Harvest and Biotechnology, special edition in conjunction with World Ocean Conference 2009, 2009, 4, 1-8. 17. Cytotoxic Cembranes from Indonesian Specimens of the Soft Coral Nephthea sp. H. I. Januar, E. Chasanah, C. A. Motti, D. M. Tapiolas, C. H. Liptrot, A. D. Wright, Marine Drugs, 2010, 8, 2142-2152. 18. In vitro antihelmintic effect of plant extracts against infective larvae of ruminants gastrointestinal nematode parasites. F. C. Moreno, I. J. Gordon, A.D. Wright, M. A. Benvenutti, C. A. Saumell, Arch. Med. Vet., 2010, 42, 155-163. 19. Sesquiterpene benzoxalzoles and sesquiterpene quinones from the marine sponge Dactylospongia elegans, S. P. B. Ovenden, J. L. Nielson, C. H. Liptrot, R. H. Willis, D. M. Tapiolas, A. D. Wright, C. A. Motti, J. Nat. Prod., 2010, 74, 65-68. 20. Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical marine sponge Cymbastela hooperi. A. D. Wright, A. McCluskey, M. J. Robertson, K. A. MacGregor, C. P. Gordon, J. Guenther, Org. Biomol. Chem., 2011, 9, 400-407. 21. Callophycin A, A cytotoxic tetrahydro--carboline from the red alga Callophycus oppositifolius, S. P. B. Ovenden, J. L. Nielson, C. Liptrot, R. H. Willis, C. A. Motti, D. M. Tapiolas, A. D. Wright, Phytochemistry Letters, 2010, 4, 69-71. 22. Comosusols A-D, and Comosone A: Novel Cytotoxic Compounds from the Brown Algae Sporochnus comosus, S. P. B. Ovenden, J. L. Nielson, C. H. Liptrot, R. H. Willis, A. D. Wright, C. A. Motti, D. M. Tapiolas, J. Nat. Prod., 2011, 74, 739-743. 23. Metachromins U-W: Cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulate, S. P. B. Ovenden, J. L. Nielson, C. H. Liptrot, R. H. Willis, D. M. Tapiolas, A. D. Wright, C. A. Motti,, J. Nat. Prod., 2011, 74, 1335-1338. 24. Hawaiian Tea: The relationship between chemical concentrations, tea leaf age, and levels of shade, R. Song, D. Kelman, K. Johns, A. D. Wright, Trop.Res. Bull., 2011, 30, 41-50. 25. Nephthea spp.: Correlation Between Natural Products Production and Pressure from Local Environmental Stressors, H. I. Januar, B. Hendrarto, E. Chasanah, A. D. Wright, J. Marine Sci. Res. Development, S8:001. doi:10.4172/2155-9910.S8-001, 2011. 26. L. Shen, E.-J. Park, T. P. Kondratyuk, D. Guendisch, L. Marler, J. M. Pezzuto, A. D. Wright, D. Sun, Synthesis of callophycin A analogues and evaluation as potential chemopreventive and anticancer agents, Bioorg. Med. Chem., 2011, 19, 6182-6195. 27. Hawaiian Tea: The relationship between chemical concentrations, tea leaf age, and levels of shade, R. Song, D. Kelman, K. Johns, A. D. Wright, Tropical Resources: The Bulletin of the Yale Tropical Resources Institute, 2011, 30, 41-50., not peer reviewed. 28. Twilight Zone Sponges from Guam Yield Theonellin Isocyanate and Psammaplysins I and J. A. D. Wright, P. J. Schupp, J-P. Schrör, A. Engemann, S. Rohde, D. Kelman, A. Carroll, C. A. Motti, J. Nat. Prod., 2012, 75, 502-506. 29. M. Schumacher, N. Wilson a, J. N. Tabudravu a, C. Edwards c, L. A. Lawton, C. Motti, A. D. Wright, M. Diederich, M. Jaspars, New nodulopeptins from Nodularia spumigena KAC 66, Tetrahedron, 2011, 68, 1622-1628. 30. E. Kromkowski Posner, K. McDermid Smith, A. D. Wright, N. K. Tabandera, P. R. Wright, D. Kelman, Antioxidant Activity of Hawaiian Macro-Algae (Limu), Marine Drugs, 2012, 10, 403-416. 31. Correlation between tea leaf age, chemical content, and shade levels, R. Song, D. Kelman, K. Johns, A. D. Wright, Food Chem., 2012, 133, 707-714. 32. Marine Natural Products: Value, Sustainability, Funding, and the Future (Editorial), A. D. Wright, J. Marine Sci. Res. Development, 2012, 2:e105. doi:10.4172/2155-9910.1000e. 33. Update of Spectroscopic data for 4-Hydroxydictyolactone and Dictyol E isolated from a Halimeda stuposa and Dictyota sp., assemblage, S. P. B. Ovenden, J. L. Nielson, C. H. Liptrot, R. H. Willis, D. M. Tapiolas, A. D. Wright, C. A. Motti, Molecules, 2012, 17, 2929-2938; doi:10.3390/molecules17032929. 34. The importance of structure validation of internal standards in quantitative analytical chemistry methods and metabolomics, D. Kelman, A. D. Wright, PLoS-ONE, 2012. http://dx.plos.org/10.1371/journal.pone.0042061. 35. A Great Barrier Reef Sinularia sp., yields two new cytotoxic diterpenes, A. D. Wright, J. L. Nielson, D. M. Tapiolas, C. H. Liptrot, C. A. Motti, Marine Drugs, 2012, 10, 1619-1630.

Ghee Tan, PhD, Assistant Professor, Pharmaceutical Sciences

1. C.-Y. Ma, S. F. Musoke, G. T. Tan, H.-J. Zhang, K. Sydara, S. Bouamanivong, B. Southavong, D. D. Soejarto, and H. H. S. Fong. (2008) Antimalarial compounds from Diospyros quaesita Thw. (Ebenaceae). Chemistry & Biodiversity 5, 2442-2448.

2. A. Libman, H.-J. Zhang, C.-Y. Ma, B. Southavong, K. Sydara, S. Bouamanivong, G. T. Tan, H. H. S. Fong, and D. D. Soejarto (2008) A first antimalarial pregnane glycoside from Gongronema napalense. Asian J. Tradit. Med. 3(6), 203-210.

3. G. Yao, T. P. Kondratyuk, G. T. Tan, J. M. Pezzuto and L. C. Chang (2009) Bioactive sulfated sesterterpene alkaloids and sesterterpene sulfates from the marine sponge Fasciospongia sp. J. Nat. Prod., 72(2), 19–323.

4. S. F. Musoke, O. Odyek, W. W. Anokbonggo, J. Ogwal-Okeng, E. J. Carcache-Blanco, C.-Y. Ma, J. Orjala, and G. T. Tan (2010) Antimalarial activity of Aspilia pruliseta, a medicinal plant from Uganda. Planta Med., 76, 1870–1873.

5. G.-M. Yao, F. M. Sebisubi, L. Y. C. Voo, C. C. Ho, G. T. Tan, L. C. Chang (2011) Citrinin derivatives from the soil filamentous fungus Penicillium sp. H9318, J. Braz. Chem. Soc. 22, 1125-1129.

6. C. Gyllenhaal, M. R. Kadushin, B. Southavong, K. Sydara, S. Bouamanivong, M. Xaiveu, L. T. Xuan, N. T. Hiep, N. V. Hung, P. K. Loc, L. X. Dac, T. Q. Bich, N. M. Cuong, H. M. Ly, H. J. Zhang, S. G. Franzblau, H. Xie, M. C. Riley, B. G. Elkington, H. T. Nguyen, D. P. Waller, C. Y. Ma, P. Tamez, G. T. Tan, J. M. Pezzuto, and D. D. Soejarto (2012) Ethnobotanical approach versus random approach in the search for new bioactive compounds: Support of a hypothesis. Pharm. Biol., 50(1), 30–41.

7. D. D. Soejarto, C. Gyllenhaal, M. R. Kadushin, B. Southavong, K. Sydara, S. Bouamanivong, 8. M. Xaiveu, H.-J. Zhang, S.G. Franzblau, G. T. Tan, J. M. Pezzuto, M. C. Riley, B. G. Elkington, and D. P. Waller (2012) An ethnobotanical survey of medicinal plants of Laos toward the discovery of bioactive compounds as potential candidates for pharmaceutical development. Pharm. Biol. 50(1): 42–60.

9. M. Pieroni, S. Girmay, D.-Q. Sun, R. Sahu, B. L. Tekwani, and G. T. Tan (2012) Synthesis and structure–activity relationships of unique lansine analogs as antileishmanial agents. Chem.Med.Chem., in press.

Refereed Book Chapters

1. G. T. Tan, J. M. Pezutto, and A. D. Kinghorn (1992) Screening of natural products as HIV-1 and HIV-2 reverse transcriptase (RT) inhibitors, In: "Natural Products as Antiviral Agents", C. K. Chu, and H. Cutler, eds., Plenum Press, New York., pp 195-222.

2. G. T. Tan and J. M. Pezzuto (1996) Toxic alkaloids pertinent to cancer chemotherapy, In: "Chemistry and Toxicology of Diverse Classes of Alkaloids", M. S. Blum, ed., Alaken, Inc., Fort Collins, pp 1-120.

3. G. T. Tan, C. K. Angerhofer, H. Mehdi and J. M. Pezzuto. (1998) Novel Approaches to the Discovery and Characterization of Natural Product Drugs, In: “New Trends and Methods in Natural Products’ Research”, Ihsan Calis, Tayfun Ersoz, and A. Ahmet Basaran, eds., Tubitak Press, Ankara, Turkey, pp 225-250.

Refereed Reviews

1. G. T. Tan, C. Gyllenhaal and D. Soejarto (2006) Biodiversity as a Source of Anticancer Agents. Curr. Drug Targets, 7(3), 265-277.

3. F. M. Sebisubi and G.T. Tan (2010) Natural Products with Promising Antimalarial Activity, in Natural Products, edited by J.M. Pezzuto and M.J. Kato, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, [http://www.eolss.net].

Sheri Tokumaru, PharmD, Assistant Professor, Pharmacy Practice

Juarez DT, Sentell T, Tokumaru S, Goo R, Davis JW, Mau MM. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in hawaii, 2006-2009. Prev Chronic Dis. 2012;9. doi: 10.5888/pcd9.120065. PMID: 23017247 [PubMed - in process]

Nakagawa K, Chang CW, Koenig MA, Yu M, Tokumaru S. Treatment of refractory intracranial hypertension with 23.4% saline in children with severe traumatic brain injury. J Clin Anesth. 2012 Jun;24(4):318-23.

Heinrich LS, Tokumaru S, Clark NM, Garofalo J, Paek JL, Grim SA. Development and implementation of a piperacillin-tazobactam extended infusion guideline. J Pharm Pract. 2011 Dec;24(6):571-6.

Golembiewski J, Tokumaru S. Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. Review.

Supakit Wongwiwatthananukit, Associate Professor, Pharmacy Practice

1. Wongwiwatthananukit, S., Sansanayudh, N., Dhummaupakorn, R., & Kitiyadisai, C. (2007) Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother, 40, 1917-1923.

2. Wongwiwatthananukit, S., Dhumma-upakorn, R., & Kaenboon, K. (2009) Effectiveness of oral maintenance terbutaline therapy after threatened preterm labor. J Health Res, 23, 37-42.

3. Wongwiwatthananukit, S., Benchanakatkul, P., Suwanamajo, S., Weerrachai W., & Songsak, T. (2009) Efficacy of Vernonia cinerea for smoking cessation. J Health Res, 23, 31-36.

4. Dumrongpiwat, S., Wongwiwatthananukit, S., Krittiyanunt, S. (2009) Tobacco smoking behavior in youth offenders. J Health Res, 23, 103-109.

5. Wongwiwatthananukit, S., Wongwiwatthananukit, S., Dhumma-upakorn, R.& Naktuan, T. (2009). Development of smoking cessation health-related quality of life scale. Silpakorn U Science & Tech J, 3, 18-32.

6. Sansanayudh, N., Wongwiwatthananukit, S., Putwai, P., & Dhummauppakorn, R. (2010) Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother, 44, 415-423.

7. Sansanayudh, N., Wongwiwatthananukit, S., & Veerayuthvilai, S. (2010) Comparison of changes in body water between lercanidipine and amlodipine therapy in hypertensive patients. J Med Assoc Thai, 93 (suppl. 6),s84-s92.

8. Youn UJ., Park EJ., Kondratyuk TP., Simmons CJ., Borris R., Wongwiwatthananukit S., Tanamatayarat, P., Toyama, O., Songsak, T., Pezzuto, JM., & Chang, LC. (2012). Anti-inflammatory sesquiterpene lactones from the flower of Vernonia cinerea. Bioorg Med Chem,22,5559-5562.

9. Phetkrajaysang N., Sansanayudh, N., Wongwiwatthananukit, S., & Krittiyanunt, S. (2013) Prevalence of Vitamin D Deficiency and Association of Serum Vitamin D Level with Anthropometric and Metabolic Factors in Metabolic Syndrome Patients. Asian Biomed, (in press)

BOOKS

1. Supakit Wongwiwatthananukit (2007). Pharmacotherapy in smoking cessation. In S.Wattanasirichaikul (Ed.), Textbook of Tobacco Control. (1st ed. pp.465-492). Bangkok, Thai Healthcare Professional Against Tobacco Network.

2. Supakit Wongwiwatthananukit (2007). Dictionary of Research and Statistics, 1st edition, Bangkok, Darnsutha Press. ISBN: 978-974-03-2018-0

3. Rawadee Dhumma-upakorn, Sarinee Krittiyanunt, & Supakit Wongwiwatthananukit (2008). Medicine Use – You Must Know, 1st edition, Bangkok, Chulalongkorn University Press. ISBN: 978-974-03-2053-1

4. Supakit Wongwiwatthananukit (2008). Dictionary of Research and Statistics, 2nd edition, Bangkok, Chulalongkorn University Press. ISBN: 978- 974-03-2018-0

5. Rawadee Dhumma-upakorn, Sarinee Krittiyanunt, & Supakit Wongwiwatthananukit (2010). Medicine Use – You Must Know, 2nd edition, Bangkok, Chulalongkorn University Press. ISBN : 978-974-03-2053-1

6. Supakit Wongwiwatthananukit (2012). Dictionary of Research and Statistics, 3rd edition, Bangkok, Chulalongkorn University Press. ISBN: 978- 974-03-2018-0